Johnson & Johnson (JNJ) 10-K 16 Feb 23 2022 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Billions	12 Months Ended
	Jan. 01, 2023	Feb. 10, 2023	Jul. 03, 2022
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jan. 01, 2023
Document Transition Report	false
Entity File Number	1-3215
Entity Registrant Name	JOHNSON & JOHNSON
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732
Local Phone Number	524-0400
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 472
Entity Common Stock, Shares Outstanding		2,604,286,303
Entity Central Index Key	0000200406
Current Fiscal Year End Date	--01-01
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false
Common Stock, Par Value $1.00
Document Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.650% Notes Due May 2024
Document Information [Line Items]
Title of 12(b) Security	0.650% Notes Due May 2024
Trading Symbol	JNJ24C
Security Exchange Name	NYSE
5.50% Notes Due November 2024
Document Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ24BP
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Document Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ28
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Document Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ35
Security Exchange Name	NYSE

Audit Information

Audit Information	12 Months Ended
	Jan. 01, 2023
Auditor Information [Abstract]
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Florham Park, New Jersey
Auditor Firm ID	238

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jan. 01, 2023	Jan. 02, 2022
Current assets:
Cash and cash equivalents (Notes 1 and 2)	$ 14,127	$ 14,487
Marketable securities (Notes 1 and 2)	9,392	17,121
Accounts receivable trade, less allowances for doubtful accounts $203 (2021, $230)	16,160	15,283
Inventories (Notes 1 and 3)	12,483	10,387
Prepaid expenses and other receivables	3,132	3,701
Total current assets	55,294	60,979
Property, plant and equipment, net (Notes 1 and 4)	19,803	18,962
Intangible assets, net (Notes 1 and 5)	48,325	46,392
Goodwill (Notes 1 and 5)	45,231	35,246
Deferred taxes on income (Note 8)	9,123	10,223
Other assets	9,602	10,216
Total assets	187,378	182,018
Current liabilities
Loans and notes payable (Note 7)	12,771	3,766
Accounts payable	11,703	11,055
Accrued liabilities	11,456	13,612
Accrued rebates, returns and promotions	14,417	12,095
Accrued compensation and employee related obligations	3,328	3,586
Accrued taxes on income (Note 8)	2,127	1,112
Total current liabilities	55,802	45,226
Long-term debt (Note 7)	26,888	29,985
Deferred taxes on income (Note 8)	6,374	7,487
Employee related obligations (Notes 9 and 10)	6,767	8,898
Long-term taxes payable (Note 1)	4,306	5,713
Other liabilities	10,437	10,686
Total liabilities	110,574	107,995
Commitments and Contingencies (Note 19)
Shareholders’ equity
Preferred stock — without par value (authorized and unissued 2,000,000 shares)	0	0
Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 13)	(12,967)	(13,058)
Retained earnings	128,345	123,060
Stockholders' Equity before Treasury Stock	118,498	113,122
Less: common stock held in treasury, at cost (Note 12) (506,246,000 shares and 490,878,000 shares)	41,694	39,099
Total shareholders’ equity	76,804	74,023
Total liabilities and shareholders’ equity	$ 187,378	$ 182,018

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jan. 01, 2023	Jan. 02, 2022
Current assets:
Allowances for doubtful accounts	$ 203	$ 230
Shareholders’ equity
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Common stock, par value per share (in dollars per share)	$ 1	$ 1
Common stock, shares authorized (in shares)	4,320,000,000	4,320,000,000
Common stock, shares issued (in shares)	3,119,843,000	3,119,843,000
Treasury stock, shares	506,246,000	490,878,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Income Statement [Abstract]
Sales to customers	$ 94,943	$ 93,775	$ 82,584
Cost of products sold	31,089	29,855	28,427
Gross profit	63,854	63,920	54,157
Selling, marketing and administrative expenses	24,765	24,659	22,084
Research and development expense	14,603	14,714	12,159
In-process research and development (Note 5)	783	900	181
Interest income	(490)	(53)	(111)
Interest expense, net of portion capitalized (Note 4)	276	183	201
Other (income) expense, net	1,871	489	2,899
Restructuring (Note 20)	321	252	247
Earnings before provision for taxes on income	21,725	22,776	16,497
Provision for taxes on income (Note 8)	3,784	1,898	1,783
Net earnings	$ 17,941	$ 20,878	$ 14,714
Net earnings per share (Notes 1 and 15)
Basic (in dollars per share)	$ 6.83	$ 7.93	$ 5.59
Diluted (in dollars per share)	$ 6.73	$ 7.81	$ 5.51
Average shares outstanding (Notes 1 and 15)
Basic (in shares)	2,625.2	2,632.1	2,632.8
Diluted (in shares)	2,663.9	2,674	2,670.7

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Statement of Comprehensive Income [Abstract]
Net earnings	$ 17,941	$ 20,878	$ 14,714
Other comprehensive income (loss), net of tax
Foreign currency translation	(1,796)	(1,079)	(233)
Securities:
Unrealized holding gain (loss) arising during period	(24)	(4)	1
Reclassifications to earnings	0	0	0
Net change	(24)	(4)	1
Employee benefit plans:
Prior service credit (cost), net of amortization	(160)	(169)	1,298
Gain (loss), net of amortization	1,854	4,318	(1,135)
Effect of exchange rates	111	106	(229)
Net change	1,805	4,255	(66)
Derivatives & hedges:
Unrealized gain (loss) arising during period	454	(199)	1,000
Reclassifications to earnings	(348)	(789)	(53)
Net change	106	(988)	947
Other comprehensive income (loss)	91	2,184	649
Comprehensive income	$ 18,032	$ 23,062	$ 15,363

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Statement of Comprehensive Income [Abstract]
Foreign currency translation	$ (460)	$ (346)	$ 536
Securities	6	1
Employee benefits	461	1,198	(21)
Derivatives & hedges	$ 30	$ (263)	$ (252)

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Common Stock Issued Amount	Treasury Stock Amount
Beginning Balance at Dec. 29, 2019	$ 59,471	$ 110,659	$ (15,891)	$ 3,120	$ (38,417)
Net earnings	14,714	14,714
Cash dividends paid	(10,481)	(10,481)
Employee compensation and stock option plans	2,217	(931)			3,148
Repurchase of common stock	(3,221)				(3,221)
Other	(71)	(71)
Other comprehensive income (loss), net of tax	649		649
Ending Balance at Jan. 03, 2021	63,278	113,890	(15,242)	3,120	(38,490)
Net earnings	20,878	20,878
Cash dividends paid	(11,032)	(11,032)
Employee compensation and stock option plans	2,171	(676)			2,847
Repurchase of common stock	(3,456)				(3,456)
Other comprehensive income (loss), net of tax	2,184		2,184
Ending Balance at Jan. 02, 2022	74,023	123,060	(13,058)	3,120	(39,099)
Net earnings	17,941	17,941
Cash dividends paid	(11,682)	(11,682)
Employee compensation and stock option plans	2,466	(974)			3,440
Repurchase of common stock	(6,035)				(6,035)
Other comprehensive income (loss), net of tax	91		91
Ending Balance at Jan. 01, 2023	$ 76,804	$ 128,345	$ (12,967)	$ 3,120	$ (41,694)

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - $ / shares	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollars per share)	$ 4.45	$ 4.19	$ 3.98

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Cash flows from operating activities
Net earnings	$ 17,941	$ 20,878	$ 14,714
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	6,970	7,390	7,231
Stock based compensation	1,138	1,135	1,005
Asset write-downs	1,216	989	233
Contingent consideration reversal	0	0	(1,148)
Net gain on sale of assets/businesses	(380)	(617)	(111)
Deferred tax provision	(1,663)	(2,079)	(1,141)
Credit losses and accounts receivable allowances	(17)	(48)	63
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
(Increase)/Decrease in accounts receivable	(1,290)	(2,402)	774
Increase in inventories	(2,527)	(1,248)	(265)
Increase in accounts payable and accrued liabilities	1,098	2,437	5,141
Decrease/(Increase) in other current and non-current assets	687	(1,964)	(3,704)
(Decrease)/Increase in other current and non-current liabilities	(1,979)	(1,061)	744
Net cash flows from operating activities	21,194	23,410	23,536
Cash flows from investing activities
Additions to property, plant and equipment	(4,009)	(3,652)	(3,347)
Proceeds from the disposal of assets/businesses, net	543	711	305
Acquisitions, net of cash acquired (Note 18)	(17,652)	(60)	(7,323)
Purchases of investments	(32,384)	(30,394)	(21,089)
Sales of investments	41,609	25,006	12,137
Credit support agreements activity, net	(249)	214	(987)
Other (primarily licenses and milestones)	(229)	(508)	(521)
Net cash used by investing activities	(12,371)	(8,683)	(20,825)
Cash flows from financing activities
Dividends to shareholders	(11,682)	(11,032)	(10,481)
Repurchase of common stock	(6,035)	(3,456)	(3,221)
Proceeds from short-term debt	16,134	1,997	3,391
Repayment of short-term debt	(6,550)	(1,190)	(2,663)
Proceeds from long-term debt, net of issuance costs	2	5	7,431
Repayment of long-term debt	(2,134)	(1,802)	(1,064)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	1,329	1,036	1,114
Credit support agreements activity, net	(28)	281	(333)
Other	93	114	(294)
Net cash used by financing activities	(8,871)	(14,047)	(6,120)
Effect of exchange rate changes on cash and cash equivalents	(312)	(178)	89
(Decrease)/Increase in cash and cash equivalents	(360)	502	(3,320)
Cash and cash equivalents, beginning of year (Note 1)	14,487	13,985	17,305
Cash and cash equivalents, end of year (Note 1)	14,127	14,487	13,985
Cash paid during the year for:
Interest	982	990	904
Interest, net of amount capitalized	933	941	841
Income taxes	5,223	4,768	4,619
Supplemental schedule of non-cash investing and financing activities
Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards	2,114	1,811	1,937
Conversion of debt	0	0	27
Acquisitions
Fair value of assets acquired	18,710	61	7,755
Fair value of liabilities assumed	(1,058)	(1)	(432)
Net cash paid for acquisitions (Note 18)	$ 17,652	$ 60	$ 7,323

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jan. 01, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Johnson & Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures. Description of the Company and Business Segments The Company has approximately 152,700 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being. The Company is organized into three business segments: Consumer Health, Pharmaceutical and MedTech. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women’s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on the following therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. In November 2021, the Company announced its intention to separate the Company’s Consumer Health business (Kenvue as the name for the planned New Consumer Health Company), with the intention to create a new, publicly traded company by the end of the fiscal year 2023. New Accounting Standards Recently Adopted Accounting Standards There were no new material accounting standards adopted in fiscal 2022. Recently Issued Accounting Standards Not Adopted as of January 1, 2023 ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) – Disclosure of Supplier Finance Program Obligations This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity’s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures and will adopt this standard in the fiscal first quarter of 2023. Cash Equivalents The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs). RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities. Investments Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required. Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows. Revenue Recognition The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily t he Managed Care, Medicare and Medicaid programs, which amounted to $9.6 billion and $7.7 billion as of January 1, 2023 and January 2, 2022, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years 2022, 2021 and 2020. Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in fiscal year 2022 and less than 3.0% of the total revenues in fiscal years 2021 and 2020 and are included in sales to customers. See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue. Shipping and Handling Shipping and handling costs incurred were $1.1 billion, $1.1 billion and $1.0 billion in fiscal years 2022, 2021 and 2020, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 1.0% of sales to customers for all periods presented. Inventories Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method. Intangible Assets and Goodwill The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2022 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying program. Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill. Financial Instruments As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments. Leases The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in Other assets Accrued liabilities Other liabilities ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $1.1 billion and $0.9 billion in fiscal years 2022 and 2021, respectively. The lease liability was $1.3 billion and $1.0 billion in fiscal years 2022 and 2021, respectively. The operating lease costs were $0.3 billion in fiscal years 2022, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3 billion in fiscal years 2022, 2021 and 2020, respectively. Product Liability Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. Research and Development Research and development expenses are expensed as incurred in accordance with ASC 730, Research and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows: Nature/Type of Collaboration Statement of Earnings Presentation Third-party sale of product & profit share payments received Sales to customers Royalties/milestones paid to collaborative partner (post-regulatory approval)* Cost of products sold Royalties received from collaborative partner Other income (expense), net Upfront payments & milestones paid to collaborative partner (pre-regulatory approval) Research and development expense Research and development payments to collaborative partner Research and development expense Research and development payments received from collaborative partner or government entity Reduction of Research and development expense * Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life. For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense. The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG and IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company. Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S. Advertising Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.1 billion, $2.7 billion and $2.1 billion in fiscal years 2022, 2021 and 2020, respectively. Income Taxes Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2022 was approximately $6.1 billion, of which $4.6 billion is classified as noncurrent and reflected as “Long-term taxes payable” on the Company’s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., “period cost”) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., “deferred method”). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost. See Note 8 to the Consolidated Financial Statements for further information regarding income taxes. Net Earnings Per Share Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued. Annual Closing Date The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026. Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Cash, Cash Equivalents and Curr

Cash, Cash Equivalents and Current Marketable Securities	12 Months Ended
	Jan. 01, 2023
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Current Marketable Securities	Cash, Cash Equivalents and Current Marketable Securities At the end of the fiscal year 2022 and 2021, cash, cash equivalents and current marketable securities were comprised of: (Dollars in Millions) 2022 Carrying Amount Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 4,926 — 4,926 4,926 — U.S. Reverse repurchase agreements 1,419 — 1,419 1,419 — Corporate debt securities (1) 873 (1) 872 — 873 Money market funds 5,368 — 5,368 5,368 — Time deposits (1) 446 — 446 446 — Subtotal $ 13,032 (1) 13,031 12,159 873 U.S. Gov't Securities $ 9,959 (28) 9,931 1,922 8,009 U.S. Gov't Agencies 210 (5) 205 — 205 Corporate and other debt securities 352 (1) 351 46 305 Subtotal available for sale (2) $ 10,521 (34) 10,487 1,968 8,519 Total cash, cash equivalents and current marketable securities $ 14,127 9,392 (Dollars in Millions) 2021 Carrying Amount Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,936 — 2,936 2,936 — Non-U.S. Sovereign Securities (1) 1,006 — 1,006 90 916 U.S. Reverse repurchase agreements 1,659 — 1,659 1,659 — Corporate debt securities (1) 3,479 (1) 3,478 200 3,279 Money market funds 1,901 — 1,901 1,901 — Time deposits (1) 900 — 900 900 — Subtotal 11,881 (1) 11,880 7,686 4,195 U.S. Gov't Securities $ 19,485 (4) 19,481 6,785 12,696 Corporate and other debt securities 246 — 246 16 230 Subtotal available for sale (2) $ 19,731 (4) 19,727 6,801 12,926 Total cash, cash equivalents and current marketable securities $ 14,487 17,121 (1) Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs. The contractual maturities of the available for sale debt securities at January 1, 2023 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 10,430 10,399 Due after one year through five years 91 88 Due after five years through ten years — — Total debt securities $ 10,521 10,487 The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.

Inventories

Inventories	12 Months Ended
	Jan. 01, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories At the end of fiscal years 2022 and 2021, inventories were comprised of: (Dollars in Millions) 2022 2021 Raw materials and supplies $ 2,070 1,592 Goods in process 1,700 2,287 Finished goods 8,713 6,508 Total inventories $ 12,483 10,387

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Jan. 01, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment At the end of fiscal years 2022 and 2021, property, plant and equipment at cost and accumulated depreciation were: (Dollars in Millions) 2022 2021 Land and land improvements $ 859 884 Buildings and building equipment 12,989 12,882 Machinery and equipment 30,431 29,774 Construction in progress 4,974 4,139 Total property, plant and equipment, gross $ 49,253 47,679 Less accumulated depreciation 29,450 28,717 Total property, plant and equipment, net $ 19,803 18,962 The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2022, 2021 and 2020 was $49 million, $49 million and $63 million, respectively. Depreciation expense, including the amortization of capitalized interest in fiscal years 2022, 2021 and 2020 was $2.7 billion, $2.7 billion and $2.6 billion, respectively. Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Jan. 01, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets and Goodwill At the end of fiscal years 2022 and 2021, the gross and net amounts of intangible assets were: (Dollars in Millions) 2022 2021 Intangible assets with definite lives: Patents and trademarks — gross $ 44,012 38,572 Less accumulated amortization (22,266) (20,088) Patents and trademarks — net (1) $ 21,746 18,484 Customer relationships and other intangibles — gross $ 22,987 23,011 Less accumulated amortization (12,901) (11,925) Customer relationships and other intangibles — net (2) $ 10,086 11,086 Intangible assets with indefinite lives: Trademarks $ 6,807 6,985 Purchased in-process research and development (3) 9,686 9,837 Total intangible assets with indefinite lives $ 16,493 16,822 Total intangible assets — net $ 48,325 46,392 (1) The change was primarily related to the intangible assets acquired with the acquisition of Abiomed, Inc. which was partially offset by amortization expense of previously existing intangible assets and the result of currency translation effects. (2) The majority is comprised of customer relationships (3) The reduction was primarily related to an intangible asset impairment charge of approximately $0.8 billion recorded in the fiscal year 2022 related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS. An additional reduction of $0.7 billion was driven by Monarch assets that reached commercialization and are now classified as having definite lives. This was partially offset by approximately $1.1 billion of IPR&D acquired with Abiomed, Inc. Goodwill as of January 1, 2023 and January 2, 2022, as allocated by segment of business, was as follows: (Dollars in Millions) Consumer Health Pharmaceutical MedTech Total Goodwill at January 3, 2021 $ 10,336 11,009 15,048 36,393 Goodwill, related to acquisitions — — — — Goodwill, related to divestitures (9) — — (9) Currency translation/other (517) (429) (192) (1,138) Goodwill at January 2, 2022 $ 9,810 10,580 14,856 35,246 Goodwill, related to acquisitions — — 11,056 11,056 Goodwill, related to divestitures — — — — Currency translation/other (626) (396) (49) (1,071) Goodwill at January 1, 2023 $ 9,184 10,184 25,863 45,231 The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable assets included in Cost of products sold was $4.3 billion, $4.7 billion and $4.7 billion before tax, for the fiscal years ended January 1, 2023, January 2, 2022 and January 3, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net. The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2023 2024 2025 2026 2027 $4,600 4,400 3,600 3,000 2,400 See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jan. 01, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company primarily uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. In the fiscal fourth quarter of 2022, the Company entered into forward starting interest rate swaps with notional amounts totaling $2.4 billion in contemplation of hedging interest rate risk associated with long-term financing for the Consumer Health segment separation. These forward starting interest rate swaps are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings. At the end of the fiscal year 2022, the changes in fair value was not material and therefore not included in the table below. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of January 1, 2023, the total amount of cash collateral paid by the Company under the CSA amounted to $0.8 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of January 1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $43.3 billion, $36.2 billion and $12.4 billion, respectively. As of January 2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion, $37.4 billion and $10.0 billion, respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. As of January 1, 2023, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $230 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January 1, 2023 and January 2, 2022, net of tax: January 1, 2023 January 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (1,098) — — — — (109) — Derivatives designated as hedging instruments — — — 1,098 — — — — 109 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing $ — — — 140 — — — — 174 — Amount of gain or (loss) recognized in AOCI — — — 140 — — — — 174 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (72) (271) 149 — (23) 17 119 30 — 47 Amount of gain or (loss) recognized in AOCI 5 319 61 — (113) (94) (557) 123 — 146 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 425 — — — — 402 — Amount of gain or (loss) recognized in AOCI $ — — — 42 — — — — 9 — As of January 1, 2023 and January 2, 2022, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) January 1, 2023 January 2, 2022 January 1, 2023 January 2, 2022 Long-term Debt $ 8,665 $ 9,793 $ (1,435) $ (142) The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January 1, 2023 and January 2, 2022: (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Gain/(Loss) Derivatives Not Designated as Hedging Instruments January 1, 2023 January 2, 2022 Foreign Exchange Contracts Other (income) expense $ 94 (70) The following table is the effect of net investment hedges for the fiscal years ended January 1, 2023 and January 2, 2022: Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) January 1, 2023 January 2, 2022 January 1, 2023 January 2, 2022 Debt $ 197 387 Interest (income) expense — — Cross Currency interest rate swaps $ 766 548 Interest (income) expense — — The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments for the fiscal years ended January 1, 2023 and January 2, 2022: January 2, 2022 January 1, 2023 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,884 (538) (770) 576 576 Equity Investments without readily determinable value $ 500 91 107 698 698 January 3, 2021 January 2, 2022 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,481 198 205 1,884 1,884 Equity Investments without readily determinable value $ 738 394 (632) 500 500 (1) Recorded in Other Income/Expense (2) Other includes impact of currency For the fiscal years ended January 1, 2023 and January 2, 2022 for equity investments without readily determinable market values, $51 million and $28 million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were offsetting impacts of $142 million and $422 million, respectively, of changes in the fair value reflected in net income due to changes in observable prices and gains on the disposal of investments. The impact in fiscal year 2021, was driven by the gain on disposal of the Grail investment. In fiscal year 2022, the Company sold all of its equity investments in argenx SE for proceeds of $0.6 billion. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 having the highest priority and Level 3 having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of the fiscal year ended January 1, 2023 and January 2, 2022 were as follows: 2022 2021 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 629 — 629 540 Interest rate contracts (2) — 1,534 — 1,534 796 Total $ — 2,163 — 2,163 1,336 Liabilities: Forward foreign exchange contracts — 511 — 511 881 Interest rate contracts (2) — 2,778 — 2,778 979 Total $ — 3,289 — 3,289 1,860 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 38 — 38 24 Liabilities: Forward foreign exchange contracts — 68 — 68 28 Available For Sale Other Investments: Equity investments (3) 576 — — 576 1,884 Debt securities (4) — 10,487 — 10,487 19,727 Other Liabilities Contingent Consideration (5) $ 1,120 1,120 533 Gross to Net Derivative Reconciliation 2022 2021 (Dollars in Millions) Total Gross Assets $ 2,201 1,360 Credit Support Agreement (CSA) (2,176) (1,285) Total Net Asset 25 75 Total Gross Liabilities 3,357 1,888 Credit Support Agreement (CSA) (3,023) (1,855) Total Net Liabilities $ 334 33 Summarized information about changes in liabilities for contingent consideration is as follows: 2022 2021 2020 (Dollars in Millions) Beginning Balance $ 533 633 1,715 Changes in estimated fair value (6) (194) (52) (1,089) Additions (7) 792 — 106 Payments (11) (48) (99) Ending Balance $ 1,120 533 633 (1) 2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3. (2) Includes cross currency interest rate swaps and interest rate swaps. (3) Classified as non-current other assets. (4) Classified as cash equivalents and current marketable securities. (5) Includes $1,116 million, $520 million and $594 million, classified as non-current other liabilities as of January 1, 2023, January 2, 2022 and January 3, 2021, respectively. Includes $4 million, $13 million and $39 million classified as current liabilities as of January 1, 2023, January 2, 2022 and January 3, 2021, respectively. (6) Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense. The Company recorded a contingent consideration reversal of $1,148 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense. (7) In fiscal year 2022, the Company recorded $704 million of contingent consideration related to Abiomed. See Notes 2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.

Borrowings

Borrowings	12 Months Ended
	Jan. 01, 2023
Debt Disclosure [Abstract]
Borrowings	Borrowings The components of long-term debt are as follows: (Dollars in Millions) 2022 Effective Rate % 2021 Effective Rate % 0.250% Notes due 2022 (1B Euro 1.1311) (3) $ — — % $ 1,131 (3) 0.26 % 2.25% Notes due 2022 — — 1,000 2.31 6.73% Debentures due 2023 250 6.73 250 6.73 3.375% Notes due 2023 801 3.17 802 3.18 2.05% Notes due 2023 500 2.09 499 2.09 0.650% Notes due 2024 (750MM Euro 1.0651) (2) /(750MM Euro 1.1311) (3) 792 (2) 0.68 847 (3) 0.68 5.50% Notes due 2024 (500MM 1.2037 GBP ) (2) /(500MM GBP 1.3485) (3) 600 (2) 6.75 672 (3) 6.75 2.625% Notes due 2025 749 2.63 749 2.63 0.55% Notes due 2025 918 0.57 983 0.57 2.45% Notes due 2026 1,996 2.47 1,995 2.47 2.95% Notes due 2027 877 2.96 978 2.96 0.95% Notes due 2027 1,394 0.96 1,478 0.96 1.150% Notes due 2028 (750MM Euro 1.0651) (2) /(750MM Euro 1.1311) (3) 794 (2) 1.21 843 (3) 1.21 2.90% Notes due 2028 1,496 2.91 1,495 2.91 6.95% Notes due 2029 298 7.14 298 7.14 1.30% Notes due 2030 1,607 1.30 1,723 1.30 4.95% Debentures due 2033 498 4.95 498 4.95 4.375% Notes due 2033 854 4.24 854 4.24 1.650% Notes due 2035 (1.5B Euro 1.0651) (2) /(1.5B Euro 1.1311) (3) 1,591 (2) 1.68 1,683 (3) 1.68 3.55% Notes due 2036 842 3.59 974 3.59 5.95% Notes due 2037 993 5.99 993 5.99 3.625% Notes due 2037 1,336 3.64 1,475 3.64 5.85% Debentures due 2038 697 5.85 696 5.85 3.400% Notes due 2038 992 3.42 992 3.42 4.50% Debentures due 2040 540 4.63 540 4.63 2.10% Notes due 2040 828 2.14 974 2.14 4.85% Notes due 2041 297 4.89 297 4.89 4.50% Notes due 2043 496 4.52 496 4.52 3.70% Notes due 2046 1,976 3.74 1,975 3.74 3.75% Notes due 2047 812 3.76 971 3.76 3.500% Notes due 2048 743 3.52 743 3.52 2.250% Notes due 2050 808 2.29 983 2.29 2.450% Notes due 2060 1,055 2.49 1,222 2.49 Other 9 — 7 — Subtotal 28,439 (4) 3.04 % (1) 32,116 (4) 2.89 % (1) Less current portion 1,551 2,131 Total long-term debt $ 26,888 $ 29,985 (1) Weighted average effective rate. (2) Translation rate at January 1, 2023. (3) Translation rate at January 2, 2022. (4) The excess of the carrying value over the fair value of debt was $1.6 billion at the end of fiscal year 2022 and the excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021. Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs. The Company has access to substantial sources of funds at numerous banks worldwide. In September 2022, the Company secured a new 364-day Credit Facility of $10 billion, which expires on September 7, 2023. In November 2022, the Company secured an additional 364-day Credit Facility of $10 billion, which expires on November 21, 2023. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not material. Throughout fiscal years 2022 and 2021, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $12.8 billion and $3.8 billion at the end of fiscal years 2022 and 2021, respectively. The current portion of the long term debt was $1.6 billion and $2.1 billion in 2022 and 2021, respectively, and the remainder is commercial paper and local borrowing by international subsi diaries. The current debt balance as of January 1, 2023 includes $11.2 billion of commercial paper which has a weighted average interest rate of 4.23% and a weighted average maturity of approximately two months. Aggregate maturities of long-term debt obligations commencing in 2023 are: (Dollars in Millions) 2023 2024 2025 2026 2027 After 2026 $1,551 1,392 1,667 1,996 2,271 19,562

Income Taxes

Income Taxes	12 Months Ended
	Jan. 03, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The provision for taxes on income consists of: (Dollars in Millions) 2022 2021 2020 Currently payable: U.S. taxes $ 2,378 1,525 1,026 International taxes 3,069 2,452 1,898 Total currently payable 5,447 3,977 2,924 Deferred: U.S. taxes (2,081) 583 (76) International taxes 418 (2,662) (1,065) Total deferred (1,663) (2,079) (1,141) Provision for taxes on income $ 3,784 1,898 1,783 A comparison of income tax expense at the U.S. statutory rate of 21% in fiscal years 2022, 2021 and 2020, to the Company’s effective tax rate is as follows: (Dollars in Millions) 2022 2021 2020 U.S. $ 5,369 6,110 4,312 International 16,356 16,666 12,185 Earnings before taxes on income: $ 21,725 22,776 16,497 Tax rates: U.S. statutory rate 21.0 % 21.0 21.0 International operations (1) (4.5) (16.4) (9.9) Consumer health separation 2.2 — — U.S. taxes on international income (2) (1.9) 6.7 2.7 Tax benefits from loss on capital assets — (1.3) (1.2) Tax benefits on share-based compensation (1.3) (1.0) (1.5) All other (3) 1.9 (0.7) (0.3) Effective Rate 17.4 % 8.3 10.8 (1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below. (2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2022 amount includes the impact of certain provisions of the 2017 TCJA that became effective in fiscal 2022. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below. (3) Certain prior year amounts have been reclassified to conform to current year presentation. The fiscal year 2022 effective tax rate increased 9.1% as compared to the fiscal year 2021 effective tax rate. As part of the planned separation of the Company’s Consumer Health business, the Company has recognized approximately $0.5 billion in net incremental tax costs in fiscal year 2022, which increased the 2022 effective tax rate by approximately 2.2%. Additionally, the Company recorded certain non-recurring favorable tax items in fiscal year 2021 which resulted in an unfavorable impact to the Company’s fiscal 2022 effective tax rate when compared to the prior fiscal year. These items are described below. The Company’s 2022 tax rate also benefited from certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal 2022, the impairment of bermekimab for AD and HS IPR&D (for further information see Note 5 of the 2022 10-K Consolidated Financial Statements) and changes in the fair value of securities in the Company’s investment portfolio, both recorded at the U.S. statutory rate. The fiscal year 2021 tax rate decreased by 2.5% compared to the fiscal year 2020 tax rate, which was primarily driven by the following items. In fiscal year 2021, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with applicable local regulations. The net impact of this restructuring was approximately $0.6 billion net benefit or 2.7% benefit to the Company’s annual effective tax rate, comprised of the following items: • approximately $2.3 billion of local deferred tax assets to record the remeasurement of the tax basis of these assets to fair value, this benefit has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • approximately $1.7 billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of these deferred tax assets. This expense has been reflected as “U.S. tax on international income” on the Company’s effective tax rate reconciliation. Also, in the fiscal fourth quarter of 2021, the Company recognized a loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2021 tax rate by approximately 1.3% which is reflected as a “Tax benefits from loss on capital assets” on the effective tax rate reconciliation. Additionally other fiscal 2021 impacts to the rate were primarily driven by litigation and acquisition related items as follows: • the Company accrued additional legal expenses, of approximately $1.6 billion for talc at an effective tax rate of 23.5% and $0.8 billion for Risperdal Gynecomastia settlements at an effective tax rate of 16.4% (See Note 19 to the Consolidated Financial Statements for more details). • the Company recorded a partial IPR&D charge of $0.9 billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of 22.4%. In fiscal year 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF) and became effective for fiscal year 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust the tax basis in certain assets to fair value (i.e., “step-up”) to be depreciated and amortized resulting in an incremental Swiss tax deduction over the transitional period. TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and additional research and development tax deductions. The cantonal transitional provisions of TRAF allowed companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company has operations located in various Swiss cantons. During the fiscal year 2020, the final canton where the Company maintains significant operations enacted TRAF legislation. Additionally, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., “step-up”) for its assets and as a result, the Company recorded additional deferred tax benefits in 2020. The Company recognized a net benefit in the fiscal year 2020 for Swiss Tax Reform of approximately $0.4 billion or 2.6% benefit to the Company’s annual effective tax rate, comprised of the following items: • approximately $0.3 billion tax benefit relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred in the fiscal year 2020; this benefit has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • a $450 million deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company’s Swiss subsidiaries’ assets as described above; this benefit has been reflected as “International Operations” on the Company’s effective tax rate reconciliation. • approximately $0.3 billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities in the fiscal year 2020. This benefit has been reflected as “U.S. tax on international income” on the Company’s effective tax rate reconciliation. The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. Also, in the fiscal year 2020, the Company recognized a capital loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2020 tax rate by approximately 1.2% which is reflected as a “Tax benefits from loss on capital assets” on the effective tax rate reconciliation. In addition, in the fiscal year 2020, the Company had lower income in higher tax jurisdictions, primarily driven by: • the impact of the accrual of litigation costs related to talc for $4.0 billion which reduced the U.S. earnings before taxes at an effective tax rate of 23.5%; • the accrual of additional legal costs, including an additional $1.0 billion associated with a revised agreement in principle to settle opioid litigation at an effective tax rate of 21.4% The Company also reduced the contingent consideration liability related to the Auris Health acquisition in 2019 and reversed some of its unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions during the fiscal year 2020. Temporary differences and carryforwards at the end of fiscal years 2022 and 2021 were as follows: 2022 Deferred Tax 2021 Deferred Tax (1) (Dollars in Millions) Asset Liability Asset Liability Employee related obligations $ 725 1,244 Stock based compensation 687 679 Depreciation of property, plant and equipment (858) (876) Goodwill and intangibles (4,271) (3) (2,659) (2) R&D capitalized for tax 2,611 1,664 Reserves & liabilities 2,761 2,882 Income reported for tax purposes 2,045 2,566 Net realizable operating loss carryforwards (4) 1,260 1,720 Undistributed foreign earnings 1,565 (1,693) 1,015 (1,461) Global intangible low-taxed income (3,547) (4,853) Miscellaneous international 1,053 (65) 870 (39) Miscellaneous U.S. 476 (16) Total deferred income taxes $ 13,183 (10,434) 12,640 (9,904) (1) Certain prior year amounts have been reclassified to conform to current year presentation. (2) Amount is inclusive of the $2.3 billion deferred tax asset established as part of the reorganized ownership structure of certain wholly-owned international subsidiaries, as previously described. (3) Amount is inclusive of the $1.8 billion deferred tax liability due to the acquisition of Abiomed. (4) Net of valuation allowances of $0.9 billion in both 2022 and 2021. The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets. However, in certain jurisdictions, valuation allowances have been recorded against deferred tax assets for loss carryforwards that are not more likely than not to be realized. The following table summarizes the activity related to unrecognized tax benefits: (Dollars in Millions) 2022 2021 2020 Beginning of year $ 3,323 3,373 3,853 Increases related to current year tax positions 523 242 265 Increases related to prior period tax positions 143 23 668 Decreases related to prior period tax positions (148) (128) (551) Settlements (1) (187) (839) Lapse of statute of limitations (11) — (23) End of year $ 3,829 3,323 3,373 The unrecognized tax benefits of $3.8 billion at January 1, 2023, if recognized, would affect the Company’s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In the fiscal year 2020, the Company made its final payments for approximately $0.7 billion to the U.S. Treasury related to the final settlement of 2010-2012 tax audit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audits go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions, including in the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments or change in uncertain tax positions, if any. The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $139 million, $44 million and $32 million in fiscal years 2022, 2021 and 2020, respectively. The total amount of accrued interest was $651 million and $512 million in fiscal years 2022 and 2021, respectively.

Employee Related Obligations

Employee Related Obligations	12 Months Ended
	Jan. 01, 2023
Compensation Related Costs [Abstract]
Employee Related Obligations	Employee Related Obligations At the end of fiscal 2022 and fiscal 2021, employee related obligations recorded on the Consolidated Balance Sheets were: (Dollars in Millions) 2022 2021 Pension benefits $ 2,698 4,088 Postretirement benefits 1,734 2,069 Postemployment benefits 2,832 3,117 Deferred compensation 100 181 Total employee obligations 7,364 9,455 Less current benefits payable 597 557 Employee related obligations — non-current $ 6,767 8,898 Prepaid employee related obligations of $4,581 million and $4,436 million for 2022 and 2021, respectively, are included in Other assets on the Consolidated Balance Sheets.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	12 Months Ended
	Jan. 01, 2023
Retirement Benefits [Abstract]
Pensions and Other Benefit Plans	Pensions and Other Benefit Plans The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily healthcare, to all eligible U.S. retired employees and their dependents. Many international employees are covered by government-sponsored programs and the cost to the Company is not significant. In the U.S, non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee’s compensation during the last five years before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula). In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026. International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. The Company does not fund retiree healthcare benefits in advance and has the right to modify these plans in the future. In 2022 and 2021 the Company used December 31, 2022 and December 31, 2021, respectively, as the measurement date for all U.S. and international retirement and other benefit plans. Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2022, 2021 and 2020 include the following components: Retirement Plans Other Benefit Plans (Dollars in Millions) 2022 2021 2020 2022 2021 2020 Service cost $ 1,327 1,421 1,380 320 309 287 Interest cost 911 770 955 105 81 133 Expected return on plan assets (2,757) (2,645) (2,461) (8) (7) (7) Amortization of prior service cost (184) (181) 2 (5) (31) (31) Recognized actuarial losses (gains) 655 1,257 891 121 151 142 Curtailments and settlements 1 1 23 — — — Net periodic benefit cost (credit) $ (47) 623 790 533 503 524 The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings. Unrecognized gains and losses for the U.S. pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S. benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service. Prior service costs/benefits for the U.S. pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S. benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment. The following table represents the weighted-average actuarial assumptions: Retirement Plans Other Benefit Plans Worldwide Benefit Plans 2022 2021 2020 2022 2021 2020 Net Periodic Benefit Cost Service cost discount rate 2.46 % 2.14 2.82 2.59 2.09 3.04 Interest cost discount rate 2.80 % 2.34 3.13 2.64 2.33 3.08 Rate of increase in compensation levels 4.02 % 4.01 4.00 4.21 4.25 4.25 Expected long-term rate of return on plan assets 7.25 % 7.71 8.12 Benefit Obligation Discount rate 5.01 % 2.49 2.14 5.42 2.68 2.23 Rate of increase in compensation levels 4.00 % 4.01 4.00 4.21 4.21 4.27 The Company’s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows. The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. The following table displays the assumed healthcare cost trend rates, for all individuals: Healthcare Plans 2022 2021 Healthcare cost trend rate assumed for next year 5.99 % 5.33 % Rate to which the cost trend rate is assumed to decline (ultimate trend) 4.01 % 3.73 % Year the rate reaches the ultimate trend rate 2047 2046 The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2022 and 2021 for the Company’s defined benefit retirement plans and other post-retirement plans: Retirement Plans Other Benefit Plans (Dollars in Millions) 2022 2021 2022 2021 Change in Benefit Obligation Projected benefit obligation — beginning of year $ 41,582 43,300 4,878 5,028 Service cost 1,327 1,421 320 309 Interest cost 911 770 105 81 Plan participant contributions 67 67 — — Amendments 7 5 — — Actuarial (gains) losses (1) (12,213) (2,132) (704) (188) Divestitures & acquisitions — (2) — — Curtailments, settlements & restructuring (7) (7) — — Benefits paid from plan (1,228) (1,157) (393) (348) Effect of exchange rates (815) (683) (9) (4) Projected benefit obligation — end of year $ 29,631 41,582 4,197 4,878 Change in Plan Assets Plan assets at fair value — beginning of year $ 41,930 38,195 102 90 Actual return (loss) on plan assets (8,665) 4,439 (17) 17 Company contributions 270 969 386 343 Plan participant contributions 67 67 — — Settlements (5) (7) — — Divestitures & acquisitions — (2) — — Benefits paid from plan assets (1,228) (1,157) (393) (348) Effect of exchange rates (855) (574) — — Plan assets at fair value — end of year $ 31,514 41,930 78 102 Funded status — end of year $ 1,883 348 (4,119) (4,776) Amounts Recognized in the Company’s Balance Sheet consist of the following: Non-current assets $ 4,581 4,436 — — Current liabilities (132) (115) (461) (438) Non-current liabilities (2,566) (3,973) (3,658) (4,338) Total recognized in the consolidated balance sheet — end of year $ 1,883 348 (4,119) (4,776) Amounts Recognized in Accumulated Other Comprehensive Income consist of the following: Net actuarial loss $ 3,948 5,539 239 1,113 Prior service cost (credit) (1) (1,417) (1,610) (7) (13) Unrecognized net transition obligation — — — — Total before tax effects $ 2,531 3,929 232 1,100 Accumulated Benefit Obligations — end of year $ 28,023 39,049 (1) The actuarial gain for retirement plans in 2022 and 2021 was primarily related to increases in discount rates. Retirement Plans Other Benefit Plans (Dollars in Millions) 2022 2021 2022 2021 Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income Net periodic benefit cost (credit) $ (47) 623 533 503 Net actuarial (gain) loss (793) (3,927) (751) (199) Amortization of net actuarial loss (655) (1,257) (121) (151) Prior service cost (credit) 7 5 — — Amortization of prior service (cost) credit 183 181 5 31 Effect of exchange rates (140) (136) (1) — Total loss/(income) recognized in other comprehensive income, before tax $ (1,398) (5,134) (868) (319) Total recognized in net periodic benefit cost and other comprehensive income $ (1,445) (4,511) (335) 184 The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. In 2022, the Company contributed $119 million and $151 million to its U.S. and international pension plans, respectively. The following table displays the funded status of the Company's U.S. Qualified & Non-Qualified pension plans and international funded and unfunded pension plans at December 31, 2022 and December 31, 2021, respectively: U.S. Plans International Plans Qualified Plans Non-Qualified Plans Funded Plans Unfunded Plans (Dollars in Millions) 2022 2021 2022 2021 2022 2021 2022 2021 Plan Assets $ 20,937 27,944 — — 10,577 13,986 — — Projected Benefit Obligation 18,394 25,041 1,937 2,703 9,024 13,428 276 410 Accumulated Benefit Obligation 17,696 23,985 1,872 2,479 8,202 12,212 253 373 Over (Under) Funded Status Projected Benefit Obligation $ 2,543 2,903 (1,937) (2,703) 1,553 558 (276) (410) Accumulated Benefit Obligation 3,241 3,959 (1,872) (2,479) 2,375 1,774 (253) (373) Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $2.9 billion, $2.9 billion and $0.3 billion, respectively, at the end of 2022, and $3.9 billion, $4.2 billion and $0.3 billion, respectively, at the end of 2021. The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans: (Dollars in Millions) 2023 2024 2025 2026 2027 2028-2032 Projected future benefit payments Retirement plans $ 1,445 1,457 1,532 1,609 1,708 10,034 Other benefit plans $ 471 485 433 447 462 2,539 The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future. (Dollars in Millions) 2023 2024 2025 2026 2027 2028-2032 Projected future contributions $ 123 128 136 141 146 816 Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company’s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds. The Company’s retirement plan asset allocation at the end of 2022 and 2021 and target allocations for 2023 are as follows: Percent of Target 2022 2021 2023 Worldwide Retirement Plans Equity securities 62 % 65 % 61 % Debt securities 38 35 39 Total plan assets 100 % 100 % 100 % Determination of Fair Value of Plan Assets The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves. While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. Valuation Hierarchy The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level 1 having the highest priority and Level 3 having the lowest. The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Following is a description of the valuation methodologies used for the investments measured at fair value. • Short-term investment funds — Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level 2. • Government and agency securities — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level 2. • Debt instruments — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level 1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs. • Equity securities — Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level 1 of the valuation hierarchy. • Commingled funds — These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level 2 category have a quoted market price. • Other assets — Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level 1, while inactively traded assets are classified as Level 2. The following table sets forth the Retirement Plans' investments measured at fair value as of December 31, 2022 and December 31, 2021: Quoted Prices Significant Significant Unobservable Inputs (1) Investments Measured at Net Asset Value (Level 1) (Level 2) (Level 3) Total Assets (Dollars in Millions) 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 Short-term investment funds $ 33 102 13 1,033 — — — — 46 1,135 Government and agency securities — — 5,863 7,016 — — — — 5,863 7,016 Debt instruments — — 3,681 3,505 — — — — 3,681 3,505 Equity securities 8,846 14,107 2 2 — — — — 8,848 14,109 Commingled funds — — 4,362 5,496 56 105 6,106 8,708 10,524 14,309 Other assets — — 33 34 13 15 2,506 1,807 2,552 1,856 Investments at fair value $ 8,879 14,209 13,954 17,086 69 120 8,612 10,515 31,514 41,930 (1) The activity for the Level 3 assets is not significant for all years presented. The Company's Other Benefit Plans are unfunded except for U.S. commingled funds (Level 2) of $78 million and $102 million at December 31, 2022 and December 31, 2021, respectively.

Savings Plan

Savings Plan	12 Months Ended
	Jan. 01, 2023
Savings Plan [Abstract]
Savings Plan	Savings PlanThe Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $275 million, $256 million and $243 million in fiscal years 2022, 2021 and 2020, respectively.

Capital and Treasury Stock

Capital and Treasury Stock	12 Months Ended
	Jan. 01, 2023
Equity [Abstract]
Capital and Treasury Stock	Capital and Treasury Stock Changes in treasury stock were: Treasury Stock (Amounts in Millions Except Treasury Stock Shares in Thousands) Shares Amount Balance at December 29, 2019 487,336 $ 38,417 Employee compensation and stock option plans (21,765) (3,148) Repurchase of common stock 21,760 3,221 Balance at January 3, 2021 487,331 38,490 Employee compensation and stock option plans (17,399) (2,847) Repurchase of common stock 20,946 3,456 Balance at January 2, 2022 490,878 39,099 Employee compensation and stock option plans (20,007) (3,440) Repurchase of common stock 35,375 6,035 Balance at January 1, 2023 506,246 $ 41,694 Aggregate shares of common stock issued were approximately 3,119,843,000 shares at the end of fiscal years 2022, 2021 and 2020. Cash dividends paid were $4.45 per share in fiscal year 2022, compared with dividends of $4.19 per share in fiscal year 2021, and $3.98 per share in fiscal year 2020. On January 3, 2023, the Board of Directors declared a regular cash dividend of $1.13 per share, payable on March 7, 2023 to shareholders of record as of February 21, 2023. On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. Share repurchases may be made at management’s discretion from time to time on the open market or through privately negotiated transactions. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Through January 1, 2023, approximately $2.5 billion has been repurchased under the program.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	Jan. 01, 2023
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Components of other comprehensive income (loss) consist of the following: (Dollars in Millions) Foreign Gain/(Loss) On Securities Employee Benefit Plans Gain/ Total December 29, 2019 $ (8,705) — (6,891) (295) (15,891) Net 2020 changes (233) 1 (66) 947 649 January 3, 2021 (8,938) 1 (6,957) 652 (15,242) Net 2021 changes (1,079) (4) 4,255 (988) 2,184 January 2, 2022 (10,017) (3) (2,702) (336) (13,058) Net 2022 changes (1,796) (24) 1,805 106 91 January 1, 2023 $ (11,813) (27) (897) (230) (12,967) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction. See Note 6 for additional details.

International Currency Translat

International Currency Translation	12 Months Ended
	Jan. 01, 2023
Foreign Currency Translation [Abstract]
International Currency Transalation	International Currency Translation For translation of its subsidiaries operating in non-U.S. Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non-current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies, (Argentina and Venezuela). Beginning in the fiscal second quarter of 2022, the Company also accounted for operations in Turkey as highly inflationary. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results. A rollforward of the changes during fiscal years 2022, 2021 and 2020 for foreign currency translation adjustments is included in Note 13. Net currency transaction gains and losses included in Other (income) expense were losses of $328 million, $236 million and $209 million in fiscal years 2022, 2021 and 2020, respectively.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Jan. 01, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January 1, 2023, January 2, 2022 and January 3, 2021: (In Millions Except Per Share Amounts) 2022 2021 2020 Basic net earnings per share $ 6.83 7.93 5.59 Average shares outstanding — basic 2,625.2 2,632.1 2,632.8 Potential shares exercisable under stock option plans 140.1 138.0 118.3 Less: shares repurchased under treasury stock method (101.4) (96.1) (80.4) Adjusted average shares outstanding — diluted 2,663.9 2,674.0 2,670.7 Diluted net earnings per share $ 6.73 7.81 5.51 The diluted net earnings per share calculation for the fiscal years 2022 and 2021 included all shares related to stock options, as the exercise price of these options was less than the average market value of the Company's stock.

Common Stock, Stock Option Plan

Common Stock, Stock Option Plans and Stock Compensation Agreements	12 Months Ended
	Jan. 01, 2023
Share-Based Payment Arrangement [Abstract]
Common Stock, Stock Option Plans and Stock Compensation Agreements	Common Stock, Stock Option Plans and Stock Compensation Agreements At January 1, 2023, the Company had one stock-based compensation plan. The shares outstanding are for contracts under the Company's 2012 Long-Term Incentive Plan and the 2022 Long-Term Incentive Plan. The 2012 Long-Term Incentive Plan expired on April 26, 2022. All awards (stock options, restricted shares units and performance share units) granted subsequent to that date were under the 2022 Long-Term Incentive Plan. Under the 2022 Long-Term Incentive Plan, the Company may issue up to 150 million shares of common stock, of which up to 110 million shares of common stock may be issued subject to stock options or stock appreciation rights and up to 40 million shares of common stock may be issued subject to full value awards. Awards will generally be counted on a 1-for-1 basis against the share reserve, provided that if more than 40 million full value awards are granted, each full value award in excess of 40 million will be counted on a 5-for-1 basis against the share reserve. Shares available for future grants under the 2022 Long-Term Incentive Plan were 150 million at the end of fiscal year 2022. The compensation cost that has been charged against income for these plans was $1,138 million, $1,135 million and $1,005 million for fiscal years 2022, 2021 and 2020, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $196 million, $218 million and $210 million for fiscal years 2022, 2021 and 2020, respectively. The Company also recognized additional income tax benefits of $282 million, $223 million and $248 million for fiscal years 2022, 2021 and 2020, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $939 million, $862 million and $804 million for fiscal years 2022, 2021 and 2020, respectively. The weighted average period for this cost to be recognized was 1.80 years, 1.78 years and 1.76 years for fiscal years 2022, 2021, and 2020, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods. The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. Stock Options Stock options expire 10 years from the date of grant and vest over service periods that range from 6 months to 4 years. All options are granted at the average of the high and low prices of the Company’s Common Stock on the New York Stock Exchange on the date of grant. The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2022, 2021, and 2020 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson & Johnson options with a life of 2 years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant. The average fair value of options granted was $23.23, $20.86 and $16.42, in fiscal years 2022, 2021 and 2020, respectively. The fair value was estimated based on the weighted average assumptions of: 2022 2021 2020 Risk-free rate 1.98 % 0.83 % 1.47 % Expected volatility 18.00 % 18.59 % 15.33 % Expected life (in years) 7.0 7.0 7.0 Expected dividend yield 2.70 % 2.50 % 2.60 % A summary of option activity under the Plan as of January 1, 2023, January 2, 2022 and January 3, 2021, and changes during the years ending on those dates is presented below: (Shares in Thousands) Outstanding Shares Weighted Aggregate Shares at December 29, 2019 111,637 $ 105.63 $ 4,478 Options granted 20,723 151.41 Options exercised (16,275) 86.05 Options canceled/forfeited (1,835) 137.62 Shares at January 3, 2021 114,250 116.22 4,703 Options granted 18,525 164.62 Options exercised (13,248) 97.48 Options canceled/forfeited (2,166) 149.75 Shares at January 2, 2022 117,361 125.36 5,364 Options granted 19,809 165.89 Options exercised (16,310) 100.15 Options canceled/forfeited (2,188) 160.56 Shares at January 1, 2023 118,672 $ 134.95 $ 4,949 The total intrinsic value of options exercised was $1,228 million, $919 million and $1,021 million in fiscal years 2022, 2021 and 2020, respectively. The following table summarizes stock options outstanding and exercisable at January 1, 2023: (Shares in Thousands) Outstanding Exercisable Exercise Price Range Options Average Life (1) Weighted Average Exercise Price Options Weighted Average Exercise Price $72.54-$100.48 17,221 1.5 $93.07 17,221 $93.07 $101.87-$115.67 22,039 3.6 $108.78 22,039 $108.78 $129.51-$141.06 24,870 5.7 $130.88 24,228 $130.85 $151.41-$164.62 35,465 7.6 $157.75 150 $156.21 $164.63-$165.89 19,077 9.1 $165.89 23 $165.89 118,672 5.8 $134.95 63,661 $113.06 (1) Average contractual life remaining in years. Stock options outstanding at January 2, 2022 and January 3, 2021 were 117,361 and an average life of 5.8 years and 114,250 and an average life of 6.0 years, respectively. Stock options exercisable at January 2, 2022 and January 3, 2021 were 62,742 at an average price of $104.42 and 61,289 at an average price of $96.97, respectively. Restricted Share Units and Performance Share Units The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson & Johnson Common Stock after the end of a three-year performance period. Performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted . A summary of the restricted share units and performance share units activity under the Plans as of January 1, 2023 is presented below: (Shares in Thousands) Outstanding Restricted Share Units Outstanding Performance Share Units Shares at January 2, 2022 14,122 2,312 Granted 5,154 753 Issued (4,866) (637) Canceled/forfeited/adjusted (794) (71) Shares at January 1, 2023 13,616 2,357 The average fair value of the restricted share units granted was $153.67, $152.62 and $139.58 in fiscal years 2022, 2021 and 2020, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $591 million, $611 million and $650 million in 2022, 2021 and 2020, respectively. The weighted average fair value of the performance share units granted was $170.46, $179.35 and $160.54 in fiscal years 2022, 2021 and 2020, calculated using the weighted average fair market value for each of the component goals at the date of grant.

Segments of Business and Geogra

Segments of Business and Geographic Areas	12 Months Ended
	Jan. 02, 2022
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	Segments of Business* and Geographic Areas Sales to Customers % Change (Dollars in Millions) 2022 2021 2020 ’22 vs. ’21 ’21 vs. ’20 CONSUMER HEALTH (1) OTC U.S. $ 2,782 2,594 2,460 7.3 % 5.4 International 3,249 3,034 2,761 7.1 9.9 Worldwide 6,031 5,627 5,221 7.2 7.8 Skin Health/Beauty U.S. 2,337 2,400 2,350 (2.6) 2.1 International 2,015 2,141 2,100 (5.9) 1.9 Worldwide 4,352 4,541 4,450 (4.2) 2.0 Oral Care U.S. 635 637 683 (0.3) (6.7) International 871 1,008 958 (13.6) 5.1 Worldwide 1,505 1,645 1,641 (8.5) 0.2 Baby Care U.S. 357 378 376 (5.5) 0.5 International 1,104 1,188 1,141 (7.1) 4.1 Worldwide 1,461 1,566 1,517 (6.7) 3.2 Women's Health U.S. 13 13 13 1.7 (1.6) International 891 905 888 (1.5) 1.8 Worldwide 904 917 901 (1.5) 1.8 Wound Care/Other U.S. 475 495 480 (4.0) 3.1 International 224 243 240 (8.0) 1.7 Worldwide 700 739 720 (5.3) 2.6 TOTAL CONSUMER HEALTH U.S. 6,599 6,516 6,362 1.3 2.4 International 8,354 8,519 8,088 (1.9) 5.3 Worldwide 14,953 15,035 14,450 (0.5) 4.0 PHARMACEUTICAL (1) Immunology U.S. 11,036 10,843 10,175 1.8 6.6 International 5,899 5,907 4,880 (0.1) 21.0 Worldwide 16,935 16,750 15,055 1.1 11.3 REMICADE U.S. 1,417 2,019 2,508 (29.8) (19.5) U.S. Exports 204 236 346 (13.6) (31.9) International 722 935 893 (22.8) 4.8 Worldwide 2,343 3,190 3,747 (26.6) (14.9) SIMPONI / SIMPONI ARIA U.S. 1,166 1,127 1,155 3.5 (2.4) International 1,017 1,148 1,088 (11.4) 5.5 Worldwide 2,184 2,276 2,243 (4.0) 1.4 STELARA U.S. 6,388 5,938 5,240 7.6 13.3 International 3,335 3,196 2,467 4.4 29.6 Worldwide 9,723 9,134 7,707 6.5 18.5 TREMFYA U.S. 1,844 1,503 926 22.7 62.3 International 824 624 421 32.0 48.2 Worldwide 2,668 2,127 1,347 25.4 57.9 OTHER IMMUNOLOGY U.S. 17 21 — (18.4) ** International 0 3 11 ** (73.3) Worldwide 17 24 11 (28.2) ** Infectious Diseases U.S. 1,680 2,249 1,735 (25.3) 29.7 International 3,769 3,576 1,808 5.4 97.8 Worldwide 5,449 5,825 3,543 (6.5) 64.4 COVID-19 VACCINE U.S. 120 634 — (81.1) ** International 2,059 1,751 — 17.6 ** Worldwide 2,179 2,385 — (8.6) ** EDURANT / rilpivirine U.S. 36 41 44 (10.8) (7.6) International 972 953 920 2.0 3.6 Worldwide 1,008 994 964 1.5 3.1 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 1,494 1,508 1,587 (1.0) (4.9) International 449 575 597 (21.9) (3.6) Worldwide 1,943 2,083 2,184 (6.7) (4.6) OTHER INFECTIOUS DISEASES U.S. 30 66 104 (55.5) (36.0) International 289 297 292 (2.6) 1.7 Worldwide 318 363 396 (12.3) (8.3) Neuroscience U.S. 3,570 3,347 3,091 6.7 8.3 International 3,323 3,641 3,435 (8.7) 6.0 Worldwide 6,893 6,988 6,526 (1.4) 7.1 CONCERTA / methylphenidate U.S. 151 172 183 (12.5) (5.8) International 493 495 439 (0.4) 12.8 Worldwide 644 667 622 (3.5) 7.3 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 2,714 2,550 2,314 6.5 10.2 International 1,426 1,472 1,339 (3.1) 10.0 Worldwide 4,140 4,022 3,653 3.0 10.1 RISPERDAL CONSTA U.S. 257 287 296 (10.4) (2.9) International 228 305 346 (25.3) (11.8) Worldwide 485 592 642 (18.1) (7.7) OTHER NEUROSCIENCE U.S. 447 338 298 32.4 13.3 International 1,176 1,368 1,312 (14.1) 4.3 Worldwide 1,623 1,706 1,610 (4.9) 6.0 Oncology U.S. 6,930 5,958 5,092 16.3 17.0 International 9,052 8,590 7,275 5.4 18.1 Worldwide 15,983 14,548 12,367 9.9 17.6 DARZALEX U.S. 4,210 3,169 2,232 32.8 42.0 International 3,767 2,854 1,958 32.0 45.8 Worldwide 7,977 6,023 4,190 32.4 43.8 ERLEADA U.S. 968 813 583 19.2 39.3 International 913 478 176 ** * * Worldwide 1,881 1,291 760 45.7 70.0 IMBRUVICA U.S. 1,390 1,747 1,821 (20.4) (4.0) International 2,394 2,622 2,307 (8.7) 13.6 Worldwide 3,784 4,369 4,128 (13.4) 5.8 ZYTIGA / abiraterone acetate U.S. 74 119 373 (37.8) (68.1) International 1,696 2,178 2,097 (22.1) 3.9 Worldwide 1,770 2,297 2,470 (22.9) (7.0) OTHER ONCOLOGY U.S. 289 110 83 ** 31.7 International 283 458 738 (38.3) (37.9) Worldwide 571 568 821 0.6 (30.8) Pulmonary Hypertension U.S. 2,346 2,365 2,133 (0.8) 10.9 International 1,071 1,085 1,015 (1.3) 6.9 Worldwide 3,417 3,450 3,148 (1.0) 9.6 OPSUMIT U.S. 1,132 1,147 1,008 (1.3) 13.7 International 651 672 631 (3.2) 6.6 Worldwide 1,783 1,819 1,639 (2.0) 11.0 UPTRAVI U.S. 1,104 1,056 955 4.5 10.5 International 218 181 138 20.4 31.1 Worldwide 1,322 1,237 1,093 6.9 13.1 OTHER U.S. 110 163 169 (32.3) (3.7) International 202 232 247 (12.8) (5.9) Worldwide 313 395 416 (20.8) (5.0) Cardiovascular / Metabolism / Other U.S. 3,042 3,192 3,509 (4.7) (9.0) International 845 927 1,025 (8.9) (9.6) Worldwide 3,887 4,119 4,534 (5.6) (9.2) XARELTO U.S. 2,473 2,438 2,345 1.4 4.0 International — — — — — Worldwide 2,473 2,438 2,345 1.4 4.0 INVOKANA/ INVOKAMET U.S. 193 308 564 (37.4) (45.4) International 255 254 231 0.1 9.9 Worldwide 448 563 795 (20.4) (29.3) OTHER (2) U.S. 376 446 600 (15.5) (25.7) International 590 673 794 (12.3) (15.2) Worldwide 966 1,119 1,394 (13.6) (19.7) TOTAL PHARMACEUTICAL U.S. 28,604 27,954 25,735 2.3 8.6 International 23,959 23,726 19,440 1.0 22.0 Worldwide 52,563 51,680 45,175 1.7 14.4 MEDTECH* (3) Interventional Solutions U.S. 2,169 1,836 1,452 18.2 26.4 International 2,131 2,135 1,594 (0.2) 34.0 Worldwide 4,300 3,971 3,046 8.3 30.4 Orthopaedics U.S. 5,321 5,126 4,779 3.8 7.3 International 3,267 3,462 2,984 (5.6) 16.0 Worldwide 8,587 8,588 7,763 0.0 10.6 HIPS U.S. 943 878 793 7.3 10.7 International 571 602 487 (5.1) 23.6 Worldwide 1,514 1,480 1,280 2.3 15.6 KNEES U.S. 851 787 743 8.2 5.9 International 508 538 427 (5.7) 26.1 Worldwide 1,359 1,325 1,170 2.6 13.3 TRAUMA U.S. 1,882 1,819 1,648 3.5 10.4 International 989 1,066 966 (7.2) 10.4 Worldwide 2,871 2,885 2,614 (0.5) 10.4 SPINE, SPORTS & OTHER U.S. 1,645 1,642 1,595 0.2 2.9 International 1,198 1,256 1,104 (4.6) 13.8 Worldwide 2,843 2,898 2,699 (1.9) 7.4 Surgery U.S. 3,897 3,867 3,249 0.8 19.0 International 5,793 5,945 4,983 (2.6) 19.3 Worldwide 9,690 9,812 8,232 (1.2) 19.2 ADVANCED U.S. 1,784 1,761 1,535 1.3 14.9 International 2,785 2,861 2,304 (2.6) 24.1 Worldwide 4,569 4,622 3,839 (1.1) 20.4 GENERAL U.S. 2,113 2,105 1,714 0.4 22.7 International 3,008 3,085 2,679 (2.5) 15.2 Worldwide 5,121 5,190 4,392 (1.3) 18.1 Vision U.S. 1,990 1,857 1,557 7.2 19.3 International 2,859 2,831 2,362 1.0 19.8 Worldwide 4,849 4,688 3,919 3.4 19.6 CONTACT LENSES / OTHER U.S. 1,522 1,398 1,213 8.9 15.2 International 2,022 2,043 1,781 (1.0) 14.7 Worldwide 3,543 3,440 2,994 3.0 14.9 SURGICAL U.S. 468 459 344 2.0 33.5 International 837 788 581 6.2 35.7 Worldwide 1,306 1,248 925 4.6 34.9 TOTAL MEDTECH U.S. 13,377 12,686 11,036 5.4 14.9 International 14,050 14,374 11,923 (2.3) 20.6 Worldwide 27,427 27,060 22,959 1.4 17.9 WORLDWIDE U.S. 48,580 47,156 43,133 3.0 9.3 International 46,363 46,619 39,451 (0.6) 18.2 Worldwide $ 94,943 93,775 82,584 1.3 % 13.6 *Certain prior year amounts have been reclassified to conform to current year presentation **Percentage greater than 100% or not meaningful (1) Approximately $0.4 billion in both the fiscal 2021 and 2020, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes (2) Inclusive of PROCRIT / EPREX which was previously disclosed separately (3) Pr eviously referred to as Medical Devices Income (Loss) Before Tax* Identifiable Assets (Dollars in Millions) 2022 (3) 2021 (4) 2020 (5) 2022 2021 Consumer Health $ 2,930 1,573 (852) $ 24,068 25,081 Pharmaceutical 15,901 17,969 15,250 58,436 64,376 MedTech 4,607 4,373 3,044 70,956 53,372 Total 23,438 23,915 17,442 153,460 142,829 Less: Expense not allocated to segments (1) 624 1,072 945 Less: Consumer Health separation costs 1,089 67 General corporate (2) 33,918 39,189 Worldwide total $ 21,725 22,776 16,497 $ 187,378 182,018 *Income before tax of approximately $0.2 billion and $0.2 billion in the fiscal years 2021 and 2020, respectively, has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes Additions to Property, Depreciation and (Dollars in Millions) 2022 2021 2020 2022 2021 2020 Consumer Health $ 323 331 248 $ 658 759 785 Pharmaceutical 1,374 1,198 863 3,687 4,029 4,006 MedTech 2,120 1,933 1,980 2,302 2,286 2,140 Segments total 3,817 3,462 3,091 6,647 7,074 6,931 General corporate 192 190 256 323 316 300 Worldwide total $ 4,009 3,652 3,347 $ 6,970 7,390 7,231 Sales to Customers Long-Lived Assets (6) (Dollars in Millions) 2022 2021 2020 2022 2021 United States $ 48,580 47,156 43,133 $ 66,283 48,586 Europe 23,449 23,594 18,980 38,774 43,257 Western Hemisphere excluding U.S. 6,125 5,750 5,335 2,737 2,708 Asia-Pacific, Africa 16,789 17,275 15,136 4,431 5,035 Segments total 94,943 93,775 82,584 112,225 99,586 General corporate 1,134 1,014 Other non long-lived assets 74,019 81,418 Worldwide total $ 94,943 93,775 82,584 $ 187,378 182,018 See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In fiscal year 2022, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.5%, 13.0% and 12.0% of the total consolidated revenues. In fiscal year 2021, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0%, and 12.0% of the total consolidated revenues. (1) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. (2) General corporate includes cash, cash equivalents and marketable securities. (3) Consumer Health includes: • Litigation expense of $0.2 billion • A restructuring related charge of $0.1 billion Pharmaceutical includes: • One-time COVID-19 Vaccine manufacturing exit related costs of $1.5 billion • An intangible asset impairment charge of approximately $0.8 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS • Litigation expense of $0.1 billion • Loss of $0.7 billion related to the change in the fair value of securities • A restructuring related charge of $0.1 billion MedTech includes: • Litigation expense of $0.6 billion primarily for pelvic mesh related costs • A restructuring related charge of $0.3 billion • Acquisition and integration related costs of $0.3 billion primarily related to the acquisition of Abiomed • A Medical Device Regulation charge of $0.3 billion (4) Consumer Health includes: • Litigation expense of $1.6 billion, primarily talc related costs • A restructuring related charge of $0.1 billion Pharmaceutical includes: • Litigation expense of $0.6 billion, primarily related to Risperdal Gynecomastia • Divestiture gains of $0.6 billion • Gains of $0.5 billion related to the change in the fair value of securities • A restructuring related charge of $0.1 billion MedTech includes: • A restructuring related charge of $0.3 billion • An in-process research and development expense of $0.9 billion related to Ottava • A Medical Device Regulation charge of $0.2 billion • Litigation expense of $0.1 billion (5) Consumer Health includes: • Litigation expense of $3.9 billion, primarily talc related costs and certain settlements. Pharmaceutical includes: • Litigation expense of $0.8 billion, primarily related to the agreement in principle to settle opioid litigation • A gain of $0.5 billion related to the change in the fair value of securities • A restructuring related charge of $0.1 billion MedTech includes: • A contingent consideration reversal of $1.1 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. • Litigation expense of $0.3 billion • A restructuring related charge of $0.3 billion • An in-process research and development expense of $0.2 billion • A Medical Device Regulation charge of $0.1 billion (6) Long-lived assets include property, plant and equipment, net for fiscal years 2022, and 2021 of $19,803 and $18,962, respectively, and intangible assets and goodwill, net for fiscal years 2022 and 2021 of $93,556 and $81,638, respectively.

Acquisitions and Divestitures

Acquisitions and Divestitures	12 Months Ended
	Jan. 02, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions and Divestitures	Acquisitions and Divestitures During the fiscal year 2022, certain businesses were acquired for $17.7 billion in cash and $1.1 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $17.3 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. The fiscal year 2022 acquisitions primarily included Abiomed, Inc. (Abiomed). The remaining acquisitions were not material. On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Company’s position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcare’s largest areas of unmet need. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $380.00 per share in cash, amounting to $17.1 billion, net of cash acquired, as well as a non-tradeable contingent value right (“CVR”) entitling the holder to receive up to $35.00 per share in cash (which with respect to the CVRs total approximately $1.6 billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $16.5 billion includes cash, cash equivalents and marketable securities acquired. The milestones of the CVR consist of: a. $17.50 per share, payable if net sales for Abiomed products exceeds $3.7 billion during Johnson & Johnson’s fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson & Johnson’s fiscal first quarter of 2029, $8.75 per share; b. $7.50 per share payable upon FDA premarket application approval of the use of Impella ® products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028; and c. $10.00 per share payable upon the first publication of a Class I recommendation for the use of Impella ® products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029. The fair value of the acquisition was allocated to assets acquired of $19.9 billion (net of $0.3 billion cash acquired), primarily to goodwill for $10.9 billion, amortizable intangible assets for $6.6 billion, IPR&D for $1.1 billion, marketable securities of $0.6 billion and liabilities assumed of $2.8 billion, which includes the fair value of the contingent consideration mentioned above for $0.7 billion and deferred taxes of $1.8 billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities on the Consolidated Balance Sheet. As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date. The amortizable intangible assets were primarily comprised of already in-market products of the Impella ® platform with an average weighted life of 14 years. The IPR&D assets were valued for technology programs for unapproved products. The value of the IPR&D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52% to 70%. The discount rate applied was 9.5%. In 2022, the Company recorded acquisition related costs before tax of approximately $0.3 billion, which was recorded in Other (income)/expense. During fiscal year 2021, the Company did not make any material acquisitions. During fiscal year 2020, certain businesses were acquired for $7.3 billion in cash and $0.4 billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition. The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $7.5 billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. The fiscal year 2020 acquisitions primarily included: all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc. (XBiotech), Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases and the outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities. During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8 billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.8 billion applying a probability of success factor that ranged from 20% to 60% to reflect inherent development, regulatory and commercial risk for the different indications. The discount rate applied was approximately 16%. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. In fiscal 2022, the Company recorded an intangible asset impairment charge of approximately $0.8 billion related to this in-process research and development asset. Additionally, in the fiscal first quarter of 2020, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the MedTech segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&D, for $0.4 billion, goodwill for $0.2 billion, other assets of $0.2 billion and liabilities assumed of $0.3 billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4 billion. On October 1, 2020, the Company completed the acquisition of Momenta for a purchase price of approximately $6.1 billion, net of cash acquired. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets (IPR&D) of $6.0 billion, goodwill of $1.2 billion, other assets of $0.5 billion and liabilities of $1.6 billion. The assets acquired are intended to address substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Depending on the asset, probability of success factors ranging from 20% to 77% were used in the fair value calculation to reflect inherent development and regulatory risk of the IPR&D. The discount rate applied was approximately 13%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. In accordance with U.S. GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2022, 2021 and 2020 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company’s results of operations. Divestitures During fiscal year 2022, the Company did not make any material divestitures. During fiscal year 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6 billion.

Legal Proceedings

Legal Proceedings	12 Months Ended
	Jan. 01, 2023
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal Proceedings Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of January 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period. PRODUCT LIABILITY The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; body powders containing talc, primarily JOHNSON'S Baby Powder; ETHICON PHYSIOMESH Flexible Composite Mesh; ELMIRON; and TYLENOL. As of January 1, 2023, in the United States there were approximately 170 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; 1,400 with respect to the PINNACLE Acetabular Cup System; 9,000 with respect to pelvic meshes; 1,100 with respect to RISPERDAL; 40,300 with respect to body powders containing talc; 2,100 with respect to ETHICON PHYSIOMESH Flexible Composite Mesh; 2,000 with respect to ELMIRON; and 170 with respect to TYLENOL. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation. Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. Prior to 2019, several adverse verdicts had been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon’s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company’s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon’s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia, pending Federal Court approval. In November 2022, the application for approval of the settlement was filed, and a hearing on the settlement has been scheduled for the end of February 2023. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon’s pelvic mesh products. Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 2,236 have been dismissed with prejudice. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of January 2023, there are approximately 208 active cases subject to these orders which are being reviewed and evaluated. Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products. All litigation activities in the two New Jersey MCLs are stayed pending resolution of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements. The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company’s accruals. Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); the Company; and JPI’s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and the Company announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation. A significant number of personal injury claims alleging that talc causes cancer were made against Johnson & Johnson Consumer Inc. and the Company arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor’s direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI’s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers’ compensation statute or act (the Talc-Related Liabilities). In October 2021, notwithstanding the Company’s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay. In May 2022, the Third Circuit Court of Appeals granted the petitions to appeal. The briefing and oral argument on the appeal were completed in September 2022. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court’s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy. LTL filed a petition for rehearing on the decision. While the New Jersey Bankruptcy Court’s order effectively stays all of the Company’s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed. The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $2 billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2 billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued. A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that the Company fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by the Company’s then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New Jersey. In July 2022, Imerys filed a motion in the Imerys Bankruptcy to stay the Edley Class Action, which was denied in August 2022. In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants’ Committee (TCC), and the Future Claimants’ Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent’s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn. In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, certain of Imerys’s insurers, and certain parties in the Cyprus Mines chapter 11 case (described below) (collectively the Mediation Parties) agreed to engage in mediation. The most recent term of the mediation ended on December 31, 2022. In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company’s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys Adversary Proceeding. In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC) (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing “talc-related claims” against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023. In February 2021, several of the Company’s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the LTL automatic stay applied to the Coverage Action. In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder, and that purchasers of the Company’s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiff’s motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff’s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In April 2022, Defendants filed a second motion to supplement the class certification record. In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action. Plaintiff has appealed the Bankruptcy Court’s order. A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California’s Consumer Legal Remedies Act (CLRA) relating to JOHNSON’S Baby Powder. In that lawsuit, the plaintiffs allege that the Company violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company’s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance. In February 2022, the Bankruptcy Court issued an order extending the stay. The appeal continues to be held in abeyance, with the Company being required to file periodic status updates. In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries. Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of INVOKANA, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability laws

Restructuring

Restructuring	12 Months Ended
	Jan. 01, 2023
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the fiscal second quarter of 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In fiscal year 2022, the Company recorded a pre-tax charge of $0.5 billion, which is included on the following lines of the Consolidated Statement of Earnings, $0.3 billion in restructuring, $0.1 billion in other (income) expense and $0.1 billion in cost of products sold. Total project costs of approximately $2.2 billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2022. The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2022: (Dollars in Millions) Severance Asset Write-offs/Sales Other (2) Total Reserve balance, January 3, 2021 $ 135 — 9 144 2021 activity (23) — 16 (7) Reserve balance, January 2, 2022 112 — 25 137 Current year activity: Charges — 15 448 463 Cash settlements (37) 44 (3) (439) (432) Settled non cash — (59) (59) Reserve balance, January 1, 2023 (1) $ 75 — 34 109 (1) Although the restructuring program has been completed in the fiscal year 2022, the Company expects that severance charges will continue beyond that date. The reserve balance as of January 1, 2023 is recorded in the Employee Related Obligation account in the Consolidated Balance Sheet. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Represents gain on sale of assets

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jan. 01, 2023
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Johnson & Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.
Description of the Company And Business Segments	Description of the Company and Business Segments The Company has approximately 152,700 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being. The Company is organized into three business segments: Consumer Health, Pharmaceutical and MedTech. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women’s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on the following therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. In November 2021, the Company announced its intention to separate the Company’s Consumer Health business (Kenvue as the name for the planned New Consumer Health Company), with the intention to create a new, publicly traded company by the end of the fiscal year 2023.
New Accounting Standards	New Accounting Standards Recently Adopted Accounting Standards There were no new material accounting standards adopted in fiscal 2022. Recently Issued Accounting Standards Not Adopted as of January 1, 2023 ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) – Disclosure of Supplier Finance Program Obligations This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity’s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures and will adopt this standard in the fiscal first quarter of 2023.
Cash Equivalents	Cash Equivalents The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs). RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.
Investments	Investments Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and
Property, Plant and Equipment and Depreciation	Property, Plant and Equipment and Depreciation Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily t he Managed Care, Medicare and Medicaid programs, which amounted to $9.6 billion and $7.7 billion as of January 1, 2023 and January 2, 2022, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information. Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals. Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years 2022, 2021 and 2020. Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in fiscal year 2022 and less than 3.0% of the total revenues in fiscal years 2021 and 2020 and are included in sales to customers.
Shipping and Handling	Shipping and Handling Shipping and handling costs incurred were $1.1 billion, $1.1 billion and $1.0 billion in fiscal years 2022, 2021 and 2020, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 1.0% of sales to customers for all periods presented.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.
Intangible Assets and Goodwill	Intangible Assets and Goodwill The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2022 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying program. Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill.
Financial Instruments	Financial Instruments As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments.
Leases	Leases The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in Other assets Accrued liabilities Other liabilities ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $1.1 billion and $0.9 billion in fiscal years 2022 and 2021, respectively. The lease liability was $1.3 billion and $1.0 billion in fiscal years 2022 and 2021, respectively. The operating lease costs were $0.3 billion in fiscal years 2022, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3 billion in fiscal years 2022, 2021 and 2020, respectively.
Product Liability	Product Liability Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company
Research and Development	Research and Development Research and development expenses are expensed as incurred in accordance with ASC 730, Research and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows: Nature/Type of Collaboration Statement of Earnings Presentation Third-party sale of product & profit share payments received Sales to customers Royalties/milestones paid to collaborative partner (post-regulatory approval)* Cost of products sold Royalties received from collaborative partner Other income (expense), net Upfront payments & milestones paid to collaborative partner (pre-regulatory approval) Research and development expense Research and development payments to collaborative partner Research and development expense Research and development payments received from collaborative partner or government entity Reduction of Research and development expense * Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life. For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense. The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG and IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company. Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.
Advertising	Advertising Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.1 billion, $2.7 billion and $2.1 billion in fiscal years 2022, 2021 and 2020, respectively.
Income Taxes	Income Taxes Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2022 was approximately $6.1 billion, of which $4.6 billion is classified as noncurrent and reflected as “Long-term taxes payable” on the Company’s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., “period cost”) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., “deferred method”). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost. See Note 8 to the Consolidated Financial Statements for further information regarding income taxes.
Net Earnings Per Share	Net Earnings Per Share Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.
Annual Closing Date	Annual Closing Date The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.
Reclassification	Reclassification Certain prior period amounts have been reclassified to conform to current year presentation.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jan. 01, 2023
Accounting Policies [Abstract]
Estimated Useful Lives of Assets	Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets: Building and building equipment 30 years Land and leasehold improvements 10 - 20 years Machinery and equipment 2 - 13 years

Cash, Cash Equivalents and Cu_2

Cash, Cash Equivalents and Current Marketable Securities (Tables)	12 Months Ended
	Jan. 01, 2023
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalent Composition	At the end of the fiscal year 2022 and 2021, cash, cash equivalents and current marketable securities were comprised of: (Dollars in Millions) 2022 Carrying Amount Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 4,926 — 4,926 4,926 — U.S. Reverse repurchase agreements 1,419 — 1,419 1,419 — Corporate debt securities (1) 873 (1) 872 — 873 Money market funds 5,368 — 5,368 5,368 — Time deposits (1) 446 — 446 446 — Subtotal $ 13,032 (1) 13,031 12,159 873 U.S. Gov't Securities $ 9,959 (28) 9,931 1,922 8,009 U.S. Gov't Agencies 210 (5) 205 — 205 Corporate and other debt securities 352 (1) 351 46 305 Subtotal available for sale (2) $ 10,521 (34) 10,487 1,968 8,519 Total cash, cash equivalents and current marketable securities $ 14,127 9,392 (Dollars in Millions) 2021 Carrying Amount Unrecognized Loss Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,936 — 2,936 2,936 — Non-U.S. Sovereign Securities (1) 1,006 — 1,006 90 916 U.S. Reverse repurchase agreements 1,659 — 1,659 1,659 — Corporate debt securities (1) 3,479 (1) 3,478 200 3,279 Money market funds 1,901 — 1,901 1,901 — Time deposits (1) 900 — 900 900 — Subtotal 11,881 (1) 11,880 7,686 4,195 U.S. Gov't Securities $ 19,485 (4) 19,481 6,785 12,696 Corporate and other debt securities 246 — 246 16 230 Subtotal available for sale (2) $ 19,731 (4) 19,727 6,801 12,926 Total cash, cash equivalents and current marketable securities $ 14,487 17,121 (1) Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Contractual Maturities of Available for Sale Securities	The contractual maturities of the available for sale debt securities at January 1, 2023 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 10,430 10,399 Due after one year through five years 91 88 Due after five years through ten years — — Total debt securities $ 10,521 10,487

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Jan. 01, 2023
Inventory Disclosure [Abstract]
Summary of Inventories	At the end of fiscal years 2022 and 2021, inventories were comprised of: (Dollars in Millions) 2022 2021 Raw materials and supplies $ 2,070 1,592 Goods in process 1,700 2,287 Finished goods 8,713 6,508 Total inventories $ 12,483 10,387

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Jan. 01, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment at Cost and Accumulated Depreciation	At the end of fiscal years 2022 and 2021, property, plant and equipment at cost and accumulated depreciation were: (Dollars in Millions) 2022 2021 Land and land improvements $ 859 884 Buildings and building equipment 12,989 12,882 Machinery and equipment 30,431 29,774 Construction in progress 4,974 4,139 Total property, plant and equipment, gross $ 49,253 47,679 Less accumulated depreciation 29,450 28,717 Total property, plant and equipment, net $ 19,803 18,962

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
	Jan. 01, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	At the end of fiscal years 2022 and 2021, the gross and net amounts of intangible assets were: (Dollars in Millions) 2022 2021 Intangible assets with definite lives: Patents and trademarks — gross $ 44,012 38,572 Less accumulated amortization (22,266) (20,088) Patents and trademarks — net (1) $ 21,746 18,484 Customer relationships and other intangibles — gross $ 22,987 23,011 Less accumulated amortization (12,901) (11,925) Customer relationships and other intangibles — net (2) $ 10,086 11,086 Intangible assets with indefinite lives: Trademarks $ 6,807 6,985 Purchased in-process research and development (3) 9,686 9,837 Total intangible assets with indefinite lives $ 16,493 16,822 Total intangible assets — net $ 48,325 46,392 (1) The change was primarily related to the intangible assets acquired with the acquisition of Abiomed, Inc. which was partially offset by amortization expense of previously existing intangible assets and the result of currency translation effects. (2) The majority is comprised of customer relationships (3) The reduction was primarily related to an intangible asset impairment charge of approximately
Goodwill	Goodwill as of January 1, 2023 and January 2, 2022, as allocated by segment of business, was as follows: (Dollars in Millions) Consumer Health Pharmaceutical MedTech Total Goodwill at January 3, 2021 $ 10,336 11,009 15,048 36,393 Goodwill, related to acquisitions — — — — Goodwill, related to divestitures (9) — — (9) Currency translation/other (517) (429) (192) (1,138) Goodwill at January 2, 2022 $ 9,810 10,580 14,856 35,246 Goodwill, related to acquisitions — — 11,056 11,056 Goodwill, related to divestitures — — — — Currency translation/other (626) (396) (49) (1,071) Goodwill at January 1, 2023 $ 9,184 10,184 25,863 45,231
Intangible Asset Amortization Expense	The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately: (Dollars in Millions) 2023 2024 2025 2026 2027 $4,600 4,400 3,600 3,000 2,400

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jan. 01, 2023
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January 1, 2023 and January 2, 2022, net of tax: January 1, 2023 January 2, 2022 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (1,098) — — — — (109) — Derivatives designated as hedging instruments — — — 1,098 — — — — 109 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing $ — — — 140 — — — — 174 — Amount of gain or (loss) recognized in AOCI — — — 140 — — — — 174 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (72) (271) 149 — (23) 17 119 30 — 47 Amount of gain or (loss) recognized in AOCI 5 319 61 — (113) (94) (557) 123 — 146 Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 425 — — — — 402 — Amount of gain or (loss) recognized in AOCI $ — — — 42 — — — — 9 — As of January 1, 2023 and January 2, 2022, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) January 1, 2023 January 2, 2022 January 1, 2023 January 2, 2022 Long-term Debt $ 8,665 $ 9,793 $ (1,435) $ (142)
Schedule of Effect of Derivatives not Designated as Hedging Instruments	The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January 1, 2023 and January 2, 2022: (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Gain/(Loss) Derivatives Not Designated as Hedging Instruments January 1, 2023 January 2, 2022 Foreign Exchange Contracts Other (income) expense $ 94 (70)
Schedule of Effect of Net Investment Hedges	The following table is the effect of net investment hedges for the fiscal years ended January 1, 2023 and January 2, 2022: Gain/(Loss) Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From (Dollars in Millions) January 1, 2023 January 2, 2022 January 1, 2023 January 2, 2022 Debt $ 197 387 Interest (income) expense — — Cross Currency interest rate swaps $ 766 548 Interest (income) expense — —
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments for the fiscal years ended January 1, 2023 and January 2, 2022: January 2, 2022 January 1, 2023 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,884 (538) (770) 576 576 Equity Investments without readily determinable value $ 500 91 107 698 698 January 3, 2021 January 2, 2022 (Dollars in Millions) Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 1,481 198 205 1,884 1,884 Equity Investments without readily determinable value $ 738 394 (632) 500 500 (1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of the fiscal year ended January 1, 2023 and January 2, 2022 were as follows: 2022 2021 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 629 — 629 540 Interest rate contracts (2) — 1,534 — 1,534 796 Total $ — 2,163 — 2,163 1,336 Liabilities: Forward foreign exchange contracts — 511 — 511 881 Interest rate contracts (2) — 2,778 — 2,778 979 Total $ — 3,289 — 3,289 1,860 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 38 — 38 24 Liabilities: Forward foreign exchange contracts — 68 — 68 28 Available For Sale Other Investments: Equity investments (3) 576 — — 576 1,884 Debt securities (4) — 10,487 — 10,487 19,727 Other Liabilities Contingent Consideration (5) $ 1,120 1,120 533 Gross to Net Derivative Reconciliation 2022 2021 (Dollars in Millions) Total Gross Assets $ 2,201 1,360 Credit Support Agreement (CSA) (2,176) (1,285) Total Net Asset 25 75 Total Gross Liabilities 3,357 1,888 Credit Support Agreement (CSA) (3,023) (1,855) Total Net Liabilities $ 334 33 Summarized information about changes in liabilities for contingent consideration is as follows: 2022 2021 2020 (Dollars in Millions) Beginning Balance $ 533 633 1,715 Changes in estimated fair value (6) (194) (52) (1,089) Additions (7) 792 — 106 Payments (11) (48) (99) Ending Balance $ 1,120 533 633 (1) 2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3. (2) Includes cross currency interest rate swaps and interest rate swaps. (3) Classified as non-current other assets. (4) Classified as cash equivalents and current marketable securities. (5) Includes $1,116 million, $520 million and $594 million, classified as non-current other liabilities as of January 1, 2023, January 2, 2022 and January 3, 2021, respectively. Includes $4 million, $13 million and $39 million classified as current liabilities as of January 1, 2023, January 2, 2022 and January 3, 2021, respectively. (6) Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense. The Company recorded a contingent consideration reversal of $1,148 million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense. (7) In fiscal year 2022, the Company recorded $704 million of contingent consideration related to Abiomed.

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Jan. 01, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The components of long-term debt are as follows: (Dollars in Millions) 2022 Effective Rate % 2021 Effective Rate % 0.250% Notes due 2022 (1B Euro 1.1311) (3) $ — — % $ 1,131 (3) 0.26 % 2.25% Notes due 2022 — — 1,000 2.31 6.73% Debentures due 2023 250 6.73 250 6.73 3.375% Notes due 2023 801 3.17 802 3.18 2.05% Notes due 2023 500 2.09 499 2.09 0.650% Notes due 2024 (750MM Euro 1.0651) (2) /(750MM Euro 1.1311) (3) 792 (2) 0.68 847 (3) 0.68 5.50% Notes due 2024 (500MM 1.2037 GBP ) (2) /(500MM GBP 1.3485) (3) 600 (2) 6.75 672 (3) 6.75 2.625% Notes due 2025 749 2.63 749 2.63 0.55% Notes due 2025 918 0.57 983 0.57 2.45% Notes due 2026 1,996 2.47 1,995 2.47 2.95% Notes due 2027 877 2.96 978 2.96 0.95% Notes due 2027 1,394 0.96 1,478 0.96 1.150% Notes due 2028 (750MM Euro 1.0651) (2) /(750MM Euro 1.1311) (3) 794 (2) 1.21 843 (3) 1.21 2.90% Notes due 2028 1,496 2.91 1,495 2.91 6.95% Notes due 2029 298 7.14 298 7.14 1.30% Notes due 2030 1,607 1.30 1,723 1.30 4.95% Debentures due 2033 498 4.95 498 4.95 4.375% Notes due 2033 854 4.24 854 4.24 1.650% Notes due 2035 (1.5B Euro 1.0651) (2) /(1.5B Euro 1.1311) (3) 1,591 (2) 1.68 1,683 (3) 1.68 3.55% Notes due 2036 842 3.59 974 3.59 5.95% Notes due 2037 993 5.99 993 5.99 3.625% Notes due 2037 1,336 3.64 1,475 3.64 5.85% Debentures due 2038 697 5.85 696 5.85 3.400% Notes due 2038 992 3.42 992 3.42 4.50% Debentures due 2040 540 4.63 540 4.63 2.10% Notes due 2040 828 2.14 974 2.14 4.85% Notes due 2041 297 4.89 297 4.89 4.50% Notes due 2043 496 4.52 496 4.52 3.70% Notes due 2046 1,976 3.74 1,975 3.74 3.75% Notes due 2047 812 3.76 971 3.76 3.500% Notes due 2048 743 3.52 743 3.52 2.250% Notes due 2050 808 2.29 983 2.29 2.450% Notes due 2060 1,055 2.49 1,222 2.49 Other 9 — 7 — Subtotal 28,439 (4) 3.04 % (1) 32,116 (4) 2.89 % (1) Less current portion 1,551 2,131 Total long-term debt $ 26,888 $ 29,985 (1) Weighted average effective rate. (2) Translation rate at January 1, 2023. (3) Translation rate at January 2, 2022. (4) The excess of the carrying value over the fair value of debt was $1.6 billion at the end of fiscal year 2022 and the excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021.
Aggregate Maturities of Long Term Obligations	Aggregate maturities of long-term debt obligations commencing in 2023 are: (Dollars in Millions) 2023 2024 2025 2026 2027 After 2026 $1,551 1,392 1,667 1,996 2,271 19,562

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jan. 01, 2023
Income Tax Disclosure [Abstract]
Provision for Income Taxes	The provision for taxes on income consists of: (Dollars in Millions) 2022 2021 2020 Currently payable: U.S. taxes $ 2,378 1,525 1,026 International taxes 3,069 2,452 1,898 Total currently payable 5,447 3,977 2,924 Deferred: U.S. taxes (2,081) 583 (76) International taxes 418 (2,662) (1,065) Total deferred (1,663) (2,079) (1,141) Provision for taxes on income $ 3,784 1,898 1,783
Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate	A comparison of income tax expense at the U.S. statutory rate of 21% in fiscal years 2022, 2021 and 2020, to the Company’s effective tax rate is as follows: (Dollars in Millions) 2022 2021 2020 U.S. $ 5,369 6,110 4,312 International 16,356 16,666 12,185 Earnings before taxes on income: $ 21,725 22,776 16,497 Tax rates: U.S. statutory rate 21.0 % 21.0 21.0 International operations (1) (4.5) (16.4) (9.9) Consumer health separation 2.2 — — U.S. taxes on international income (2) (1.9) 6.7 2.7 Tax benefits from loss on capital assets — (1.3) (1.2) Tax benefits on share-based compensation (1.3) (1.0) (1.5) All other (3) 1.9 (0.7) (0.3) Effective Rate 17.4 % 8.3 10.8 (1) For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below. (2) Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2022 amount includes the impact of certain provisions of the 2017 TCJA that became effective in fiscal 2022. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below. (3) Certain prior year amounts have been reclassified to conform to current year presentation.
Temporary Differences and Carryforwards	Temporary differences and carryforwards at the end of fiscal years 2022 and 2021 were as follows: 2022 Deferred Tax 2021 Deferred Tax (1) (Dollars in Millions) Asset Liability Asset Liability Employee related obligations $ 725 1,244 Stock based compensation 687 679 Depreciation of property, plant and equipment (858) (876) Goodwill and intangibles (4,271) (3) (2,659) (2) R&D capitalized for tax 2,611 1,664 Reserves & liabilities 2,761 2,882 Income reported for tax purposes 2,045 2,566 Net realizable operating loss carryforwards (4) 1,260 1,720 Undistributed foreign earnings 1,565 (1,693) 1,015 (1,461) Global intangible low-taxed income (3,547) (4,853) Miscellaneous international 1,053 (65) 870 (39) Miscellaneous U.S. 476 (16) Total deferred income taxes $ 13,183 (10,434) 12,640 (9,904) (1) Certain prior year amounts have been reclassified to conform to current year presentation. (2) Amount is inclusive of the $2.3 billion deferred tax asset established as part of the reorganized ownership structure of certain wholly-owned international subsidiaries, as previously described. (3) Amount is inclusive of the $1.8 billion deferred tax liability due to the acquisition of Abiomed.
Summary of Activity Related to Unrecognized Tax Benefits	The following table summarizes the activity related to unrecognized tax benefits: (Dollars in Millions) 2022 2021 2020 Beginning of year $ 3,323 3,373 3,853 Increases related to current year tax positions 523 242 265 Increases related to prior period tax positions 143 23 668 Decreases related to prior period tax positions (148) (128) (551) Settlements (1) (187) (839) Lapse of statute of limitations (11) — (23) End of year $ 3,829 3,323 3,373

Employee Related Obligations (T

Employee Related Obligations (Tables)	12 Months Ended
	Jan. 01, 2023
Compensation Related Costs [Abstract]
Employee Related Obligations	At the end of fiscal 2022 and fiscal 2021, employee related obligations recorded on the Consolidated Balance Sheets were: (Dollars in Millions) 2022 2021 Pension benefits $ 2,698 4,088 Postretirement benefits 1,734 2,069 Postemployment benefits 2,832 3,117 Deferred compensation 100 181 Total employee obligations 7,364 9,455 Less current benefits payable 597 557 Employee related obligations — non-current $ 6,767 8,898

Pensions and Other Benefit Pl_2

Pensions and Other Benefit Plans (Tables)	12 Months Ended
	Jan. 01, 2023
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2022, 2021 and 2020 include the following components: Retirement Plans Other Benefit Plans (Dollars in Millions) 2022 2021 2020 2022 2021 2020 Service cost $ 1,327 1,421 1,380 320 309 287 Interest cost 911 770 955 105 81 133 Expected return on plan assets (2,757) (2,645) (2,461) (8) (7) (7) Amortization of prior service cost (184) (181) 2 (5) (31) (31) Recognized actuarial losses (gains) 655 1,257 891 121 151 142 Curtailments and settlements 1 1 23 — — — Net periodic benefit cost (credit) $ (47) 623 790 533 503 524
Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation	The following table represents the weighted-average actuarial assumptions: Retirement Plans Other Benefit Plans Worldwide Benefit Plans 2022 2021 2020 2022 2021 2020 Net Periodic Benefit Cost Service cost discount rate 2.46 % 2.14 2.82 2.59 2.09 3.04 Interest cost discount rate 2.80 % 2.34 3.13 2.64 2.33 3.08 Rate of increase in compensation levels 4.02 % 4.01 4.00 4.21 4.25 4.25 Expected long-term rate of return on plan assets 7.25 % 7.71 8.12 Benefit Obligation Discount rate 5.01 % 2.49 2.14 5.42 2.68 2.23 Rate of increase in compensation levels 4.00 % 4.01 4.00 4.21 4.21 4.27
Assumed Health Care Cost Trend Rates	The following table displays the assumed healthcare cost trend rates, for all individuals: Healthcare Plans 2022 2021 Healthcare cost trend rate assumed for next year 5.99 % 5.33 % Rate to which the cost trend rate is assumed to decline (ultimate trend) 4.01 % 3.73 % Year the rate reaches the ultimate trend rate 2047 2046
Schedule of Net Funded Status	The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2022 and 2021 for the Company’s defined benefit retirement plans and other post-retirement plans: Retirement Plans Other Benefit Plans (Dollars in Millions) 2022 2021 2022 2021 Change in Benefit Obligation Projected benefit obligation — beginning of year $ 41,582 43,300 4,878 5,028 Service cost 1,327 1,421 320 309 Interest cost 911 770 105 81 Plan participant contributions 67 67 — — Amendments 7 5 — — Actuarial (gains) losses (1) (12,213) (2,132) (704) (188) Divestitures & acquisitions — (2) — — Curtailments, settlements & restructuring (7) (7) — — Benefits paid from plan (1,228) (1,157) (393) (348) Effect of exchange rates (815) (683) (9) (4) Projected benefit obligation — end of year $ 29,631 41,582 4,197 4,878 Change in Plan Assets Plan assets at fair value — beginning of year $ 41,930 38,195 102 90 Actual return (loss) on plan assets (8,665) 4,439 (17) 17 Company contributions 270 969 386 343 Plan participant contributions 67 67 — — Settlements (5) (7) — — Divestitures & acquisitions — (2) — — Benefits paid from plan assets (1,228) (1,157) (393) (348) Effect of exchange rates (855) (574) — — Plan assets at fair value — end of year $ 31,514 41,930 78 102 Funded status — end of year $ 1,883 348 (4,119) (4,776) Amounts Recognized in the Company’s Balance Sheet consist of the following: Non-current assets $ 4,581 4,436 — — Current liabilities (132) (115) (461) (438) Non-current liabilities (2,566) (3,973) (3,658) (4,338) Total recognized in the consolidated balance sheet — end of year $ 1,883 348 (4,119) (4,776) Amounts Recognized in Accumulated Other Comprehensive Income consist of the following: Net actuarial loss $ 3,948 5,539 239 1,113 Prior service cost (credit) (1) (1,417) (1,610) (7) (13) Unrecognized net transition obligation — — — — Total before tax effects $ 2,531 3,929 232 1,100 Accumulated Benefit Obligations — end of year $ 28,023 39,049 (1) The actuarial gain for retirement plans in 2022 and 2021 was primarily related to increases in discount rates. Retirement Plans Other Benefit Plans (Dollars in Millions) 2022 2021 2022 2021 Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income Net periodic benefit cost (credit) $ (47) 623 533 503 Net actuarial (gain) loss (793) (3,927) (751) (199) Amortization of net actuarial loss (655) (1,257) (121) (151) Prior service cost (credit) 7 5 — — Amortization of prior service (cost) credit 183 181 5 31 Effect of exchange rates (140) (136) (1) — Total loss/(income) recognized in other comprehensive income, before tax $ (1,398) (5,134) (868) (319) Total recognized in net periodic benefit cost and other comprehensive income $ (1,445) (4,511) (335) 184
Information Related to the Benefit Obligation and the Fair Value of Plan Assets	The following table displays the funded status of the Company's U.S. Qualified & Non-Qualified pension plans and international funded and unfunded pension plans at December 31, 2022 and December 31, 2021, respectively: U.S. Plans International Plans Qualified Plans Non-Qualified Plans Funded Plans Unfunded Plans (Dollars in Millions) 2022 2021 2022 2021 2022 2021 2022 2021 Plan Assets $ 20,937 27,944 — — 10,577 13,986 — — Projected Benefit Obligation 18,394 25,041 1,937 2,703 9,024 13,428 276 410 Accumulated Benefit Obligation 17,696 23,985 1,872 2,479 8,202 12,212 253 373 Over (Under) Funded Status Projected Benefit Obligation $ 2,543 2,903 (1,937) (2,703) 1,553 558 (276) (410) Accumulated Benefit Obligation 3,241 3,959 (1,872) (2,479) 2,375 1,774 (253) (373)
Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans	The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans: (Dollars in Millions) 2023 2024 2025 2026 2027 2028-2032 Projected future benefit payments Retirement plans $ 1,445 1,457 1,532 1,609 1,708 10,034 Other benefit plans $ 471 485 433 447 462 2,539
Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans	The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future. (Dollars in Millions) 2023 2024 2025 2026 2027 2028-2032 Projected future contributions $ 123 128 136 141 146 816
Company' Retirement Plan Asset Allocation and Target Allocations	The Company’s retirement plan asset allocation at the end of 2022 and 2021 and target allocations for 2023 are as follows: Percent of Target 2022 2021 2023 Worldwide Retirement Plans Equity securities 62 % 65 % 61 % Debt securities 38 35 39 Total plan assets 100 % 100 % 100 %
Schedule of Defined Benefit Plans Disclosures	The following table sets forth the Retirement Plans' investments measured at fair value as of December 31, 2022 and December 31, 2021: Quoted Prices Significant Significant Unobservable Inputs (1) Investments Measured at Net Asset Value (Level 1) (Level 2) (Level 3) Total Assets (Dollars in Millions) 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 Short-term investment funds $ 33 102 13 1,033 — — — — 46 1,135 Government and agency securities — — 5,863 7,016 — — — — 5,863 7,016 Debt instruments — — 3,681 3,505 — — — — 3,681 3,505 Equity securities 8,846 14,107 2 2 — — — — 8,848 14,109 Commingled funds — — 4,362 5,496 56 105 6,106 8,708 10,524 14,309 Other assets — — 33 34 13 15 2,506 1,807 2,552 1,856 Investments at fair value $ 8,879 14,209 13,954 17,086 69 120 8,612 10,515 31,514 41,930 (1) The activity for the Level 3 assets is not significant for all years presented.

Capital and Treasury Stock (Tab

Capital and Treasury Stock (Tables)	12 Months Ended
	Jan. 01, 2023
Equity [Abstract]
Changes in Treasury Stock	Changes in treasury stock were: Treasury Stock (Amounts in Millions Except Treasury Stock Shares in Thousands) Shares Amount Balance at December 29, 2019 487,336 $ 38,417 Employee compensation and stock option plans (21,765) (3,148) Repurchase of common stock 21,760 3,221 Balance at January 3, 2021 487,331 38,490 Employee compensation and stock option plans (17,399) (2,847) Repurchase of common stock 20,946 3,456 Balance at January 2, 2022 490,878 39,099 Employee compensation and stock option plans (20,007) (3,440) Repurchase of common stock 35,375 6,035 Balance at January 1, 2023 506,246 $ 41,694

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Jan. 01, 2023
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: (Dollars in Millions) Foreign Gain/(Loss) On Securities Employee Benefit Plans Gain/ Total December 29, 2019 $ (8,705) — (6,891) (295) (15,891) Net 2020 changes (233) 1 (66) 947 649 January 3, 2021 (8,938) 1 (6,957) 652 (15,242) Net 2021 changes (1,079) (4) 4,255 (988) 2,184 January 2, 2022 (10,017) (3) (2,702) (336) (13,058) Net 2022 changes (1,796) (24) 1,805 106 91 January 1, 2023 $ (11,813) (27) (897) (230) (12,967)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Jan. 01, 2023
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January 1, 2023, January 2, 2022 and January 3, 2021: (In Millions Except Per Share Amounts) 2022 2021 2020 Basic net earnings per share $ 6.83 7.93 5.59 Average shares outstanding — basic 2,625.2 2,632.1 2,632.8 Potential shares exercisable under stock option plans 140.1 138.0 118.3 Less: shares repurchased under treasury stock method (101.4) (96.1) (80.4) Adjusted average shares outstanding — diluted 2,663.9 2,674.0 2,670.7 Diluted net earnings per share $ 6.73 7.81 5.51

Common Stock, Stock Option Pl_2

Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)	12 Months Ended
	Jan. 01, 2023
Share-Based Payment Arrangement [Abstract]
Schedule Valuation Assumptions	The average fair value of options granted was $23.23, $20.86 and $16.42, in fiscal years 2022, 2021 and 2020, respectively. The fair value was estimated based on the weighted average assumptions of: 2022 2021 2020 Risk-free rate 1.98 % 0.83 % 1.47 % Expected volatility 18.00 % 18.59 % 15.33 % Expected life (in years) 7.0 7.0 7.0 Expected dividend yield 2.70 % 2.50 % 2.60 %
Summary of Stock Option Activity	A summary of option activity under the Plan as of January 1, 2023, January 2, 2022 and January 3, 2021, and changes during the years ending on those dates is presented below: (Shares in Thousands) Outstanding Shares Weighted Aggregate Shares at December 29, 2019 111,637 $ 105.63 $ 4,478 Options granted 20,723 151.41 Options exercised (16,275) 86.05 Options canceled/forfeited (1,835) 137.62 Shares at January 3, 2021 114,250 116.22 4,703 Options granted 18,525 164.62 Options exercised (13,248) 97.48 Options canceled/forfeited (2,166) 149.75 Shares at January 2, 2022 117,361 125.36 5,364 Options granted 19,809 165.89 Options exercised (16,310) 100.15 Options canceled/forfeited (2,188) 160.56 Shares at January 1, 2023 118,672 $ 134.95 $ 4,949
Summary of Options Outstanding	The following table summarizes stock options outstanding and exercisable at January 1, 2023: (Shares in Thousands) Outstanding Exercisable Exercise Price Range Options Average Life (1) Weighted Average Exercise Price Options Weighted Average Exercise Price $72.54-$100.48 17,221 1.5 $93.07 17,221 $93.07 $101.87-$115.67 22,039 3.6 $108.78 22,039 $108.78 $129.51-$141.06 24,870 5.7 $130.88 24,228 $130.85 $151.41-$164.62 35,465 7.6 $157.75 150 $156.21 $164.63-$165.89 19,077 9.1 $165.89 23 $165.89 118,672 5.8 $134.95 63,661 $113.06 (1) Average contractual life remaining in years.
Summary of Restricted Share Units	A summary of the restricted share units and performance share units activity under the Plans as of January 1, 2023 is presented below: (Shares in Thousands) Outstanding Restricted Share Units Outstanding Performance Share Units Shares at January 2, 2022 14,122 2,312 Granted 5,154 753 Issued (4,866) (637) Canceled/forfeited/adjusted (794) (71) Shares at January 1, 2023 13,616 2,357

Segments of Business and Geog_2

Segments of Business and Geographic Areas (Tables)	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022
Segment Reporting [Abstract]
Schedule of Sales by Segment of Business	Sales to Customers % Change (Dollars in Millions) 2022 2021 2020 ’22 vs. ’21 ’21 vs. ’20 CONSUMER HEALTH (1) OTC U.S. $ 2,782 2,594 2,460 7.3 % 5.4 International 3,249 3,034 2,761 7.1 9.9 Worldwide 6,031 5,627 5,221 7.2 7.8 Skin Health/Beauty U.S. 2,337 2,400 2,350 (2.6) 2.1 International 2,015 2,141 2,100 (5.9) 1.9 Worldwide 4,352 4,541 4,450 (4.2) 2.0 Oral Care U.S. 635 637 683 (0.3) (6.7) International 871 1,008 958 (13.6) 5.1 Worldwide 1,505 1,645 1,641 (8.5) 0.2 Baby Care U.S. 357 378 376 (5.5) 0.5 International 1,104 1,188 1,141 (7.1) 4.1 Worldwide 1,461 1,566 1,517 (6.7) 3.2 Women's Health U.S. 13 13 13 1.7 (1.6) International 891 905 888 (1.5) 1.8 Worldwide 904 917 901 (1.5) 1.8 Wound Care/Other U.S. 475 495 480 (4.0) 3.1 International 224 243 240 (8.0) 1.7 Worldwide 700 739 720 (5.3) 2.6 TOTAL CONSUMER HEALTH U.S. 6,599 6,516 6,362 1.3 2.4 International 8,354 8,519 8,088 (1.9) 5.3 Worldwide 14,953 15,035 14,450 (0.5) 4.0 PHARMACEUTICAL (1) Immunology U.S. 11,036 10,843 10,175 1.8 6.6 International 5,899 5,907 4,880 (0.1) 21.0 Worldwide 16,935 16,750 15,055 1.1 11.3 REMICADE U.S. 1,417 2,019 2,508 (29.8) (19.5) U.S. Exports 204 236 346 (13.6) (31.9) International 722 935 893 (22.8) 4.8 Worldwide 2,343 3,190 3,747 (26.6) (14.9) SIMPONI / SIMPONI ARIA U.S. 1,166 1,127 1,155 3.5 (2.4) International 1,017 1,148 1,088 (11.4) 5.5 Worldwide 2,184 2,276 2,243 (4.0) 1.4 STELARA U.S. 6,388 5,938 5,240 7.6 13.3 International 3,335 3,196 2,467 4.4 29.6 Worldwide 9,723 9,134 7,707 6.5 18.5 TREMFYA U.S. 1,844 1,503 926 22.7 62.3 International 824 624 421 32.0 48.2 Worldwide 2,668 2,127 1,347 25.4 57.9 OTHER IMMUNOLOGY U.S. 17 21 — (18.4) ** International 0 3 11 ** (73.3) Worldwide 17 24 11 (28.2) ** Infectious Diseases U.S. 1,680 2,249 1,735 (25.3) 29.7 International 3,769 3,576 1,808 5.4 97.8 Worldwide 5,449 5,825 3,543 (6.5) 64.4 COVID-19 VACCINE U.S. 120 634 — (81.1) ** International 2,059 1,751 — 17.6 ** Worldwide 2,179 2,385 — (8.6) ** EDURANT / rilpivirine U.S. 36 41 44 (10.8) (7.6) International 972 953 920 2.0 3.6 Worldwide 1,008 994 964 1.5 3.1 PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA U.S. 1,494 1,508 1,587 (1.0) (4.9) International 449 575 597 (21.9) (3.6) Worldwide 1,943 2,083 2,184 (6.7) (4.6) OTHER INFECTIOUS DISEASES U.S. 30 66 104 (55.5) (36.0) International 289 297 292 (2.6) 1.7 Worldwide 318 363 396 (12.3) (8.3) Neuroscience U.S. 3,570 3,347 3,091 6.7 8.3 International 3,323 3,641 3,435 (8.7) 6.0 Worldwide 6,893 6,988 6,526 (1.4) 7.1 CONCERTA / methylphenidate U.S. 151 172 183 (12.5) (5.8) International 493 495 439 (0.4) 12.8 Worldwide 644 667 622 (3.5) 7.3 INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA U.S. 2,714 2,550 2,314 6.5 10.2 International 1,426 1,472 1,339 (3.1) 10.0 Worldwide 4,140 4,022 3,653 3.0 10.1 RISPERDAL CONSTA U.S. 257 287 296 (10.4) (2.9) International 228 305 346 (25.3) (11.8) Worldwide 485 592 642 (18.1) (7.7) OTHER NEUROSCIENCE U.S. 447 338 298 32.4 13.3 International 1,176 1,368 1,312 (14.1) 4.3 Worldwide 1,623 1,706 1,610 (4.9) 6.0 Oncology U.S. 6,930 5,958 5,092 16.3 17.0 International 9,052 8,590 7,275 5.4 18.1 Worldwide 15,983 14,548 12,367 9.9 17.6 DARZALEX U.S. 4,210 3,169 2,232 32.8 42.0 International 3,767 2,854 1,958 32.0 45.8 Worldwide 7,977 6,023 4,190 32.4 43.8 ERLEADA U.S. 968 813 583 19.2 39.3 International 913 478 176 ** * * Worldwide 1,881 1,291 760 45.7 70.0 IMBRUVICA U.S. 1,390 1,747 1,821 (20.4) (4.0) International 2,394 2,622 2,307 (8.7) 13.6 Worldwide 3,784 4,369 4,128 (13.4) 5.8 ZYTIGA / abiraterone acetate U.S. 74 119 373 (37.8) (68.1) International 1,696 2,178 2,097 (22.1) 3.9 Worldwide 1,770 2,297 2,470 (22.9) (7.0) OTHER ONCOLOGY U.S. 289 110 83 ** 31.7 International 283 458 738 (38.3) (37.9) Worldwide 571 568 821 0.6 (30.8) Pulmonary Hypertension U.S. 2,346 2,365 2,133 (0.8) 10.9 International 1,071 1,085 1,015 (1.3) 6.9 Worldwide 3,417 3,450 3,148 (1.0) 9.6 OPSUMIT U.S. 1,132 1,147 1,008 (1.3) 13.7 International 651 672 631 (3.2) 6.6 Worldwide 1,783 1,819 1,639 (2.0) 11.0 UPTRAVI U.S. 1,104 1,056 955 4.5 10.5 International 218 181 138 20.4 31.1 Worldwide 1,322 1,237 1,093 6.9 13.1 OTHER U.S. 110 163 169 (32.3) (3.7) International 202 232 247 (12.8) (5.9) Worldwide 313 395 416 (20.8) (5.0) Cardiovascular / Metabolism / Other U.S. 3,042 3,192 3,509 (4.7) (9.0) International 845 927 1,025 (8.9) (9.6) Worldwide 3,887 4,119 4,534 (5.6) (9.2) XARELTO U.S. 2,473 2,438 2,345 1.4 4.0 International — — — — — Worldwide 2,473 2,438 2,345 1.4 4.0 INVOKANA/ INVOKAMET U.S. 193 308 564 (37.4) (45.4) International 255 254 231 0.1 9.9 Worldwide 448 563 795 (20.4) (29.3) OTHER (2) U.S. 376 446 600 (15.5) (25.7) International 590 673 794 (12.3) (15.2) Worldwide 966 1,119 1,394 (13.6) (19.7) TOTAL PHARMACEUTICAL U.S. 28,604 27,954 25,735 2.3 8.6 International 23,959 23,726 19,440 1.0 22.0 Worldwide 52,563 51,680 45,175 1.7 14.4 MEDTECH* (3) Interventional Solutions U.S. 2,169 1,836 1,452 18.2 26.4 International 2,131 2,135 1,594 (0.2) 34.0 Worldwide 4,300 3,971 3,046 8.3 30.4 Orthopaedics U.S. 5,321 5,126 4,779 3.8 7.3 International 3,267 3,462 2,984 (5.6) 16.0 Worldwide 8,587 8,588 7,763 0.0 10.6 HIPS U.S. 943 878 793 7.3 10.7 International 571 602 487 (5.1) 23.6 Worldwide 1,514 1,480 1,280 2.3 15.6 KNEES U.S. 851 787 743 8.2 5.9 International 508 538 427 (5.7) 26.1 Worldwide 1,359 1,325 1,170 2.6 13.3 TRAUMA U.S. 1,882 1,819 1,648 3.5 10.4 International 989 1,066 966 (7.2) 10.4 Worldwide 2,871 2,885 2,614 (0.5) 10.4 SPINE, SPORTS & OTHER U.S. 1,645 1,642 1,595 0.2 2.9 International 1,198 1,256 1,104 (4.6) 13.8 Worldwide 2,843 2,898 2,699 (1.9) 7.4 Surgery U.S. 3,897 3,867 3,249 0.8 19.0 International 5,793 5,945 4,983 (2.6) 19.3 Worldwide 9,690 9,812 8,232 (1.2) 19.2 ADVANCED U.S. 1,784 1,761 1,535 1.3 14.9 International 2,785 2,861 2,304 (2.6) 24.1 Worldwide 4,569 4,622 3,839 (1.1) 20.4 GENERAL U.S. 2,113 2,105 1,714 0.4 22.7 International 3,008 3,085 2,679 (2.5) 15.2 Worldwide 5,121 5,190 4,392 (1.3) 18.1 Vision U.S. 1,990 1,857 1,557 7.2 19.3 International 2,859 2,831 2,362 1.0 19.8 Worldwide 4,849 4,688 3,919 3.4 19.6 CONTACT LENSES / OTHER U.S. 1,522 1,398 1,213 8.9 15.2 International 2,022 2,043 1,781 (1.0) 14.7 Worldwide 3,543 3,440 2,994 3.0 14.9 SURGICAL U.S. 468 459 344 2.0 33.5 International 837 788 581 6.2 35.7 Worldwide 1,306 1,248 925 4.6 34.9 TOTAL MEDTECH U.S. 13,377 12,686 11,036 5.4 14.9 International 14,050 14,374 11,923 (2.3) 20.6 Worldwide 27,427 27,060 22,959 1.4 17.9 WORLDWIDE U.S. 48,580 47,156 43,133 3.0 9.3 International 46,363 46,619 39,451 (0.6) 18.2 Worldwide $ 94,943 93,775 82,584 1.3 % 13.6 *Certain prior year amounts have been reclassified to conform to current year presentation **Percentage greater than 100% or not meaningful (1) Approximately $0.4 billion in both the fiscal 2021 and 2020, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes (2) Inclusive of PROCRIT / EPREX which was previously disclosed separately (3) Pr eviously referred to as Medical Devices
Schedule of Segment Reporting Information	Income (Loss) Before Tax* Identifiable Assets (Dollars in Millions) 2022 (3) 2021 (4) 2020 (5) 2022 2021 Consumer Health $ 2,930 1,573 (852) $ 24,068 25,081 Pharmaceutical 15,901 17,969 15,250 58,436 64,376 MedTech 4,607 4,373 3,044 70,956 53,372 Total 23,438 23,915 17,442 153,460 142,829 Less: Expense not allocated to segments (1) 624 1,072 945 Less: Consumer Health separation costs 1,089 67 General corporate (2) 33,918 39,189 Worldwide total $ 21,725 22,776 16,497 $ 187,378 182,018 *Income before tax of approximately $0.2 billion and $0.2 billion in the fiscal years 2021 and 2020, respectively, has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes Additions to Property, Depreciation and (Dollars in Millions) 2022 2021 2020 2022 2021 2020 Consumer Health $ 323 331 248 $ 658 759 785 Pharmaceutical 1,374 1,198 863 3,687 4,029 4,006 MedTech 2,120 1,933 1,980 2,302 2,286 2,140 Segments total 3,817 3,462 3,091 6,647 7,074 6,931 General corporate 192 190 256 323 316 300 Worldwide total $ 4,009 3,652 3,347 $ 6,970 7,390 7,231
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas		Sales to Customers Long-Lived Assets (6) (Dollars in Millions) 2022 2021 2020 2022 2021 United States $ 48,580 47,156 43,133 $ 66,283 48,586 Europe 23,449 23,594 18,980 38,774 43,257 Western Hemisphere excluding U.S. 6,125 5,750 5,335 2,737 2,708 Asia-Pacific, Africa 16,789 17,275 15,136 4,431 5,035 Segments total 94,943 93,775 82,584 112,225 99,586 General corporate 1,134 1,014 Other non long-lived assets 74,019 81,418 Worldwide total $ 94,943 93,775 82,584 $ 187,378 182,018 See Note 1 for a description of the segments in which the Company operates. Export sales are not significant. In fiscal year 2022, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.5%, 13.0% and 12.0% of the total consolidated revenues. In fiscal year 2021, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0%, and 12.0% of the total consolidated revenues. (1) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. (2) General corporate includes cash, cash equivalents and marketable securities. (3) Consumer Health includes: • Litigation expense of $0.2 billion • A restructuring related charge of $0.1 billion Pharmaceutical includes: • One-time COVID-19 Vaccine manufacturing exit related costs of $1.5 billion • An intangible asset impairment charge of approximately $0.8 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS • Litigation expense of $0.1 billion • Loss of $0.7 billion related to the change in the fair value of securities • A restructuring related charge of $0.1 billion MedTech includes: • Litigation expense of $0.6 billion primarily for pelvic mesh related costs • A restructuring related charge of $0.3 billion • Acquisition and integration related costs of $0.3 billion primarily related to the acquisition of Abiomed • A Medical Device Regulation charge of $0.3 billion (4) Consumer Health includes: • Litigation expense of $1.6 billion, primarily talc related costs • A restructuring related charge of $0.1 billion Pharmaceutical includes: • Litigation expense of $0.6 billion, primarily related to Risperdal Gynecomastia • Divestiture gains of $0.6 billion • Gains of $0.5 billion related to the change in the fair value of securities • A restructuring related charge of $0.1 billion MedTech includes: • A restructuring related charge of $0.3 billion • An in-process research and development expense of $0.9 billion related to Ottava • A Medical Device Regulation charge of $0.2 billion • Litigation expense of $0.1 billion (5) Consumer Health includes: • Litigation expense of $3.9 billion, primarily talc related costs and certain settlements. Pharmaceutical includes: • Litigation expense of $0.8 billion, primarily related to the agreement in principle to settle opioid litigation • A gain of $0.5 billion related to the change in the fair value of securities • A restructuring related charge of $0.1 billion MedTech includes: • A contingent consideration reversal of $1.1 billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. • Litigation expense of $0.3 billion • A restructuring related charge of $0.3 billion • An in-process research and development expense of $0.2 billion • A Medical Device Regulation charge of $0.1 billion (6) Long-lived assets include property, plant and equipment, net for fiscal years 2022, and 2021 of $19,803 and $18,962, respectively, and intangible assets and goodwill, net for fiscal years 2022 and 2021 of $93,556 and $81,638, respectively.

Restructuring (Tables)

Restructuring (Tables)	12 Months Ended
	Jan. 01, 2023
Restructuring and Related Activities [Abstract]
Summary of Severance Charges and Associated Spending	The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2022: (Dollars in Millions) Severance Asset Write-offs/Sales Other (2) Total Reserve balance, January 3, 2021 $ 135 — 9 144 2021 activity (23) — 16 (7) Reserve balance, January 2, 2022 112 — 25 137 Current year activity: Charges — 15 448 463 Cash settlements (37) 44 (3) (439) (432) Settled non cash — (59) (59) Reserve balance, January 1, 2023 (1) $ 75 — 34 109 (1) Although the restructuring program has been completed in the fiscal year 2022, the Company expects that severance charges will continue beyond that date. The reserve balance as of January 1, 2023 is recorded in the Employee Related Obligation account in the Consolidated Balance Sheet. (2) Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses. (3) Represents gain on sale of assets

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ in Millions	12 Months Ended
	Jan. 01, 2023 USD ($) Segment Employee	Jan. 02, 2022 USD ($)	Jan. 03, 2021 USD ($)	Dec. 30, 2018	Dec. 31, 2017
Concentration of Credit Risk [Line Items]
Number of employees | Employee	152,700
Number of business segments | Segment	3
Minimum reverse repurchase agreement collateral (as a percent)	102%
Accrued Rebates Returns And Promotions	$ 14,417	$ 12,095
Sales return reserve (as a percent)	1%	1%	1%
Percentage of profit share payments (less than)	2%	3%	3%
Cost of products sold	$ 31,089	$ 29,855	$ 28,427
Shipping and handling costs as a percent of sales	1%	1%	1%
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets, noncurrent	Other assets, noncurrent
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued Liabilities, Current	Accrued Liabilities, Current
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Noncurrent	Other Liabilities, Noncurrent
Operating lease, right-of-use asset	$ 1,100	$ 900
Operating lease liabilities	1,300	1,000
Operating lease costs	300	300	$ 300
Cash paid for operating leases	300	300	300
Advertising expense	$ 2,100	$ 2,700	$ 2,100
U.S. statutory rate	21%	21%	21%	21%	35%
TCJA, undistributed foreign earnings percent related to cash and cash equivalents				15.50%
TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents				8%
TCJA, provisional liability	$ 6,100
TJCA , provisional liability, non-current	4,600
Repatriation of foreign earnings amount	$ 500
Minimum | Software Development
Concentration of Credit Risk [Line Items]
Estimated useful lives of the assets	3 years
Maximum | Software Development
Concentration of Credit Risk [Line Items]
Estimated useful lives of the assets	8 years
R&D Expense | Project Concentration Risk
Concentration of Credit Risk [Line Items]
Concentration risk, threshold percentage (as a percent)	0.05	0.05	0.05
Shipping and Handling
Concentration of Credit Risk [Line Items]
Cost of products sold	$ 1,100	$ 1,100	$ 1,000
Pharmaceutical
Concentration of Credit Risk [Line Items]
Accrued Rebates Returns And Promotions	$ 9,600	$ 7,700

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)	12 Months Ended
	Jan. 01, 2023
Minimum | Land and leasehold improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	10 years
Minimum | Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	2 years
Maximum | Building and building equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	30 years
Maximum | Land and leasehold improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	20 years
Maximum | Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the assets	13 years

Cash, Cash Equivalents and Cu_3

Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details) - USD ($) $ in Millions	Jan. 01, 2023	Jan. 02, 2022
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Fair value, available-for-sale	$ 10,487	$ 19,727
Cash and Cash Equivalents, at Carrying Value	14,127	14,487
Current Marketable Securities	9,392	17,121
Held-to-maturity Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	13,032	11,881
Fair value, held-to-maturity	13,031	11,880
Cash and Cash Equivalents, at Carrying Value	12,159	7,686
Current Marketable Securities	873	4,195
Held-to-maturity, unrecognized loss	(1)	(1)
Held-to-maturity Securities | Cash
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	4,926	2,936
Fair value, held-to-maturity	4,926	2,936
Cash and Cash Equivalents, at Carrying Value	4,926	2,936
Current Marketable Securities	0	0
Held-to-maturity, unrecognized loss	0	0
Held-to-maturity Securities | Non-U.S. Sovereign Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity		1,006
Fair value, held-to-maturity		1,006
Cash and Cash Equivalents, at Carrying Value		90
Current Marketable Securities		916
Held-to-maturity, unrecognized loss		0
Held-to-maturity Securities | U.S. Reverse repurchase agreements
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	1,419	1,659
Fair value, held-to-maturity	1,419	1,659
Cash and Cash Equivalents, at Carrying Value	1,419	1,659
Current Marketable Securities	0	0
Held-to-maturity, unrecognized loss	0	0
Held-to-maturity Securities | Corporate debt securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	873	3,479
Fair value, held-to-maturity	872	3,478
Cash and Cash Equivalents, at Carrying Value	0	200
Current Marketable Securities	873	3,279
Held-to-maturity, unrecognized loss	(1)	(1)
Held-to-maturity Securities | Money market funds
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	5,368	1,901
Fair value, held-to-maturity	5,368	1,901
Cash and Cash Equivalents, at Carrying Value	5,368	1,901
Current Marketable Securities	0	0
Held-to-maturity, unrecognized loss	0	0
Held-to-maturity Securities | Time deposits
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, held-to-maturity	446	900
Fair value, held-to-maturity	446	900
Cash and Cash Equivalents, at Carrying Value	446	900
Current Marketable Securities	0	0
Held-to-maturity, unrecognized loss	0	0
Available-for-sale Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	10,521	19,731
Fair value, available-for-sale	10,487	19,727
Cash and Cash Equivalents, at Carrying Value	1,968	6,801
Current Marketable Securities	8,519	12,926
Available-for-sale, unrecognized loss	(34)	(4)
Available-for-sale Securities | Corporate debt securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	352	246
Fair value, available-for-sale	351	246
Cash and Cash Equivalents, at Carrying Value	46	16
Current Marketable Securities	305	230
Available-for-sale, unrecognized loss	(1)	0
Available-for-sale Securities | U.S. Gov't Securities
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	9,959	19,485
Fair value, available-for-sale	9,931	19,481
Cash and Cash Equivalents, at Carrying Value	1,922	6,785
Current Marketable Securities	8,009	12,696
Available-for-sale, unrecognized loss	(28)	$ (4)
Available-for-sale Securities | U.S. Gov't Agencies
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Carrying Amount, available-for-sale	210
Fair value, available-for-sale	205
Cash and Cash Equivalents, at Carrying Value	0
Current Marketable Securities	205
Available-for-sale, unrecognized loss	$ (5)

Cash, Cash Equivalents and Cu_4

Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details) $ in Millions	Jan. 01, 2023 USD ($)
Cost Basis
Due within one year	$ 10,430
Due after one year through five years	91
Due after five years through ten years	0
Total debt securities	10,521
Fair Value
Due within one year	10,399
Due after one year through five years	88
Due after five years through ten years	0
Total debt securities	$ 10,487

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jan. 01, 2023	Jan. 02, 2022
Summary of Inventories
Raw materials and supplies	$ 2,070	$ 1,592
Goods in process	1,700	2,287
Finished goods	8,713	6,508
Total inventories	$ 12,483	$ 10,387

Property, Plant and Equipment -

Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details) - USD ($) $ in Millions	Jan. 01, 2023	Jan. 02, 2022
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 49,253	$ 47,679
Less accumulated depreciation	29,450	28,717
Total property, plant and equipment, net	19,803	18,962
Land and leasehold improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	859	884
Building and building equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	12,989	12,882
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	30,431	29,774
Construction in progress
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 4,974	$ 4,139

Property, Plant and Equipment_2

Property, Plant and Equipment - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Property, Plant and Equipment [Abstract]
Interest expense capitalized	$ 49	$ 49	$ 63
Depreciation expense, including the amortization of capitalized interest	$ 2,700	$ 2,700	$ 2,600

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details) - USD ($) $ in Millions		12 Months Ended
	Dec. 22, 2022	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Intangible assets with indefinite lives:
Indefinite lived intangible assets		$ 16,493	$ 16,822
Total intangible assets - net		48,325	46,392
In-process research and development		783	900	$ 181
Trademarks
Intangible assets with indefinite lives:
Indefinite lived intangible assets		6,807	6,985
Purchased in-process research and development
Intangible assets with indefinite lives:
Indefinite lived intangible assets		9,686	9,837
Reduction in intangible assets		700
Patents And Trademarks
Intangible assets with definite lives:
Finite lived intangible assets gross		44,012	38,572
Less accumulated amortization		(22,266)	(20,088)
Finite lived intangible assets net		21,746	18,484
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite lived intangible assets gross		22,987	23,011
Less accumulated amortization		(12,901)	(11,925)
Finite lived intangible assets net		10,086	$ 11,086
Abiomed
Intangible assets with indefinite lives:
In-process research and development	$ 1,100
Abiomed | Purchased in-process research and development
Intangible assets with indefinite lives:
In-process research and development		1,100
bermekimab | In Process Research and Development
Intangible assets with indefinite lives:
Impairment of intangible assets, excluding goodwill		$ 800

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022
Goodwill [Roll Forward]
Goodwill beginning of period	$ 35,246	$ 36,393
Goodwill, related to acquisitions	11,056	0
Goodwill, related to divestitures	0	(9)
Currency translation/other	(1,071)	(1,138)
Goodwill end of period	45,231	35,246
Consumer Health
Goodwill [Roll Forward]
Goodwill beginning of period	9,810	10,336
Goodwill, related to acquisitions	0	0
Goodwill, related to divestitures	0	(9)
Currency translation/other	(626)	(517)
Goodwill end of period	9,184	9,810
Pharmaceutical
Goodwill [Roll Forward]
Goodwill beginning of period	10,580	11,009
Goodwill, related to acquisitions	0	0
Goodwill, related to divestitures	0	0
Currency translation/other	(396)	(429)
Goodwill end of period	10,184	10,580
Medical Devices
Goodwill [Roll Forward]
Goodwill beginning of period	14,856	15,048
Goodwill, related to acquisitions	11,056	0
Goodwill, related to divestitures	0	0
Currency translation/other	(49)	(192)
Goodwill end of period	$ 25,863	$ 14,856

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Billions		12 Months Ended
	Dec. 22, 2022	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life	14 years
Amortization expense of amortizable intangible assets		$ 4.3	$ 4.7	$ 4.7
Patents And Trademarks
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life		12 years
Customer relationships and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful life		21 years
In Process Research and Development | bermekimab
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, excluding goodwill		$ 0.8

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details) $ in Millions	Jan. 01, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 4,600
2024	4,400
2025	3,600
2026	3,000
2027	$ 2,400

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022
Derivative [Line Items]
Deferred net losses (gains) on derivatives included in accumulated other comprehensive income	$ (230)
Description of reclassification of cash flow hedge gain (loss)	next 12 months
Maximum length of time for hedging transaction exposure	18 months
Total Gross Assets	$ 2,201	$ 1,360
Equity investments, increase (decrease) from acquisition (sale) during period	600
Foreign exchange contracts
Derivative [Line Items]
Collateral paid	800
Derivative, notional amount	43,300	45,800
Cross currency interest rate swaps
Derivative [Line Items]
Derivative, notional amount	36,200	37,400
Interest Rate Swap
Derivative [Line Items]
Derivative, notional amount	12,400	10,000
Interest Rate Swap | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Asset, Current	2,400
Equity securities | Equity Investments without readily determinable value
Derivative [Line Items]
Equity, fair value adjustment, impairment loss	(51)	(28)
Equity, fair value adjustment, change in observable prices	142	422
Equity investments, increase (decrease) from acquisition (sale) during period	$ 107	$ (632)

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	$ 348	$ 789	$ 53
Amount of gain or (loss) recognized in AOCI	454	(199)	$ 1,000
Sales | Interest Rate Swap | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Sales | Cross currency interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Sales | Cross currency interest rate swaps contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Sales | Forward foreign exchange contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	(72)	17
Amount of gain or (loss) recognized in AOCI	5	(94)
Cost of Products Sold | Interest Rate Swap | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Cost of Products Sold | Cross currency interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Cost of Products Sold | Cross currency interest rate swaps contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Cost of Products Sold | Forward foreign exchange contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	(271)	119
Amount of gain or (loss) recognized in AOCI	319	(557)
R&D Expense | Interest Rate Swap | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
R&D Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
R&D Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
R&D Expense | Forward foreign exchange contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	149	30
Amount of gain or (loss) recognized in AOCI	61	123
Interest (Income) Expense | Interest Rate Swap | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	(1,098)	(109)
Amount of gain or (loss) recognized in AOCI	1,098	109
Interest (Income) Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	140	174
Amount of gain or (loss) recognized in AOCI	140	174
Interest (Income) Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	425	402
Amount of gain or (loss) recognized in AOCI	42	9
Interest (Income) Expense | Forward foreign exchange contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Other (Income) Expense | Interest Rate Swap | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Other (Income) Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Other (Income) Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	0	0
Amount of gain or (loss) recognized in AOCI	0	0
Other (Income) Expense | Forward foreign exchange contracts: | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) reclassified from AOCI into income	(23)	47
Amount of gain or (loss) recognized in AOCI	$ (113)	$ 146

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details) - USD ($) $ in Millions	Jan. 01, 2023	Jan. 02, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Carrying Amount of the Hedged Liability	$ 3,357	$ 1,888
Long-term Debt | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Carrying Amount of the Hedged Liability	8,665	9,793
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability	$ (1,435)	$ (142)

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)
Forward foreign exchange contracts: | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Income on Derivative	$ 94	$ (70)

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 01, 2023	Jan. 02, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI			$ 197	$ 387
Cross currency interest rate swaps contracts:
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Accumulated OCI			$ 766	$ 548
Other (Income) Expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Reclassified From Accumulated OCI Into Income	$ 0	$ 0
Other (Income) Expense | Cross currency interest rate swaps contracts:
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Reclassified From Accumulated OCI Into Income	$ 0	$ 0

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Equity Investment [Roll Forward]
Equity investments, increase (decrease) from acquisition (sale) during period	$ 600
Other assets, noncurrent	9,602	$ 10,216
Equity securities | Equity Investments with readily determinable value
Equity Investment [Roll Forward]
Marketable securities, noncurrent	576	1,884	$ 1,481
Equity, fair value adjustment	(538)	198
Equity investments, increase (decrease) from acquisition (sale) during period	(770)	205
Other assets, noncurrent	576	1,884
Equity securities | Equity Investments without readily determinable value
Equity Investment [Roll Forward]
Equity, fair value adjustment	91	394
Equity investments, increase (decrease) from acquisition (sale) during period	107	(632)
Other assets, noncurrent	698	500
Equity securities without readily determinable fair value, amount	$ 698	$ 500	$ 738

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021	Dec. 22, 2022
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$ 2,163
Derivatives designated as hedging instruments : Liabilities	3,289
Equity Investments	576	$ 1,884
Debt securities	10,487	19,727
Contingent consideration liability	1,120	533
Total Gross Assets	2,201	1,360
Credit Support Agreement (CSA)	$ (2,176)	$ (1,285)
Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag	Total Net Asset	Total Net Asset
Total Net Asset	$ 25	$ 75
Total Gross Liabilities	3,357	1,888
Credit Support Agreement (CSA)	$ (3,023)	$ (1,855)
Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag	Total Net Liabilities	Total Net Liabilities
Total Net Liabilities	$ 334	$ 33
Beginning Balance	533	633	$ 1,715
Changes in estimated fair value	(194)	(52)	(1,089)
Additions (7)	792	0	106
Payments	(11)	(48)	(99)
Ending Balance	1,120	533	633
Contingent consideration reversal	0	0	(1,148)
Other Noncurrent Liabilities
Financial assets and liabilities at fair value
Contingent consideration liability	1,116	520	594
Other Current Liabilities
Financial assets and liabilities at fair value
Contingent consideration liability	4	13	$ 39
Auris Health
Financial assets and liabilities at fair value
Contingent consideration reversal	(1,148)
Abiomed
Financial assets and liabilities at fair value
Contingent consideration liability	704			$ 700
Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Equity Investments	576	1,884
Debt securities	0
Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	2,163	1,336
Derivatives designated as hedging instruments : Liabilities	3,289	1,860
Equity Investments	0
Debt securities	10,487
Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Equity Investments	0
Debt securities	0
Contingent consideration liability	1,120	533
Interest rate swaps contracts:
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,534
Derivatives designated as hedging instruments : Liabilities	2,778
Interest rate swaps contracts: | Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Interest rate swaps contracts: | Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,534	796
Derivatives designated as hedging instruments : Liabilities	2,778	979
Interest rate swaps contracts: | Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Foreign exchange contracts
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	629
Derivatives designated as hedging instruments : Liabilities	511
Derivatives not designated as hedging instruments : Assets	38
Derivatives not designated as hedging instruments : Liabilities	68
Foreign exchange contracts | Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Foreign exchange contracts | Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	629	540
Derivatives designated as hedging instruments : Liabilities	511	881
Derivatives not designated as hedging instruments : Assets	38	24
Derivatives not designated as hedging instruments : Liabilities	68	$ 28
Foreign exchange contracts | Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	$ 0

Borrowings - Schedule of Long-t

Borrowings - Schedule of Long-term Debt Instruments (Details) € in Millions, £ in Millions, $ in Millions	12 Months Ended
	Jan. 01, 2023 USD ($)	Jan. 02, 2022 USD ($)	Jan. 01, 2023 EUR (€)	Jan. 01, 2023 GBP (£)	Jan. 02, 2022 EUR (€)	Jan. 02, 2022 GBP (£)
Debt Instrument [Line Items]
Effective interest rate	3.04%	2.89%	3.04%	3.04%	2.89%	2.89%
Long-term debt	$ 28,439	$ 32,116
Less current portion	1,551	2,131
Total long-term debt	26,888	29,985
Excess of carrying value over fair value of debt	$ 1,600
Excess of fair value over carrying value of debt		$ 3,200
0.250% Notes due 2022 (1B Euro 1.1311)(3)
Debt Instrument [Line Items]
Effective interest rate	0%	0.26%	0%	0%	0.26%	0.26%
Long-term debt	$ 0	$ 1,131
Stated interest rate (as a percent)	0.25%		0.25%	0.25%
Debt Instrument, Face Amount | €			€ 1,000
Foreign currency exchange rate, translation	1.1311		1.1311	1.1311
2.25% Notes due 2022
Debt Instrument [Line Items]
Effective interest rate	0%	2.31%	0%	0%	2.31%	2.31%
Long-term debt	$ 0	$ 1,000
Stated interest rate (as a percent)	2.25%		2.25%	2.25%
6.73% Debentures due 2023
Debt Instrument [Line Items]
Effective interest rate	6.73%	6.73%	6.73%	6.73%	6.73%	6.73%
Long-term debt	$ 250	$ 250
Stated interest rate (as a percent)	6.73%		6.73%	6.73%
3.375% Notes due 2023
Debt Instrument [Line Items]
Effective interest rate	3.17%	3.18%	3.17%	3.17%	3.18%	3.18%
Long-term debt	$ 801	$ 802
Stated interest rate (as a percent)	3.375%		3.375%	3.375%
2.05% Notes due 2023
Debt Instrument [Line Items]
Effective interest rate	2.09%	2.09%	2.09%	2.09%	2.09%	2.09%
Long-term debt	$ 500	$ 499
Stated interest rate (as a percent)	2.05%		2.05%	2.05%
0.650% Notes due 2024 (750MM Euro 1.0651)(2)/(750MM Euro 1.1311)(3)
Debt Instrument [Line Items]
Effective interest rate	0.68%	0.68%	0.68%	0.68%	0.68%	0.68%
Long-term debt	$ 792	$ 847
Stated interest rate (as a percent)	0.65%		0.65%	0.65%
Debt Instrument, Face Amount | €			€ 750		€ 750
Foreign currency exchange rate, translation	1.0651	1.1311	1.0651	1.0651	1.1311	1.1311
5.50% Notes due 2024 (500MM 1.2037 GBP )(2)/(500MM GBP 1.3485)(3)
Debt Instrument [Line Items]
Effective interest rate	6.75%	6.75%	6.75%	6.75%	6.75%	6.75%
Long-term debt	$ 600	$ 672
Stated interest rate (as a percent)	5.50%		5.50%	5.50%
Debt Instrument, Face Amount | £				£ 500		£ 500
Foreign currency exchange rate, translation	1.2037	1.3485	1.2037	1.2037	1.3485	1.3485
2.625% Notes due 2025
Debt Instrument [Line Items]
Effective interest rate	2.63%	2.63%	2.63%	2.63%	2.63%	2.63%
Long-term debt	$ 749	$ 749
Stated interest rate (as a percent)	2.625%		2.625%	2.625%
0.55% Notes due 2025
Debt Instrument [Line Items]
Effective interest rate	0.57%	0.57%	0.57%	0.57%	0.57%	0.57%
Long-term debt	$ 918	$ 983
Stated interest rate (as a percent)	0.55%		0.55%	0.55%
2.45% Notes due 2026
Debt Instrument [Line Items]
Effective interest rate	2.47%	2.47%	2.47%	2.47%	2.47%	2.47%
Long-term debt	$ 1,996	$ 1,995
Stated interest rate (as a percent)	2.45%		2.45%	2.45%
2.95% Notes due 2027
Debt Instrument [Line Items]
Effective interest rate	2.96%	2.96%	2.96%	2.96%	2.96%	2.96%
Long-term debt	$ 877	$ 978
Stated interest rate (as a percent)	2.95%		2.95%	2.95%
0.95% Notes due 2027
Debt Instrument [Line Items]
Effective interest rate	0.96%	0.96%	0.96%	0.96%	0.96%	0.96%
Long-term debt	$ 1,394	$ 1,478
Stated interest rate (as a percent)	0.95%		0.95%	0.95%
1.150% Notes due 2028 (750MM Euro 1.0651)(2)/(750MM Euro 1.1311)(3)
Debt Instrument [Line Items]
Effective interest rate	1.21%	1.21%	1.21%	1.21%	1.21%	1.21%
Long-term debt	$ 794	$ 843
Stated interest rate (as a percent)	1.15%		1.15%	1.15%
Debt Instrument, Face Amount | €			€ 750		€ 750
Foreign currency exchange rate, translation	1.0651	1.1311	1.0651	1.0651	1.1311	1.1311
2.90% Notes due 2028
Debt Instrument [Line Items]
Effective interest rate	2.91%	2.91%	2.91%	2.91%	2.91%	2.91%
Long-term debt	$ 1,496	$ 1,495
Stated interest rate (as a percent)	2.90%		2.90%	2.90%
6.95% Notes due 2029
Debt Instrument [Line Items]
Effective interest rate	7.14%	7.14%	7.14%	7.14%	7.14%	7.14%
Long-term debt	$ 298	$ 298
Stated interest rate (as a percent)	6.95%		6.95%	6.95%
1.30% Notes due 2030
Debt Instrument [Line Items]
Effective interest rate	1.30%	1.30%	1.30%	1.30%	1.30%	1.30%
Long-term debt	$ 1,607	$ 1,723
Stated interest rate (as a percent)	1.30%		1.30%	1.30%
4.95% Debentures due 2033
Debt Instrument [Line Items]
Effective interest rate	4.95%	4.95%	4.95%	4.95%	4.95%	4.95%
Long-term debt	$ 498	$ 498
Stated interest rate (as a percent)	4.95%		4.95%	4.95%
4.375% Notes due 2033
Debt Instrument [Line Items]
Effective interest rate	4.24%	4.24%	4.24%	4.24%	4.24%	4.24%
Long-term debt	$ 854	$ 854
Stated interest rate (as a percent)	4.375%		4.375%	4.375%
1.650% Notes due 2035 (1.5B Euro 1.0651)(2)/(1.5B Euro 1.1311)(3)
Debt Instrument [Line Items]
Effective interest rate	1.68%	1.68%	1.68%	1.68%	1.68%	1.68%
Long-term debt	$ 1,591	$ 1,683
Stated interest rate (as a percent)	1.65%		1.65%	1.65%
Debt Instrument, Face Amount | €			€ 1,500		€ 1,500
Foreign currency exchange rate, translation	1.0651	1.1311	1.0651	1.0651	1.1311	1.1311
3.55% Notes due 2036
Debt Instrument [Line Items]
Effective interest rate	3.59%	3.59%	3.59%	3.59%	3.59%	3.59%
Long-term debt	$ 842	$ 974
Stated interest rate (as a percent)	3.55%		3.55%	3.55%
5.95% Notes due 2037
Debt Instrument [Line Items]
Effective interest rate	5.99%	5.99%	5.99%	5.99%	5.99%	5.99%
Long-term debt	$ 993	$ 993
Stated interest rate (as a percent)	5.95%		5.95%	5.95%
3.625% Notes due 2037
Debt Instrument [Line Items]
Effective interest rate	3.64%	3.64%	3.64%	3.64%	3.64%	3.64%
Long-term debt	$ 1,336	$ 1,475
Stated interest rate (as a percent)	3.625%		3.625%	3.625%
5.85% Debentures due 2038
Debt Instrument [Line Items]
Effective interest rate	5.85%	5.85%	5.85%	5.85%	5.85%	5.85%
Long-term debt	$ 697	$ 696
Stated interest rate (as a percent)	5.85%		5.85%	5.85%
3.400% Notes due 2038
Debt Instrument [Line Items]
Effective interest rate	3.42%	3.42%	3.42%	3.42%	3.42%	3.42%
Long-term debt	$ 992	$ 992
Stated interest rate (as a percent)	3.40%		3.40%	3.40%
4.50% Debentures due 2040
Debt Instrument [Line Items]
Effective interest rate	4.63%	4.63%	4.63%	4.63%	4.63%	4.63%
Long-term debt	$ 540	$ 540
Stated interest rate (as a percent)	4.50%		4.50%	4.50%
2.10% Notes due 2040
Debt Instrument [Line Items]
Effective interest rate	2.14%	2.14%	2.14%	2.14%	2.14%	2.14%
Long-term debt	$ 828	$ 974
Stated interest rate (as a percent)	2.10%		2.10%	2.10%
4.85% Notes due 2041
Debt Instrument [Line Items]
Effective interest rate	4.89%	4.89%	4.89%	4.89%	4.89%	4.89%
Long-term debt	$ 297	$ 297
Stated interest rate (as a percent)	4.85%		4.85%	4.85%
4.50% Notes due 2043
Debt Instrument [Line Items]
Effective interest rate	4.52%	4.52%	4.52%	4.52%	4.52%	4.52%
Long-term debt	$ 496	$ 496
Stated interest rate (as a percent)	4.50%		4.50%	4.50%
3.70% Notes due 2046
Debt Instrument [Line Items]
Effective interest rate	3.74%	3.74%	3.74%	3.74%	3.74%	3.74%
Long-term debt	$ 1,976	$ 1,975
Stated interest rate (as a percent)	3.70%		3.70%	3.70%
3.75% Notes due 2047
Debt Instrument [Line Items]
Effective interest rate	3.76%	3.76%	3.76%	3.76%	3.76%	3.76%
Long-term debt	$ 812	$ 971
Stated interest rate (as a percent)	3.75%		3.75%	3.75%
3.500% Notes due 2048
Debt Instrument [Line Items]
Effective interest rate	3.52%	3.52%	3.52%	3.52%	3.52%	3.52%
Long-term debt	$ 743	$ 743
Stated interest rate (as a percent)	3.50%		3.50%	3.50%
2.250% Notes due 2050
Debt Instrument [Line Items]
Effective interest rate	2.29%	2.29%	2.29%	2.29%	2.29%	2.29%
Long-term debt	$ 808	$ 983
Stated interest rate (as a percent)	2.25%		2.25%	2.25%
2.450% Notes due 2060
Debt Instrument [Line Items]
Effective interest rate	2.49%	2.49%	2.49%	2.49%	2.49%	2.49%
Long-term debt	$ 1,055	$ 1,222
Stated interest rate (as a percent)	2.45%		2.45%	2.45%
Other
Debt Instrument [Line Items]
Effective interest rate	0%	0%	0%	0%	0%	0%
Long-term debt	$ 9	$ 7

Borrowings - Narrative (Details

Borrowings - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Nov. 30, 2022	Jan. 02, 2022	Sep. 30, 2021
Debt Disclosure [Abstract]
Borrowing capacity under credit facility		$ 10,000		$ 10,000
Short-term borrowings and the current portion of long-term debt	$ 12,800		$ 3,800
Borrowed under the commercial paper program	1,600		2,100
Current portion of long term debt	1,551		2,131
Short-term Debt [Line Items]
Loans and notes payable	$ 12,771		$ 3,766
Commercial Paper
Debt Disclosure [Abstract]
Debt, weighted average interest rate	4.23%
Debt instrument, term	2 months
Short-term Debt [Line Items]
Loans and notes payable	$ 11,200
Debt, weighted average interest rate	4.23%
Debt instrument, term	2 months

Borrowings - Aggregate Maturiti

Borrowings - Aggregate Maturities of Long Term Obligations (Details) $ in Millions	Jan. 01, 2023 USD ($)
Aggregate maturities of long-term obligations
2023	$ 1,551
2024	1,392
2025	1,667
2026	1,996
2027	2,271
After 2026	$ 19,562

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Currently payable:
U.S. taxes	$ 2,378	$ 1,525	$ 1,026
International taxes	3,069	2,452	1,898
Total currently payable	5,447	3,977	2,924
Deferred:
U.S. taxes	(2,081)	583	(76)
International taxes	418	(2,662)	(1,065)
Total deferred	(1,663)	(2,079)	(1,141)
Provision for taxes on income	$ 3,784	$ 1,898	$ 1,783

Income Taxes - Comparison of In

Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jan. 02, 2022	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021	Dec. 30, 2018	Dec. 31, 2017
Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract
U.S.		$ 5,369	$ 6,110	$ 4,312
International		16,356	16,666	12,185
Earnings before provision for taxes on income		$ 21,725	$ 22,776	$ 16,497
Tax rates:
U.S. statutory rate		21%	21%	21%	21%	35%
International operations		(4.50%)	(16.40%)	(9.90%)
Consumer health separation		2.20%	0%	0%
U.S. taxes on international income		(1.90%)	6.70%	2.70%
Tax benefits from loss on capital assets	(1.30%)		(1.30%)	(1.20%)
Tax benefits on share-based compensation		(1.30%)	(1.00%)	(1.50%)
All other (3)		1.90%	(0.70%)	(0.30%)
Effective Rate		17.40%	8.30%	10.80%

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jan. 02, 2022	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Tax Credit Carryforward [Line Items]
Effective tax rate reconciliation, net increase (decrease) in tax rate, percent			(2.50%)
Deferred tax assets, tax basis increase of certain assets due to reorganization	$ 2,300		$ 2,300
Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI)			$ 1,700
Tax benefits from loss on capital assets	1.30%		1.30%	1.20%
Income tax expense recorded related to TRAF				$ 400
TRAF effect on tax rate				2.60%
Income tax expense related to change in tax rate from TRAF				$ 300
Deferred tax asset recorded related to TRAF				450
Deferred tax expense related to TRAF				$ 300
Effective income tax rate reconciliation, deduction				1.20%
Unrecognized tax benefits	$ 3,323	$ 3,829	$ 3,323	$ 3,373	$ 3,853
Unrecognized tax benefits, interest on income tax expense		139	44	32
Unrecognized tax benefits, interest on income taxes accrued	512	$ 651	512
Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent		9.10%
Incremental tax costs		$ 3,784	$ 1,898	1,783
Consumer Health Business
Tax Credit Carryforward [Line Items]
Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent		2.20%
Incremental tax costs		$ 500
State and Local Jurisdiction
Tax Credit Carryforward [Line Items]
Effective tax rate reconciliation, net increase (decrease) in tax rate, percent			2.70%
Deferred tax assets, net	600		$ 600
Auris Health | Purchased in-process research and development(1)
Tax Credit Carryforward [Line Items]
Impairment of intangible assets, excluding goodwill	$ 900
Effective income tax rate reconciliation, nondeductible expense, impairment losses, percent	22.40%
Internal Revenue Service (IRS)
Tax Credit Carryforward [Line Items]
Payment on unrecognized tax benefit liability				700
Consumer Health
Tax Credit Carryforward [Line Items]
Litigation expense			1,600	3,900
Pharmaceutical
Tax Credit Carryforward [Line Items]
Litigation expense		$ 100	600	$ 800
Talc
Tax Credit Carryforward [Line Items]
Effective income tax rate reconciliation, litigation settlement, percent				0.235
Talc | Consumer Health
Tax Credit Carryforward [Line Items]
Litigation expense			$ 1,600	$ 4,000
Effective income tax rate reconciliation, litigation settlement, percent			0.235
Risperdal | Consumer Health
Tax Credit Carryforward [Line Items]
Litigation expense			$ 800
Effective income tax rate reconciliation, litigation settlement, percent			0.164
Opiods
Tax Credit Carryforward [Line Items]
Effective income tax rate reconciliation, litigation settlement, percent				0.214
Opiods | Pharmaceutical
Tax Credit Carryforward [Line Items]
Litigation expense				$ 1,000

Income Taxes - Temporary Differ

Income Taxes - Temporary Differences and Carryforwards (Details) - USD ($) $ in Millions	Jan. 01, 2023	Jan. 02, 2022
Asset
Employee related obligations	$ 725	$ 1,244
Stock based compensation	687	679
R&D capitalized for tax	2,611	1,664
Reserves & liabilities	2,761	2,882
Income reported for tax purposes	2,045	2,566
Net realizable operating loss carryforwards(4)	1,260	1,720
Undistributed foreign earnings	1,565	1,015
Miscellaneous international	1,053	870
Miscellaneous U.S.	476
Total deferred income taxes	13,183	12,640
Liability
Depreciation of property, plant and equipment	(858)	(876)
Goodwill and intangibles	(4,271)	(2,659)
Undistributed foreign earnings	(1,693)	(1,461)
Global intangible low-taxed income	(3,547)	(4,853)
Miscellaneous international	(65)	(39)
Miscellaneous U.S.		(16)
Total deferred income taxes	(10,434)	(9,904)
Deferred tax assets, tax basis increase of certain assets due to reorganization		2,300
Deferred tax liability, acquisition	1,800
Operating Loss Carryforwards, Valuation Allowance	$ 900	$ 900

Income Taxes - Summary of Activ

Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Summary of unrecognized tax benefits
Beginning of year	$ 3,323	$ 3,373	$ 3,853
Increases related to current year tax positions	523	242	265
Increases related to prior period tax positions	143	23	668
Decreases related to prior period tax positions	(148)	(128)	(551)
Settlements	(1)	(187)	(839)
Lapse of statute of limitations	(11)	0	(23)
End of year	$ 3,829	$ 3,323	$ 3,373

Employee Related Obligations -

Employee Related Obligations - Employee Related Obligations (Details) - USD ($) $ in Millions	Jan. 01, 2023	Jan. 02, 2022
Employee-related Liabilities [Abstract]
Pension benefits	$ 2,698	$ 4,088
Postretirement benefits	1,734	2,069
Postemployment benefits	2,832	3,117
Deferred compensation	100	181
Total employee obligations	7,364	9,455
Less current benefits payable	597	557
Employee related obligations — non-current	$ 6,767	$ 8,898

Employee Related Obligations _2

Employee Related Obligations - Narrative (Details) - USD ($) $ in Millions	Jan. 01, 2023	Jan. 02, 2022
Compensation Related Costs [Abstract]
Prepaid employee related obligations	$ 4,581	$ 4,436

Pensions and Other Benefit Pl_3

Pensions and Other Benefit Plans - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Defined Benefit Plan Disclosure [Line Items]
Percentage of corridor of greater of market value of assets	10%
Accumulated benefit obligation unfunded plans	$ 2,900	$ 3,900
Projected benefit obligation, unfunded plans	2,900	4,200
Plan with accumulated benefit obligation in excess of plan assets, plan assets	300	300
Fair value of company's common stock directly held in plan assets	$ 21	$ 385
Percentage of company's common stock to plan asset	0.10%	0.90%
Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Amendments	$ 7	$ 5
Plan Assets	31,514	41,930	$ 38,195
Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Amendments	0	0
Plan Assets	78	102	$ 90
U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	119
International Plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	151
Commingled funds | Level 2 | Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 78	$ 102
Maximum | Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Retirement plan benefits Employee compensation Period	5 years

Pensions and Other Benefit Pl_4

Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 1,327	$ 1,421	$ 1,380
Interest cost	911	770	955
Expected return on plan assets	(2,757)	(2,645)	(2,461)
Amortization of prior service cost	(184)	(181)	2
Recognized actuarial losses (gains)	655	1,257	891
Curtailments and settlements	1	1	23
Net periodic benefit cost (credit)	(47)	623	790
Other Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	320	309	287
Interest cost	105	81	133
Expected return on plan assets	(8)	(7)	(7)
Amortization of prior service cost	(5)	(31)	(31)
Recognized actuarial losses (gains)	121	151	142
Curtailments and settlements	0	0	0
Net periodic benefit cost (credit)	$ 533	$ 503	$ 524

Pensions and Other Benefit Pl_5

Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Retirement Plans
Net Periodic Benefit Cost
Service cost discount rate	2.46%	2.14%	2.82%
Interest cost discount rate	2.80%	2.34%	3.13%
Rate of increase in compensation levels	4.02%	4.01%	4%
Expected long-term rate of return on plan assets	7.25%	7.71%	8.12%
Benefit Obligation
Discount rate	5.01%	2.49%	2.14%
Rate of increase in compensation levels	4%	4.01%	4%
Other Benefit Plans
Net Periodic Benefit Cost
Service cost discount rate	2.59%	2.09%	3.04%
Interest cost discount rate	2.64%	2.33%	3.08%
Rate of increase in compensation levels	4.21%	4.25%	4.25%
Benefit Obligation
Discount rate	5.42%	2.68%	2.23%
Rate of increase in compensation levels	4.21%	4.21%	4.27%

Pensions and Other Benefit Pl_6

Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022
Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]
Healthcare cost trend rate assumed for next year	5.99%	5.33%
Rate to which the cost trend rate is assumed to decline (ultimate trend)	4.01%	3.73%
Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate	2047	2046

Pensions and Other Benefit Pl_7

Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	$ 4,581	$ 4,436
Current liabilities	(597)	(557)
Non-current liabilities	(6,767)	(8,898)
Retirement Plans
Change in Benefit Obligation
Projected benefit obligation - beginning of year	41,582	43,300
Service cost	1,327	1,421	$ 1,380
Interest cost	911	770	955
Plan participant contributions	67	67
Amendments	7	5
Actuarial (gains) losses(1)	(12,213)	(2,132)
Divestitures & acquisitions	0	(2)
Curtailments, settlements & restructuring	(7)	(7)
Benefits paid from plan	(1,228)	(1,157)
Effect of exchange rates	(815)	(683)
Projected benefit obligation - end of year	29,631	41,582	43,300
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Plan assets at fair value — beginning of year	41,930	38,195
Actual return on plan assets	(8,665)	4,439
Company contributions	270	969
Plan participant contributions	67	67
Settlements	(5)	(7)
Divestitures & acquisitions	0	(2)
Benefits paid from plan assets	(1,228)	(1,157)
Effect of exchange rates	(855)	(574)
Plan assets at fair value - End of year	31,514	41,930	38,195
Funded status - end of year	1,883	348
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	4,581	4,436
Current liabilities	(132)	(115)
Non-current liabilities	(2,566)	(3,973)
Total recognized in the consolidated balance sheet — end of year	1,883	348
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Net actuarial loss	3,948	5,539
Prior service cost (credit)(1)	(1,417)	(1,610)
Unrecognized net transition obligation	0	0
Total before tax effects	2,531	3,929
Accumulated Benefit Obligation	28,023	39,049
Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]
Net periodic benefit cost (credit)	(47)	623	790
Net actuarial (gain) loss	(793)	(3,927)
Amortization of net actuarial loss	(655)	(1,257)
Prior service cost (credit)	7	5
Amortization of prior service (cost) credit	183	181
Effect of exchange rates	(140)	(136)
Total loss/(income) recognized in other comprehensive income, before tax	(1,398)	(5,134)
Total recognized in net periodic benefit cost and other comprehensive income	(1,445)	(4,511)
Other Benefit Plans
Change in Benefit Obligation
Projected benefit obligation - beginning of year	4,878	5,028
Service cost	320	309	287
Interest cost	105	81	133
Plan participant contributions	0	0
Amendments	0	0
Actuarial (gains) losses(1)	(704)	(188)
Divestitures & acquisitions	0	0
Curtailments, settlements & restructuring	0	0
Benefits paid from plan	(393)	(348)
Effect of exchange rates	(9)	(4)
Projected benefit obligation - end of year	4,197	4,878	5,028
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Plan assets at fair value — beginning of year	102	90
Actual return on plan assets	(17)	17
Company contributions	386	343
Plan participant contributions	0	0
Settlements	0	0
Divestitures & acquisitions	0	0
Benefits paid from plan assets	(393)	(348)
Effect of exchange rates	0	0
Plan assets at fair value - End of year	78	102	90
Funded status - end of year	(4,119)	(4,776)
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets	0	0
Current liabilities	(461)	(438)
Non-current liabilities	(3,658)	(4,338)
Total recognized in the consolidated balance sheet — end of year	(4,119)	(4,776)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]
Net actuarial loss	239	1,113
Prior service cost (credit)(1)	(7)	(13)
Unrecognized net transition obligation	0	0
Total before tax effects	232	1,100
Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]
Net periodic benefit cost (credit)	533	503	$ 524
Net actuarial (gain) loss	(751)	(199)
Amortization of net actuarial loss	(121)	(151)
Prior service cost (credit)	0	0
Amortization of prior service (cost) credit	5	31
Effect of exchange rates	(1)	0
Total loss/(income) recognized in other comprehensive income, before tax	(868)	(319)
Total recognized in net periodic benefit cost and other comprehensive income	$ (335)	$ 184

Pensions and Other Benefit Pl_8

Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details) - USD ($) $ in Millions	Jan. 01, 2023	Jan. 02, 2022
Qualified Plans | U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 20,937	$ 27,944
Projected Benefit Obligation	18,394	25,041
Accumulated Benefit Obligation	17,696	23,985
Projected Benefit Obligation	2,543	2,903
Accumulated Benefit Obligation	3,241	3,959
Non-Qualified Plans | U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Projected Benefit Obligation	1,937	2,703
Accumulated Benefit Obligation	1,872	2,479
Projected Benefit Obligation	(1,937)	(2,703)
Accumulated Benefit Obligation	(1,872)	(2,479)
Funded Plans | International Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	10,577	13,986
Projected Benefit Obligation	9,024	13,428
Accumulated Benefit Obligation	8,202	12,212
Projected Benefit Obligation	1,553	558
Accumulated Benefit Obligation	2,375	1,774
Unfunded Plans | International Plans
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Projected Benefit Obligation	276	410
Accumulated Benefit Obligation	253	373
Projected Benefit Obligation	(276)	(410)
Accumulated Benefit Obligation	$ (253)	$ (373)

Pensions and Other Benefit Pl_9

Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details) $ in Millions	Jan. 01, 2023 USD ($)
Retirement plans
Defined Benefit Plan Disclosure [Line Items]
2022	$ 1,445
2023	1,457
2024	1,532
2025	1,609
2026	1,708
2027-2031	10,034
Other benefit plans
Defined Benefit Plan Disclosure [Line Items]
2022	471
2023	485
2024	433
2025	447
2026	462
2027-2031	$ 2,539

Pensions and Other Benefit P_10

Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details) $ in Millions	Jan. 01, 2023 USD ($)
Retirement Benefits [Abstract]
2022	$ 123
2023	128
2024	136
2025	141
2026	146
2027-2031	$ 816

Pensions and Other Benefit P_11

Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)	Jan. 01, 2023	Jan. 02, 2022
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	100%	100%
Target Allocation	100%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	62%	65%
Target Allocation	61%
Debt securities
Defined Benefit Plan Disclosure [Line Items]
Percent of Plan Assets	38%	35%
Target Allocation	39%

Pensions and Other Benefit P_12

Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details) - Retirement plans - USD ($) $ in Millions	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 31,514	$ 41,930	$ 38,195
Fair Value, Measurements, Recurring
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	31,514	41,930
Investments Measured at Net Asset Value	8,612	10,515
Fair Value, Measurements, Recurring | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	8,879	14,209
Fair Value, Measurements, Recurring | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	13,954	17,086
Fair Value, Measurements, Recurring | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	69	120
Fair Value, Measurements, Recurring | Short-term investment funds
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	46	1,135
Fair Value, Measurements, Recurring | Short-term investment funds | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	33	102
Fair Value, Measurements, Recurring | Short-term investment funds | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	13	1,033
Fair Value, Measurements, Recurring | Short-term investment funds | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Government and agency securities
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	5,863	7,016
Fair Value, Measurements, Recurring | Government and agency securities | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Government and agency securities | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	5,863	7,016
Fair Value, Measurements, Recurring | Government and agency securities | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Debt instruments
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	3,681	3,505
Fair Value, Measurements, Recurring | Debt instruments | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Debt instruments | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	3,681	3,505
Fair Value, Measurements, Recurring | Debt instruments | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	8,848	14,109
Fair Value, Measurements, Recurring | Equity securities | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	8,846	14,107
Fair Value, Measurements, Recurring | Equity securities | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	2	2
Fair Value, Measurements, Recurring | Equity securities | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Commingled funds
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	10,524	14,309
Investments Measured at Net Asset Value	6,106	8,708
Fair Value, Measurements, Recurring | Commingled funds | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Commingled funds | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	4,362	5,496
Fair Value, Measurements, Recurring | Commingled funds | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	56	105
Fair Value, Measurements, Recurring | Other assets
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	2,552	1,856
Investments Measured at Net Asset Value	2,506	1,807
Fair Value, Measurements, Recurring | Other assets | Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	0	0
Fair Value, Measurements, Recurring | Other assets | Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	33	34
Fair Value, Measurements, Recurring | Other assets | Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan Assets	$ 13	$ 15

Savings Plan - Narrative (Detai

Savings Plan - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Savings Plan [Abstract]
Matching contributions	$ 275	$ 256	$ 243

Capital and Treasury Stock - Ch

Capital and Treasury Stock - Changes in Treasury Stock (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Changes in Treasury Stock Shares Outstanding [Roll Forward]
Treasury Stock, beginning balance (shares)	490,878	487,331	487,336
Employee compensation and stock option plans (shares)	(20,007)	(17,399)	(21,765)
Treasury Stock, ending balance (shares)	506,246	490,878	487,331
Changes in treasury stock
Treasury Stock, Balance	$ 39,099	$ 38,490	$ 38,417
Employee compensation and stock option plans	(3,440)	(2,847)	(3,148)
Repurchase of common stock	6,035	3,456	3,221
Treasury Stock, Ending Balance	$ 41,694	$ 39,099	$ 38,490
Treasury Stock
Changes in Treasury Stock Shares Outstanding [Roll Forward]
Repurchase of common stock (shares)	35,375	20,946	21,760
Changes in treasury stock
Repurchase of common stock	$ 6,035	$ 3,456	$ 3,221

Capital and Treasury Stock - Na

Capital and Treasury Stock - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Billions		4 Months Ended	12 Months Ended
	Jan. 03, 2023	Jan. 01, 2023	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021	Sep. 14, 2022
Equity, Class of Treasury Stock [Line Items]
Common stock, shares issued (in shares)		3,119,843	3,119,843	3,119,843	3,119,843
Cash dividends paid (in dollars per share)			$ 4.45	$ 4.19	$ 3.98
Stocks repurchased		$ 2.5
Subsequent Event
Equity, Class of Treasury Stock [Line Items]
Cash dividend (in dollars per share)	$ 1.13
December 17, 2018 Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount						$ 5

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	$ 74,023	$ 63,278	$ 59,471
Net change	91	2,184	649
Ending Balance	76,804	74,023	63,278
Foreign Currency Translation
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(10,017)	(8,938)	(8,705)
Net change	(1,796)	(1,079)	(233)
Ending Balance	(11,813)	(10,017)	(8,938)
Gain/(Loss) On Securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(3)	1	0
Net change	(24)	(4)	1
Ending Balance	(27)	(3)	1
Employee Benefit Plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(2,702)	(6,957)	(6,891)
Net change	1,805	4,255	(66)
Ending Balance	(897)	(2,702)	(6,957)
Gain/ (Loss) On Derivatives & Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(336)	652	(295)
Net change	106	(988)	947
Ending Balance	(230)	(336)	652
Accumulated Other Comprehensive Income (Loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(13,058)	(15,242)	(15,891)
Net change	91	2,184	649
Ending Balance	$ (12,967)	$ (13,058)	$ (15,242)

International Currency Transl_2

International Currency Translation - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Foreign Currency Translation [Abstract]
Foreign currency transaction gain (loss), before tax	$ (328)	$ (236)	$ (209)

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details) - $ / shares shares in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share (in dollars per share)	$ 6.83	$ 7.93	$ 5.59
Average shares outstanding — basic (in shares)	2,625.2	2,632.1	2,632.8
Potential shares exercisable under stock option plans (in shares)	140.1	138	118.3
Less: shares repurchased under treasury stock method (in shares)	(101.4)	(96.1)	(80.4)
Average shares outstanding - diluted (in shares)	2,663.9	2,674	2,670.7
Diluted net earnings per share (in dollars per share)	$ 6.73	$ 7.81	$ 5.51

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) shares in Millions	12 Months Ended
	Jan. 03, 2021 shares
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	18

Common Stock, Stock Option Pl_3

Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Jan. 01, 2023 USD ($) StockBasedCompensationPlans $ / shares shares	Jan. 02, 2022 USD ($) $ / shares shares	Jan. 03, 2021 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock-based compensation plans | StockBasedCompensationPlans	1
Compensation cost charged for Long term incentive plan | $	$ 1,138	$ 1,135	$ 1,005
Total income tax benefit recognized | $	196	218	210
Exercise of options, tax benefit | $	282	223	248
Total compensation cost not yet recognized for option | $	$ 939	$ 862	$ 804
Weighted average period for total compensation cost not yet recognized	1 year 9 months 18 days	1 year 9 months 10 days	1 year 9 months 3 days
Average fair value of option granted (in dollars per share) | $ / shares	$ 23.23	$ 20.86	$ 16.42
Total intrinsic value of options exercised | $	$ 1,228	$ 919	$ 1,021
Stock options outstanding (in shares) | shares	118,672	117,361	114,250
Stock option average life	5 years 9 months 18 days	5 years 9 months 18 days	6 years
Stock options exercisable | shares		62,742	61,289
Stock options average price | $ / shares		$ 104.42	$ 96.97
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options expiration period	10 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average fair value of RSU's and PSU's granted | $ / shares	$ 153.67	$ 152.62	$ 139.58
Fair Value of RSU or PSU units settled | $	$ 591	$ 611	$ 650
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Average fair value of RSU's and PSU's granted | $ / shares	$ 170.46	$ 179.35	$ 160.54
Fair Value of RSU or PSU units settled | $	$ 94	$ 83	$ 91
Minimum | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Minimum | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	6 months
Minimum | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	0%
Maximum | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Maximum | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Maximum | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	200%
2022 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance under long-term incentive plan | shares	150,000
Shares available for future grants under long-term incentive plan | shares	150,000
Shares issued subject to stock options or stock appreciation rights (in shares) | shares	110,000
Shares subject to full value awards (in shares) | shares	40,000
Shares subject to full value award, excess (in shares) | shares	40,000

Common Stock, Stock Option Pl_4

Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Weighted average assumptions of fair value of options
Risk-free rate	1.98%	0.83%	1.47%
Expected volatility	18%	18.59%	15.33%
Expected life (in years)	7 years	7 years	7 years
Expected dividend yield	2.70%	2.50%	2.60%

Common Stock, Stock Option Pl_5

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021	Dec. 29, 2019
Outstanding Shares
Options outstanding beginning of period	117,361	114,250	111,637
Options granted	19,809	18,525	20,723
Options exercised	(16,310)	(13,248)	(16,275)
Options canceled/forfeited	(2,188)	(2,166)	(1,835)
Options outstanding end of period	118,672	117,361	114,250
Weighted Average Exercise Price
Options exercise price beginning of period (in dollars per share)	$ 125.36	$ 116.22	$ 105.63
Options granted, average exercise price (in dollars per share)	165.89	164.62	151.41
Options exercised, average exercise price (in dollars per share)	100.15	97.48	86.05
Options canceled/forfeited, average exercise price (in dollars per share)	160.56	149.75	137.62
Options exercise price end of period (in dollars per share)	$ 134.95	$ 125.36	$ 116.22
Aggregate intrinsic value	$ 4,949	$ 5,364	$ 4,703	$ 4,478

Common Stock, Stock Option Pl_6

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details) - $ / shares shares in Thousands	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Stock options outstanding and exercisable
Outstanding number of Options (in shares)	118,672	117,361	114,250
Outstanding, Average Life	5 years 9 months 18 days	5 years 9 months 18 days	6 years
Outstanding Average Exercise Price (in dollars per share)	$ 134.95
Exercisable number of Options (in shares)	63,661
Exercisable, Average Exercise Price (in dollars per share)	$ 113.06
$72.54-$100.48
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	72.54
Price Range, Maximum (in dollars per share)	$ 100.48
Outstanding number of Options (in shares)	17,221
Outstanding, Average Life	1 year 6 months
Outstanding Average Exercise Price (in dollars per share)	$ 93.07
Exercisable number of Options (in shares)	17,221
Exercisable, Average Exercise Price (in dollars per share)	$ 93.07
$101.87-$115.67
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	101.87
Price Range, Maximum (in dollars per share)	$ 115.67
Outstanding number of Options (in shares)	22,039
Outstanding, Average Life	3 years 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 108.78
Exercisable number of Options (in shares)	22,039
Exercisable, Average Exercise Price (in dollars per share)	$ 108.78
$129.51-$141.06
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	129.51
Price Range, Maximum (in dollars per share)	$ 141.06
Outstanding number of Options (in shares)	24,870
Outstanding, Average Life	5 years 8 months 12 days
Outstanding Average Exercise Price (in dollars per share)	$ 130.88
Exercisable number of Options (in shares)	24,228
Exercisable, Average Exercise Price (in dollars per share)	$ 130.85
$151.41-$164.62
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	151.41
Price Range, Maximum (in dollars per share)	$ 164.62
Outstanding number of Options (in shares)	35,465
Outstanding, Average Life	7 years 7 months 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 157.75
Exercisable number of Options (in shares)	150
Exercisable, Average Exercise Price (in dollars per share)	$ 156.21
$164.63-$165.89
Stock options outstanding and exercisable
Price Range, Minimum (in dollars per share)	164.63
Price Range, Maximum (in dollars per share)	$ 165.89
Outstanding number of Options (in shares)	19,077
Outstanding, Average Life	9 years 1 month 6 days
Outstanding Average Exercise Price (in dollars per share)	$ 165.89
Exercisable number of Options (in shares)	23
Exercisable, Average Exercise Price (in dollars per share)	$ 165.89

Common Stock, Stock Option Pl_7

Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details) shares in Thousands	12 Months Ended
	Jan. 01, 2023 shares
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Beginning balance (in shares)	14,122
Granted (in shares)	5,154
Issued (in shares)	(4,866)
Canceled/forfeited/adjusted (in shares)	794
Ending balance (in shares)	13,616
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Beginning balance (in shares)	2,312
Granted (in shares)	753
Issued (in shares)	(637)
Canceled/forfeited/adjusted (in shares)	(71)
Ending balance (in shares)	2,357

Segments of Business and Geog_3

Segments of Business and Geographic Areas - Sales by Segment of Business (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Segment Reporting Information [Line Items]
Sales to Customers	$ 94,943	$ 93,775	$ 82,584
Percentage Change In Sales By Segment Of Business	1.30%	13.60%
Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 14,953	$ 15,035	14,450
Percentage Change In Sales By Segment Of Business	(0.50%)	4%
Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	$ 52,563	$ 51,680	45,175
Percentage Change In Sales By Segment Of Business	1.70%	14.40%
Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 16,935	$ 16,750	15,055
Percentage Change In Sales By Segment Of Business	1.10%	11.30%
Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,449	$ 5,825	3,543
Percentage Change In Sales By Segment Of Business	(6.50%)	64.40%
Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 6,893	$ 6,988	6,526
Percentage Change In Sales By Segment Of Business	(1.40%)	7.10%
Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 15,983	$ 14,548	12,367
Percentage Change In Sales By Segment Of Business	9.90%	17.60%
Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,417	$ 3,450	3,148
Percentage Change In Sales By Segment Of Business	(1.00%)	9.60%
Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,887	$ 4,119	4,534
Percentage Change In Sales By Segment Of Business	(5.60%)	(9.20%)
Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers	$ 27,427	$ 27,060	22,959
Percentage Change In Sales By Segment Of Business	1.40%	17.90%
Medical Devices | Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,300	$ 3,971	3,046
Percentage Change In Sales By Segment Of Business	8.30%	30.40%
Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 8,587	$ 8,588	7,763
Percentage Change In Sales By Segment Of Business	0%	10.60%
Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 9,690	$ 9,812	8,232
Percentage Change In Sales By Segment Of Business	(1.20%)	19.20%
Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,849	$ 4,688	3,919
Percentage Change In Sales By Segment Of Business	3.40%	19.60%
OTC | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 6,031	$ 5,627	5,221
Percentage Change In Sales By Segment Of Business	7.20%	7.80%
Skin health/Beauty | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,352	$ 4,541	4,450
Percentage Change In Sales By Segment Of Business	(4.20%)	2%
Oral Care | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,505	$ 1,645	1,641
Percentage Change In Sales By Segment Of Business	(8.50%)	0.20%
Baby Care | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,461	$ 1,566	1,517
Percentage Change In Sales By Segment Of Business	(6.70%)	3.20%
Women's Health | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 904	$ 917	901
Percentage Change In Sales By Segment Of Business	(1.50%)	1.80%
Wound Care and Other | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 700	$ 739	720
Percentage Change In Sales By Segment Of Business	(5.30%)	2.60%
Remicade | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,343	$ 3,190	3,747
Percentage Change In Sales By Segment Of Business	(26.60%)	(14.90%)
Simponi/Simponi Aria | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,184	$ 2,276	2,243
Percentage Change In Sales By Segment Of Business	(4.00%)	1.40%
Stelara | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 9,723	$ 9,134	7,707
Percentage Change In Sales By Segment Of Business	6.50%	18.50%
Tremfya | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,668	$ 2,127	1,347
Percentage Change In Sales By Segment Of Business	25.40%	57.90%
Other Immunology | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 17	$ 24	11
Percentage Change In Sales By Segment Of Business	(28.20%)
COVID-19 | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,179	2,385	0
Percentage Change In Sales By Segment Of Business	(8.60%)
EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,008	$ 994	964
Percentage Change In Sales By Segment Of Business	1.50%	3.10%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,943	$ 2,083	2,184
Percentage Change In Sales By Segment Of Business	(6.70%)	(4.60%)
Other Infectious Diseases | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 318	$ 363	396
Percentage Change In Sales By Segment Of Business	(12.30%)	(8.30%)
CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 644	$ 667	622
Percentage Change In Sales By Segment Of Business	(3.50%)	7.30%
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,140	$ 4,022	3,653
Percentage Change In Sales By Segment Of Business	3%	10.10%
RISPERDAL CONSTA | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 485	$ 592	642
Percentage Change In Sales By Segment Of Business	(18.10%)	(7.70%)
OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,623	$ 1,706	1,610
Percentage Change In Sales By Segment Of Business	(4.90%)	6%
DARZALEX | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 7,977	$ 6,023	4,190
Percentage Change In Sales By Segment Of Business	32.40%	43.80%
ERLEADA | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,881	$ 1,291	760
Percentage Change In Sales By Segment Of Business	45.70%	70%
IMBRUVICA | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,784	$ 4,369	4,128
Percentage Change In Sales By Segment Of Business	(13.40%)	5.80%
ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,770	$ 2,297	2,470
Percentage Change In Sales By Segment Of Business	(22.90%)	(7.00%)
Other Oncology | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 571	$ 568	821
Percentage Change In Sales By Segment Of Business	0.60%	(30.80%)
OPSUMIT | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,783	$ 1,819	1,639
Percentage Change In Sales By Segment Of Business	(2.00%)	11%
UPTRAVI | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,322	$ 1,237	1,093
Percentage Change In Sales By Segment Of Business	6.90%	13.10%
Other | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 313	$ 395	416
Percentage Change In Sales By Segment Of Business	(20.80%)	(5.00%)
Other | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 966	$ 1,119	1,394
Percentage Change In Sales By Segment Of Business	(13.60%)	(19.70%)
XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,473	$ 2,438	2,345
Percentage Change In Sales By Segment Of Business	1.40%	4%
INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 448	$ 563	795
Percentage Change In Sales By Segment Of Business	(20.40%)	(29.30%)
HIPS | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,514	$ 1,480	1,280
Percentage Change In Sales By Segment Of Business	2.30%	15.60%
KNEES | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,359	$ 1,325	1,170
Percentage Change In Sales By Segment Of Business	2.60%	13.30%
TRAUMA | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,871	$ 2,885	2,614
Percentage Change In Sales By Segment Of Business	(0.50%)	10.40%
SPINE,SPORTS & OTHER | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,843	$ 2,898	2,699
Percentage Change In Sales By Segment Of Business	(1.90%)	7.40%
ADVANCED | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,569	$ 4,622	3,839
Percentage Change In Sales By Segment Of Business	(1.10%)	20.40%
GENERAL | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,121	$ 5,190	4,392
Percentage Change In Sales By Segment Of Business	(1.30%)	18.10%
CONTACT LENSES/OTHER | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,543	$ 3,440	2,994
Percentage Change In Sales By Segment Of Business	3%	14.90%
SURGICAL | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,306	$ 1,248	925
Percentage Change In Sales By Segment Of Business	4.60%	34.90%
United States
Segment Reporting Information [Line Items]
Sales to Customers	$ 48,580	$ 47,156	43,133
Percentage Change In Sales By Segment Of Business	3%	9.30%
United States | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 6,599	$ 6,516	6,362
Percentage Change In Sales By Segment Of Business	1.30%	2.40%
United States | Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	$ 28,604	$ 27,954	25,735
Percentage Change In Sales By Segment Of Business	2.30%	8.60%
United States | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 11,036	$ 10,843	10,175
Percentage Change In Sales By Segment Of Business	1.80%	6.60%
United States | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,680	$ 2,249	1,735
Percentage Change In Sales By Segment Of Business	(25.30%)	29.70%
United States | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,570	$ 3,347	3,091
Percentage Change In Sales By Segment Of Business	6.70%	8.30%
United States | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 6,930	$ 5,958	5,092
Percentage Change In Sales By Segment Of Business	16.30%	17%
United States | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,346	$ 2,365	2,133
Percentage Change In Sales By Segment Of Business	(0.80%)	10.90%
United States | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,042	$ 3,192	3,509
Percentage Change In Sales By Segment Of Business	(4.70%)	(9.00%)
United States | Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers	$ 13,377	$ 12,686	11,036
Percentage Change In Sales By Segment Of Business	5.40%	14.90%
United States | Medical Devices | Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,169	$ 1,836	1,452
Percentage Change In Sales By Segment Of Business	18.20%	26.40%
United States | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,321	$ 5,126	4,779
Percentage Change In Sales By Segment Of Business	3.80%	7.30%
United States | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,897	$ 3,867	3,249
Percentage Change In Sales By Segment Of Business	0.80%	19%
United States | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,990	$ 1,857	1,557
Percentage Change In Sales By Segment Of Business	7.20%	19.30%
United States | OTC | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,782	$ 2,594	2,460
Percentage Change In Sales By Segment Of Business	7.30%	5.40%
United States | Skin health/Beauty | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,337	$ 2,400	2,350
Percentage Change In Sales By Segment Of Business	(2.60%)	2.10%
United States | Oral Care | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 635	$ 637	683
Percentage Change In Sales By Segment Of Business	(0.30%)	(6.70%)
United States | Baby Care | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 357	$ 378	376
Percentage Change In Sales By Segment Of Business	(5.50%)	0.50%
United States | Women's Health | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 13	$ 13	13
Percentage Change In Sales By Segment Of Business	1.70%	(1.60%)
United States | Wound Care and Other | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 475	$ 495	480
Percentage Change In Sales By Segment Of Business	(4.00%)	3.10%
United States | Remicade | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,417	$ 2,019	2,508
Percentage Change In Sales By Segment Of Business	(29.80%)	(19.50%)
United States | Simponi/Simponi Aria | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,166	$ 1,127	1,155
Percentage Change In Sales By Segment Of Business	3.50%	(2.40%)
United States | Stelara | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 6,388	$ 5,938	5,240
Percentage Change In Sales By Segment Of Business	7.60%	13.30%
United States | Tremfya | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,844	$ 1,503	926
Percentage Change In Sales By Segment Of Business	22.70%	62.30%
United States | Other Immunology | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 17	$ 21	0
Percentage Change In Sales By Segment Of Business	(18.40%)
United States | COVID-19 | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 120	634	0
Percentage Change In Sales By Segment Of Business	(81.10%)
United States | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 36	$ 41	44
Percentage Change In Sales By Segment Of Business	(10.80%)	(7.60%)
United States | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,494	$ 1,508	1,587
Percentage Change In Sales By Segment Of Business	(1.00%)	(4.90%)
United States | Other Infectious Diseases | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 30	$ 66	104
Percentage Change In Sales By Segment Of Business	(55.50%)	(36.00%)
United States | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 151	$ 172	183
Percentage Change In Sales By Segment Of Business	(12.50%)	(5.80%)
United States | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,714	$ 2,550	2,314
Percentage Change In Sales By Segment Of Business	6.50%	10.20%
United States | RISPERDAL CONSTA | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 257	$ 287	296
Percentage Change In Sales By Segment Of Business	(10.40%)	(2.90%)
United States | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 447	$ 338	298
Percentage Change In Sales By Segment Of Business	32.40%	13.30%
United States | DARZALEX | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 4,210	$ 3,169	2,232
Percentage Change In Sales By Segment Of Business	32.80%	42%
United States | ERLEADA | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 968	$ 813	583
Percentage Change In Sales By Segment Of Business	19.20%	39.30%
United States | IMBRUVICA | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,390	$ 1,747	1,821
Percentage Change In Sales By Segment Of Business	(20.40%)	(4.00%)
United States | ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 74	$ 119	373
Percentage Change In Sales By Segment Of Business	(37.80%)	(68.10%)
United States | Other Oncology | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 289	$ 110	83
Percentage Change In Sales By Segment Of Business		31.70%
United States | OPSUMIT | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,132	$ 1,147	1,008
Percentage Change In Sales By Segment Of Business	(1.30%)	13.70%
United States | UPTRAVI | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,104	$ 1,056	955
Percentage Change In Sales By Segment Of Business	4.50%	10.50%
United States | Other | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 110	$ 163	169
Percentage Change In Sales By Segment Of Business	(32.30%)	(3.70%)
United States | Other | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 376	$ 446	600
Percentage Change In Sales By Segment Of Business	(15.50%)	(25.70%)
United States | XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,473	$ 2,438	2,345
Percentage Change In Sales By Segment Of Business	1.40%	4%
United States | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 193	$ 308	564
Percentage Change In Sales By Segment Of Business	(37.40%)	(45.40%)
United States | HIPS | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 943	$ 878	793
Percentage Change In Sales By Segment Of Business	7.30%	10.70%
United States | KNEES | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 851	$ 787	743
Percentage Change In Sales By Segment Of Business	8.20%	5.90%
United States | TRAUMA | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,882	$ 1,819	1,648
Percentage Change In Sales By Segment Of Business	3.50%	10.40%
United States | SPINE,SPORTS & OTHER | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,645	$ 1,642	1,595
Percentage Change In Sales By Segment Of Business	0.20%	2.90%
United States | ADVANCED | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,784	$ 1,761	1,535
Percentage Change In Sales By Segment Of Business	1.30%	14.90%
United States | GENERAL | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,113	$ 2,105	1,714
Percentage Change In Sales By Segment Of Business	0.40%	22.70%
United States | CONTACT LENSES/OTHER | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,522	$ 1,398	1,213
Percentage Change In Sales By Segment Of Business	8.90%	15.20%
United States | SURGICAL | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 468	$ 459	344
Percentage Change In Sales By Segment Of Business	2%	33.50%
Non-US
Segment Reporting Information [Line Items]
Sales to Customers	$ 46,363	$ 46,619	39,451
Percentage Change In Sales By Segment Of Business	(0.60%)	18.20%
Non-US | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 8,354	$ 8,519	8,088
Percentage Change In Sales By Segment Of Business	(1.90%)	5.30%
Non-US | Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	$ 23,959	$ 23,726	19,440
Percentage Change In Sales By Segment Of Business	1%	22%
Non-US | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,899	$ 5,907	4,880
Percentage Change In Sales By Segment Of Business	(0.10%)	21%
Non-US | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,769	$ 3,576	1,808
Percentage Change In Sales By Segment Of Business	5.40%	97.80%
Non-US | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,323	$ 3,641	3,435
Percentage Change In Sales By Segment Of Business	(8.70%)	6%
Non-US | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 9,052	$ 8,590	7,275
Percentage Change In Sales By Segment Of Business	5.40%	18.10%
Non-US | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,071	$ 1,085	1,015
Percentage Change In Sales By Segment Of Business	(1.30%)	6.90%
Non-US | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 845	$ 927	1,025
Percentage Change In Sales By Segment Of Business	(8.90%)	(9.60%)
Non-US | Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers	$ 14,050	$ 14,374	11,923
Percentage Change In Sales By Segment Of Business	(2.30%)	20.60%
Non-US | Medical Devices | Interventional Solutions
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,131	$ 2,135	1,594
Percentage Change In Sales By Segment Of Business	(0.20%)	34%
Non-US | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,267	$ 3,462	2,984
Percentage Change In Sales By Segment Of Business	(5.60%)	16%
Non-US | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 5,793	$ 5,945	4,983
Percentage Change In Sales By Segment Of Business	(2.60%)	19.30%
Non-US | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,859	$ 2,831	2,362
Percentage Change In Sales By Segment Of Business	1%	19.80%
Non-US | OTC | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,249	$ 3,034	2,761
Percentage Change In Sales By Segment Of Business	7.10%	9.90%
Non-US | Skin health/Beauty | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,015	$ 2,141	2,100
Percentage Change In Sales By Segment Of Business	(5.90%)	1.90%
Non-US | Oral Care | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 871	$ 1,008	958
Percentage Change In Sales By Segment Of Business	(13.60%)	5.10%
Non-US | Baby Care | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,104	$ 1,188	1,141
Percentage Change In Sales By Segment Of Business	(7.10%)	4.10%
Non-US | Women's Health | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 891	$ 905	888
Percentage Change In Sales By Segment Of Business	(1.50%)	1.80%
Non-US | Wound Care and Other | Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	$ 224	$ 243	240
Percentage Change In Sales By Segment Of Business	(8.00%)	1.70%
Non-US | Remicade | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 722	$ 935	893
Percentage Change In Sales By Segment Of Business	(22.80%)	4.80%
Non-US | Simponi/Simponi Aria | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,017	$ 1,148	1,088
Percentage Change In Sales By Segment Of Business	(11.40%)	5.50%
Non-US | Stelara | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,335	$ 3,196	2,467
Percentage Change In Sales By Segment Of Business	4.40%	29.60%
Non-US | Tremfya | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 824	$ 624	421
Percentage Change In Sales By Segment Of Business	32%	48.20%
Non-US | Other Immunology | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 0	$ 3	11
Percentage Change In Sales By Segment Of Business		(73.30%)
Non-US | COVID-19 | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,059	$ 1,751	0
Percentage Change In Sales By Segment Of Business	17.60%
Non-US | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 972	$ 953	920
Percentage Change In Sales By Segment Of Business	2%	3.60%
Non-US | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 449	$ 575	597
Percentage Change In Sales By Segment Of Business	(21.90%)	(3.60%)
Non-US | Other Infectious Diseases | Pharmaceutical | Infectious Diseases
Segment Reporting Information [Line Items]
Sales to Customers	$ 289	$ 297	292
Percentage Change In Sales By Segment Of Business	(2.60%)	1.70%
Non-US | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 493	$ 495	439
Percentage Change In Sales By Segment Of Business	(0.40%)	12.80%
Non-US | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,426	$ 1,472	1,339
Percentage Change In Sales By Segment Of Business	(3.10%)	10%
Non-US | RISPERDAL CONSTA | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 228	$ 305	346
Percentage Change In Sales By Segment Of Business	(25.30%)	(11.80%)
Non-US | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,176	$ 1,368	1,312
Percentage Change In Sales By Segment Of Business	(14.10%)	4.30%
Non-US | DARZALEX | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,767	$ 2,854	1,958
Percentage Change In Sales By Segment Of Business	32%	45.80%
Non-US | ERLEADA | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 913	$ 478	176
Non-US | IMBRUVICA | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,394	$ 2,622	2,307
Percentage Change In Sales By Segment Of Business	(8.70%)	13.60%
Non-US | ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,696	$ 2,178	2,097
Percentage Change In Sales By Segment Of Business	(22.10%)	3.90%
Non-US | Other Oncology | Pharmaceutical | Oncology
Segment Reporting Information [Line Items]
Sales to Customers	$ 283	$ 458	738
Percentage Change In Sales By Segment Of Business	(38.30%)	(37.90%)
Non-US | OPSUMIT | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 651	$ 672	631
Percentage Change In Sales By Segment Of Business	(3.20%)	6.60%
Non-US | UPTRAVI | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 218	$ 181	138
Percentage Change In Sales By Segment Of Business	20.40%	31.10%
Non-US | Other | Pharmaceutical | Pulmonary Hypertension
Segment Reporting Information [Line Items]
Sales to Customers	$ 202	$ 232	247
Percentage Change In Sales By Segment Of Business	(12.80%)	(5.90%)
Non-US | Other | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 590	$ 673	794
Percentage Change In Sales By Segment Of Business	(12.30%)	(15.20%)
Non-US | XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 0	$ 0	0
Percentage Change In Sales By Segment Of Business	0%	0%
Non-US | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other
Segment Reporting Information [Line Items]
Sales to Customers	$ 255	$ 254	231
Percentage Change In Sales By Segment Of Business	0.10%	9.90%
Non-US | HIPS | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 571	$ 602	487
Percentage Change In Sales By Segment Of Business	(5.10%)	23.60%
Non-US | KNEES | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 508	$ 538	427
Percentage Change In Sales By Segment Of Business	(5.70%)	26.10%
Non-US | TRAUMA | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 989	$ 1,066	966
Percentage Change In Sales By Segment Of Business	(7.20%)	10.40%
Non-US | SPINE,SPORTS & OTHER | Medical Devices | Orthopaedics
Segment Reporting Information [Line Items]
Sales to Customers	$ 1,198	$ 1,256	1,104
Percentage Change In Sales By Segment Of Business	(4.60%)	13.80%
Non-US | ADVANCED | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,785	$ 2,861	2,304
Percentage Change In Sales By Segment Of Business	(2.60%)	24.10%
Non-US | GENERAL | Medical Devices | Surgery
Segment Reporting Information [Line Items]
Sales to Customers	$ 3,008	$ 3,085	2,679
Percentage Change In Sales By Segment Of Business	(2.50%)	15.20%
Non-US | CONTACT LENSES/OTHER | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 2,022	$ 2,043	1,781
Percentage Change In Sales By Segment Of Business	(1.00%)	14.70%
Non-US | SURGICAL | Medical Devices | Vision
Segment Reporting Information [Line Items]
Sales to Customers	$ 837	$ 788	581
Percentage Change In Sales By Segment Of Business	6.20%	35.70%
UNITED STATES Exports | Remicade | Pharmaceutical | Immunology
Segment Reporting Information [Line Items]
Sales to Customers	$ 204	$ 236	346
Percentage Change In Sales By Segment Of Business	(13.60%)	(31.90%)
CHINA | OTC | CONSUMER HEALTH and PHARMACEUTICAL
Segment Reporting Information [Line Items]
Sales to Customers		$ 400	$ 400

Segments of Business and Geog_4

Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details) $ in Millions	12 Months Ended
	Jan. 01, 2023 USD ($) Segment	Jan. 02, 2022 USD ($) Segment	Jan. 03, 2021 USD ($) Segment
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	$ 21,725	$ 22,776	$ 16,497
Identifiable Assets	187,378	182,018
Results of Operations, Income before Income Taxes		200	200
Additions to Property, Plant & Equipment	4,009	3,652	3,347
Depreciation and Amortization	6,970	7,390	7,231
Sales to Customers	$ 94,943	$ 93,775	$ 82,584
Number of segments | Segment	3	3	3
Charges	$ 321	$ 252	$ 247
In-process research and development	783	900	181
Contingent consideration reversal	0	0	$ (1,148)
Property, Plant and Equipment
Segment Reporting Information [Line Items]
Long-Lived Assets	19,803	18,962
Other Intangible Assets
Segment Reporting Information [Line Items]
Long-Lived Assets	93,556	$ 81,638
Auris Health
Segment Reporting Information [Line Items]
Contingent consideration reversal	(1,148)
bermekimab | In Process Research and Development
Segment Reporting Information [Line Items]
Impairment of intangible assets, excluding goodwill	$ 800
Wholesaler 1 | Sales Revenue, Net | Wholesaler Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk (as a percent)	16.50%	14%	16%
Wholesaler 2 | Sales Revenue, Net | Wholesaler Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk (as a percent)	13%	11%	12%
Wholesaler 3 | Sales Revenue, Net | Wholesaler Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk (as a percent)	12%	11%	12%
United States
Segment Reporting Information [Line Items]
Sales to Customers	$ 48,580	$ 47,156	$ 43,133
Consumer Health
Segment Reporting Information [Line Items]
Sales to Customers	14,953	15,035	14,450
Litigation expense		1,600	3,900
Charges	100	100
Consumer Health | United States
Segment Reporting Information [Line Items]
Sales to Customers	6,599	6,516	6,362
Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	52,563	51,680	45,175
Litigation expense	100	600	800
Charges		100	100
Gain (loss) on divestiture		600
Marketable securities, realized gain (loss)	(700)	500
Pharmaceutical | United States
Segment Reporting Information [Line Items]
Sales to Customers	28,604	27,954	25,735
Medical Devices
Segment Reporting Information [Line Items]
Sales to Customers	27,427	27,060	22,959
Litigation expense	600	100	300
Charges	300	300	300
In-process research and development		900	200
Regulation charge	300	200	100
Acquisition Costs, Period Cost	300
Medical Devices | Auris Health | Other Income
Segment Reporting Information [Line Items]
Contingent consideration reversal			(1,100)
Medical Devices | United States
Segment Reporting Information [Line Items]
Sales to Customers	13,377	12,686	11,036
Segments Total
Segment Reporting Information [Line Items]
Identifiable Assets	153,460	142,829
Additions to Property, Plant & Equipment	3,817	3,462	3,091
Depreciation and Amortization	6,647	7,074	6,931
Consumer Health Business
Segment Reporting Information [Line Items]
Litigation expense	200
Charges	100
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Less: Expense not allocated to segments	624	1,072	945
Other Non Long Lived Assets	74,019	81,418
Corporate, Non-Segment | Consumer Health Business
Segment Reporting Information [Line Items]
Less: Expense not allocated to segments	1,089	67
Corporate, Non-Segment | General Corporate
Segment Reporting Information [Line Items]
Identifiable Assets	33,918	39,189
Additions to Property, Plant & Equipment	192	190	256
Depreciation and Amortization	323	316	300
Long-Lived Assets	1,134	1,014
Operating Segments
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	23,438	23,915	17,442
Sales to Customers	94,943	93,775	82,584
Long-Lived Assets	112,225	99,586
Operating Segments | United States
Segment Reporting Information [Line Items]
Sales to Customers	48,580	47,156	43,133
Long-Lived Assets	66,283	48,586
Operating Segments | Europe
Segment Reporting Information [Line Items]
Sales to Customers	23,449	23,594	18,980
Long-Lived Assets	38,774	43,257
Operating Segments | Western Hemisphere excluding U.S.
Segment Reporting Information [Line Items]
Sales to Customers	6,125	5,750	5,335
Long-Lived Assets	2,737	2,708
Operating Segments | Asia-Pacific, Africa
Segment Reporting Information [Line Items]
Sales to Customers	16,789	17,275	15,136
Long-Lived Assets	4,431	5,035
Operating Segments | Consumer Health
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	2,930	1,573	(852)
Identifiable Assets	24,068	25,081
Additions to Property, Plant & Equipment	323	331	248
Depreciation and Amortization	658	759	785
Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	15,901	17,969	15,250
Identifiable Assets	58,436	64,376
Additions to Property, Plant & Equipment	1,374	1,198	863
Depreciation and Amortization	3,687	4,029	4,006
Unrealized gain (loss) on securities			500
Supplies Expense	1,500
Operating Segments | Medical Devices
Segment Reporting Information [Line Items]
Earnings before provision for taxes on income	4,607	4,373	3,044
Identifiable Assets	70,956	53,372
Additions to Property, Plant & Equipment	2,120	1,933	1,980
Depreciation and Amortization	2,302	2,286	2,140
Immunology | Pharmaceutical
Segment Reporting Information [Line Items]
Sales to Customers	16,935	16,750	15,055
Immunology | Pharmaceutical | United States
Segment Reporting Information [Line Items]
Sales to Customers	$ 11,036	$ 10,843	$ 10,175

Acquisitions and Divestitures -

Acquisitions and Divestitures - Narrative (Details) $ / shares in Units, shares in Millions, SFr in Millions, $ in Millions			3 Months Ended	12 Months Ended
	Dec. 22, 2022 USD ($) $ / shares	Oct. 01, 2020 USD ($)	Apr. 04, 2021 USD ($)	Jan. 01, 2023 USD ($)	Jan. 02, 2022 USD ($) shares	Jan. 02, 2022 CHF (SFr) shares	Jan. 03, 2021 USD ($) $ / shares shares	Jan. 03, 2021 CHF (SFr) shares	Jan. 03, 2021 CHF (SFr)
Business Acquisition [Line Items]
Consideration transferred					$ 7,300
Liabilities assumed					400
Goodwill (Notes 1 and 5)				$ 45,231	35,246		$ 36,393
Long-term debt				28,439	32,116
Asset write-downs				1,216	989		233
Payments to Acquire Businesses, Gross				17,700
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities				1,100
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets				17,300
Finite-Lived Intangible Asset, Useful Life	14 years
Contingent consideration liability				1,120	533
Deferred tax liability, acquisition				1,800
Goodwill, related to acquisitions				11,056	0
In-process research and development				783	900		$ 181
Acquisition related costs				300
Non-Tradeable Contingent Value Right
Business Acquisition [Line Items]
Dividends Payable, Amount Per Share | $ / shares	$ 8.75
Non-Tradeable Contingent Value Right | Class I Recommendation For Impella
Business Acquisition [Line Items]
Dividends Payable, Amount Per Share | $ / shares	$ 10
Idorsia
Business Acquisition [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares							11.8	11.8
Sale of stock, percentage of ownership before transaction							8.30%	8.30%
Proceeds from sale of equity interests							$ 357	SFr 337
Sale of stock (in USD per share) | $ / shares							$ 28.55
Convertible note, equity Interest (in shares) | shares							38.7	38.7
Momenta
Business Acquisition [Line Items]
Consideration transferred		$ 6,100
Liabilities assumed		$ 1,600
Discount rate		13%
Goodwill (Notes 1 and 5)		$ 1,200
Other assets assumed		500
Momenta | In Process Research and Development
Business Acquisition [Line Items]
Intangible assets assumed		$ 6,000
2020 Acquisitions | In Process Research and Development
Business Acquisition [Line Items]
Purchase price over fair value of assets acquired					7,500
bermekimab
Business Acquisition [Line Items]
Consideration transferred			$ 800
Intangible assets assumed			$ 800
Discount rate			16%
Asset write-downs				800
Verb Surgical Inc.
Business Acquisition [Line Items]
Liabilities assumed			$ 300
Intangible assets assumed			400
Goodwill (Notes 1 and 5)			200
Other assets assumed			200
Equity method investments, fair value			$ 400
Abiomed
Business Acquisition [Line Items]
Discount rate	9.50%
Other assets assumed	$ 19,900
Marketable securities assumed	600
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	$ 2,800
Acquisition price (in dollars per share) | $ / shares	$ 380
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 17,100
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	16,500
Contingent consideration liability	700			$ 704
Deferred tax liability, acquisition	1,800
Cash Acquired from Acquisition	300
Goodwill, related to acquisitions	10,900
Finite-lived Intangible Assets Acquired	6,600
In-process research and development	1,100
Abiomed | Non-Tradeable Contingent Value Right
Business Acquisition [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right	$ 1,600
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right | $ / shares	$ 35
Dividends Payable, Amount Per Share | $ / shares	$ 17.50
Revenues, Contingent Consideration	$ 3,700
Abiomed | Non-Tradeable Contingent Value Right | Impella
Business Acquisition [Line Items]
Dividends Payable, Amount Per Share | $ / shares	$ 7.50
Maximum | Momenta
Business Acquisition [Line Items]
Probability of success factor		77%
Maximum | bermekimab
Business Acquisition [Line Items]
Probability of success factor			60%
Maximum | Abiomed
Business Acquisition [Line Items]
Probability of success factor	70%
Minimum | Momenta
Business Acquisition [Line Items]
Probability of success factor		20%
Minimum | bermekimab
Business Acquisition [Line Items]
Probability of success factor			20%
Minimum | Abiomed
Business Acquisition [Line Items]
Probability of success factor	52%
Convertible Debt | Idorsia
Business Acquisition [Line Items]
Long-term debt | SFr									SFr 445
Convertible debt, amount of loan converted					$ 120	SFr 110
Convertible Debt, number of equity instruments (in shares) | shares					9.6	9.6
Evra and Doxil
Business Acquisition [Line Items]
Proceeds from divestiture of brands					$ 600

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions

1 Months Ended

9 Months Ended

Apr. 30, 2022 USD ($)

Mar. 22, 2022 USD ($)

Oct. 31, 2021 USD ($)

Sep. 30, 2021 cases

Jun. 30, 2021 USD ($)

Jun. 30, 2020 USD ($)

Jan. 31, 2020 USD ($)

Oct. 31, 2019 USD ($)

Jul. 31, 2018 USD ($)

Sep. 27, 2020 USD ($)

Jan. 01, 2023 claimant claim cases

May 31, 2021 cases claimant

Oct. 31, 2020 USD ($)

Legal Proceeding (Textuals)

Number of pending claims | claim

60

Loss Contingency Pending Claims, Number, Additional | claim

20

Loss Contingency, Pending Claims, Number, Remaining | claim

570

Rasmussen Instruments, LLC

Legal Proceeding (Textuals)

Damages awarded | $

$ 20

ASR

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

170

Pinnacle Acetabular Cup System

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

1,400

Pelvic Meshes

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

9,000

Risperdal

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

1,100

Talc

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

40,300

Physiomesh

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

2,100

Opioid

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

3,500

Elmiron

Legal Proceeding (Textuals)

Product liability contingency, number of claimants

2,000

Judicial Ruling

Legal Proceeding (Textuals)

Damages awarded | $

$ 6.8

$ 8,000

Pending Litigation

Legal Proceeding (Textuals)

Loss contingency, estimate of possible loss | $

$ 4,000

$ 5,000

Loss contingency, estimate of additional possible loss | $

$ 1,000

Pending Litigation | Physiomesh

Legal Proceeding (Textuals)

Number of pending claims | cases

208

3,600

Product liability contingency, number of claimants

4,300

Number of claims within settlement agreement | cases

3,729

Loss Contingency, Claims Dismissed, Number | cases

2,236

DePuy ASR U.S. | Settled Litigation

Legal Proceeding (Textuals)

Number of patients in settlement

10,000

Baby Powder | Talc

Legal Proceeding (Textuals)

Reserve established | $

$ 2,000

Baby Powder | Judicial Ruling | Damages from Product Defects

Legal Proceeding (Textuals)

Litigation contingency | $

$ 2,100

$ 4,700

Payments for legal settlements | $

$ 2,500

Oklahoma Attorney General vs. Johnson & Johnson and JPI | Settled Litigation

Legal Proceeding (Textuals)

Damages awarded | $

$ 465

Surgical Mesh Products Marketing | Judicial Ruling

Legal Proceeding (Textuals)

Damages awarded | $

$ 302

$ 344

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Restructuring Cost and Reserve [Line Items]
Charges	$ 321	$ 252	$ 247
Supply Chain
Restructuring Cost and Reserve [Line Items]
Charges	463
Restructuring costs incurred since announced	2,200
Supply Chain | Restructuring Charges
Restructuring Cost and Reserve [Line Items]
Charges	300
Supply Chain | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Charges	100
Supply Chain | Other Income Expense Net
Restructuring Cost and Reserve [Line Items]
Charges	$ 100

Restructuring - Summary of Seve

Restructuring - Summary of Severance Charges and Associated Spending (Details) - USD ($) $ in Millions	12 Months Ended
	Jan. 01, 2023	Jan. 02, 2022	Jan. 03, 2021
Restructuring Reserve [Roll Forward]
Charges	$ 321	$ 252	$ 247
Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance beginning	137	144
Activity during the period		(7)
Charges	463
Cash settlements	(432)
Settled non cash	(59)
Reserve balance ending		137	144
Supply Chain | Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance ending	109
Severance | Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance beginning	112	135
Activity during the period		(23)
Charges	0
Cash settlements	(37)
Settled non cash	0
Reserve balance ending		112	135
Severance | Supply Chain | Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance ending	75
Asset Write-offs/Sales | Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance beginning	0	0
Activity during the period		0
Charges	15
Cash settlements	44
Settled non cash	(59)
Reserve balance ending		0	0
Asset Write-offs/Sales | Supply Chain | Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance ending	0
Other | Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance beginning	25	9
Activity during the period		16
Charges	448
Cash settlements	(439)
Settled non cash
Reserve balance ending		$ 25	$ 9
Other | Supply Chain | Supply Chain
Restructuring Reserve [Roll Forward]
Reserve balance ending	$ 34